臨床腫瘍学

672  件  
※ 登録方法の違いにより重複して表示されている場合があります。

  1. Morikawa R, Nitta K, Yasuda S, Kano Y, Noji R, Aoyama S, Sato S, Ikeda S, Okamoto R, Nagata M, Mori T, Suenaga M: Identification of risk factors for gastrointestinal immune-related adverse events associated with immune check point inhibitors. Expert opinion on drug safety. 2024.12; ( PubMed , DOI )

  2. Tanaka H, Yoshida S, Aoyama S, Ikeda S, Kunieda J, Ohashi K, Fukuda S, Waseda Y, Tanaka H, Fujii Y: A case of double-negative prostate cancer with BRCA2 mutation and high tumor mutation burden treated sequentially with olaparib and pembrolizumab. IJU case reports. 2024.09; 7 (5): 395-398. ( PubMed , DOI )

  3. Suenaga M, Mashima T, Kawata N, Dan S, Seimiya H, Yamaguchi K: Exploratory Study Identifies Matrix Metalloproteinase-14 and -9 as Potential Biomarkers of Regorafenib Efficacy in Metastatic Colorectal Cancer. Cancers. 2024.08; 16 (16): ( PubMed , DOI )

  4. Suenaga M, Yamauchi S, Morikawa R, Noji R, Kano Y, Tokunaga M, Kinugasa Y: Chemotherapy and COVID-19 Vaccination in Patients With Gastrointestinal Cancer. In vivo (Athens, Greece). 2024.05; 38 (3): 1278-1284. ( PubMed , DOI )

  5. Nobuhiko Ogasawara, Yoshihito Kano, Yosuke Yoneyama, Sakurako Kobayashi, Satoshi Watanabe, Sakura Kirino, Fausto D Velez-Bravo, Yourae Hong, Aleksandra Ostapiuk, Pavlo Lutsik, Iichiroh Onishi, Shinichi Yamauchi, Yui Hiraguri, Go Ito, Yusuke Kinugasa, Kenichi Ohashi, Mamoru Watanabe, Ryuichi Okamoto, Sabine Tejpar, Shiro Yui: Discovery of non-genomic drivers of YAP signaling modulating the cell plasticity in CRC tumor lines. iScience. 2024.03; 27 (3): 109247. ( PubMed , DOI )

  6. Shun Fujiwara, Yoshihito Kano, Yasuhiro Maejima, Tomoyuki Fujioka, Kazuhiro Tamura, Susumu Kirimura, Satoshi Miyake, Ryuichi Okamoto: Clinical Response of Primary Malignant Pericardial Mesothelioma with Peritoneal Dissemination to Nivolumab. Intern Med. 2024.02; 63 (4): 513-519. ( PubMed , DOI )

  1. Naito T, Noji R, Kugimoto T, Kuroshima T, Tomioka H, Fujiwara S, Suenaga M, Harada H, Kano Y: The Efficacy of Immunotherapy and Clinical Utility of Comprehensive Genomic Profiling in Adenoid Cystic Carcinoma of Head and Neck. Medicina (Kaunas, Lithuania). 2023.12; 59 (12): ( PubMed , DOI )

  2. Yuriko Matsumiya, Mitsukuni Suenaga, Toshiaki Ishikawa, Toshifumi Kudo, Tsuyoshi Nakagawa, Kentaro Okamoto, Masanori Tokunaga, Claudia Hurtado, Yuki Yamada, Kentaro Oka, Motomichi Takahashi, Luis Francisco Lopez Kostner, Miguel Luis O'Ryan Gallardo, Hiroyuki Uetake, Yusuke Kinugasa: Clinical significance of Bacteroides fragilis as a potential prognostic factor in colorectal cancer Anaerobe. 2023.10; ( DOI )

  3. Masayuki Miyagi, Gen Inoue, Toshitaka Yoshii, Satoru Egawa, Kenichiro Sakai, Kazuo Kusano, Yukihiro Nakagawa, Takashi Hirai, Kanichiro Wada, Keiichi Katsumi, Atsushi Kimura, Takeo Furuya, Narihito Nagoshi, Tsukasa Kanchiku, Yukitaka Nagamoto, Yasushi Oshima, Hiroaki Nakashima, Kei Ando, Masahiko Takahata, Kanji Mori, Hideaki Nakajima, Kazuma Murata, Shunji Matsunaga, Takashi Kaito, Kei Yamada, Sho Kobayashi, Satoshi Kato, Tetsuro Ohba, Satoshi Inami, Shunsuke Fujibayashi, Hiroyuki Katoh, Haruo Kanno, Masao Koda, Hiroshi Takahashi, Shinsuke Ikeda, Shiro Imagama, Yoshiharu Kawaguchi, Katsushi Takeshita, Morio Matsumoto, Masashi Takaso, Atsushi Okawa, Masashi Yamazaki: Residual Neuropathic Pain in Postoperative Patients With Cervical Ossification of Posterior Longitudinal Ligament. Clin Spine Surg. 2023.07; 36 (6): E277-E282. ( PubMed , DOI )

  4. Kano Y, Suenaga M, Uetake H: Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer. Current oncology (Toronto, Ont.). 2023.07; 30 (7): 6546-6558. ( PubMed , DOI )

  5. Hata C, Fukawa Y, Motoi T, Kinowaki Y, Akashi T, Ohashi K, Ishikawa Y, Waseda Y, Fujii Y, Kakuta R, Ikeda S, Onishi I: A Primary Kidney Giant Cell Tumor of Soft Tissue Caused Peritoneal Dissemination, Considered to Be Malignant Transformation: A Case Report. Diagnostics (Basel, Switzerland). 2023.02; 13 (4): ( PubMed , DOI )

  6. Kage H, Shinozaki-Ushiku A, Ishigaki K, Sato Y, Tanabe M, Tanaka S, Tanikawa M, Watanabe K, Kato S, Akagi K, Uchino K, Mitani K, Takahashi S, Miura Y, Ikeda S, Kojima Y, Watanabe K, Mochizuki H, Yamaguchi H, Kawazoe Y, Kashiwabara K, Kohsaka S, Tatsuno K, Ushiku T, Ohe K, Yatomi Y, Seto Y, Aburatani H, Mano H, Miyagawa K, Oda K: Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan. Cancer science. 2023.01; 114 (4): 1710-1717. ( PubMed , DOI )

  7. Kaneko S, Asahina Y, Nakagawa M, Murakawa M, Miyazaki Y, Asakage T, Fukuda S, Namiki T, Kano Y, Nagata M, Tsuchiya J, Miyoshi M, Kitahata-Kawai F, Nitta S, Itsui Y, Kakinuma S, Okamoto R: Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. Hepatology research : the official journal of the Japan Society of Hepatology. 2023.01; 53 (5): 450-459. ( PubMed , DOI )

  1. Kobayashi Sakurako, Ogasawara Nobuhiko, Watanabe Satoshi, Yoneyama Yosuke, Kirino Sakura, Hiraguri Yui, Inoue Masami, Nagata Sayaka, Okamoto-Uchida Yoshimi, Kofuji Satoshi, Shimizu Hiromichi, Ito Go, Mizutani Tomohiro, Yamauchi Shinichi, Kinugasa Yusuke, Kano Yoshihito, Nemoto Yasuhiro, Watanabe Mamoru, Tsuchiya Kiichiro, Nishina Hiroshi, Okamoto Ryuichi, Yui Shiro: Collagen type I-mediated mechanotransduction controls epithelial cell fate conversion during intestinal inflammation(タイトル和訳中) Inflammation and Regeneration. 2022.11; 42 1 of 18-18 of 18. ( 医中誌 )

  2. Sakurako Kobayashi, Nobuhiko Ogasawara, Satoshi Watanabe, Yosuke Yoneyama, Sakura Kirino, Yui Hiraguri, Masami Inoue, Sayaka Nagata, Yoshimi Okamoto-Uchida, Satoshi Kofuji, Hiromichi Shimizu, Go Ito, Tomohiro Mizutani, Shinichi Yamauchi, Yusuke Kinugasa, Yoshihito Kano, Yasuhiro Nemoto, Mamoru Watanabe, Kiichiro Tsuchiya, Hiroshi Nishina, Ryuichi Okamoto, Shiro Yui: Collagen type I-mediated mechanotransduction controls epithelial cell fate conversion during intestinal inflammation. Inflamm Regen. 2022.11; 42 (1): 49. ( PubMed , DOI )

  3. オンライン診療を用いた緩和ケアの有用性に関する検討 2022.10; 60回 O76-3. ( 医中誌 )

  4. Lazar V, Girard N, Raymond E, Martini JF, Galbraith S, Raynaud J, Bresson C, Solomon B, Magidi S, Nechushtan H, Onn A, Berger R, Chen H, Al-Omari A, Ikeda S, Lassen U, Sekacheva M, Felip E, Tabernero J, Batist G, Spatz A, Pramesh CS, Girard P, Blay JY, Philip T, Berindan-Neagoe I, Porgador A, Rubin E, Kurzrock R, Schilsky RL: Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. JCO precision oncology. 2022.09; 6 e2200072. ( PubMed , DOI )

  5. Keitaro Shimozaki, Kenro Hirata, Taro Sato, Maho Nakamura, Kyoko Kato, Hidekazu Hirano, Yosuke Kumekawa, Kaori Hino, Kentaro Kawakami, Yosuke Kito, Toshihiko Matsumoto, Takeshi Kawakami, Masato Komoda, Kengo Nagashima, Yasunori Sato, Kentaro Yamazaki, Shuichi Hironaka, Hiromasa Takaishi, Yasuo Hamamoto, Kei Muro: WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-institutional Registry-based Study (BRACELET Study) Clinical Colorectal Cancer. 2022.08; In press. ( DOI )

  6. Kudo Ryo, Kano Yoshihito, Noji Rika, Kakuta Ryota, Onishi Iichiro, Kimura Kouichiro, Tanimoto Kousuke, Miya Fuyuki, Mitsumura Takahiro, Oshima Noriko, Ariizumi Yousuke, Nakagawa Tsuyoshi, Ishikawa Toshiaki, Miyake Satoshi, Ikeda Sadakatsu: Clinical utility of comprehensive genomic profiling for patients with cancer of unknown primary site ANNALS OF ONCOLOGY. 2022.07; 33 S500. ( DOI )

  7. Noji R, Tohyama K, Kugimoto T, Kuroshima T, Hirai H, Tomioka H, Michi Y, Tasaki A, Ohno K, Ariizumi Y, Onishi I, Suenaga M, Mori T, Okamoto R, Yoshimura R, Miura M, Asakage T, Miyake S, Ikeda S, Harada H, Kano Y: Comprehensive Genomic Profiling Reveals Clinical Associations in Response to Immune Therapy in Head and Neck Cancer. Cancers. 2022.07; 14 (14): ( PubMed , DOI )

  8. Takagi M, Ogawa C, Iehara T, Aoki-Nogami Y, Ishibashi E, Imai M, Kimura T, Nagata M, Yasuhara M, Masutani M, Yoshimura K, Tomizawa D, Ogawa A, Yonemori K, Morishita A, Miyamoto S, Takita J, Kihara T, Nobori K, Hasebe K, Miya F, Ikeda S, Shioda Y, Matsumoto K, Fujimura J, Mizutani S, Morio T, Hosoi H, Koike R: First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors. Cancer. 2022.05; 128 (15): 2949-2957. ( PubMed , DOI )

  9. Satoru Aoyama, Shunichiro Yasuda, Huixin Li, Daisuke Watanabe, Yoshihiro Umezawa, Keigo Okada, Ayako Nogami, Osamu Miura, Norihiko Kawamata: A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cell‑surface proteins on target cells. International Journal of Molecular Medicine. 2022.04; 49 (4): ( PubMed , DOI )

  10. Matsudera Shotaro, Kano Yoshihito, Aoyagi Yasuko, Tohyama Kohki, Ogino Kei, Okamoto Kentaro, Yamaguchi Takeshi, Watanabe Shun, Nakajima Masanobu, Morita Shinji, Nakamura Takatoshi, Suzuki Kan, Tsuchioka Takashi, Kojima Kazuyuki, Miyake Satoshi, Takagi Masatoshi, Ikeda Sadakatsu: A Pilot Study of Comprehensive Genomic Profiling for Pediatric and Adolescent and Young Adult Solid Tumor Patients in Japan(和訳中) Dokkyo Medical Journal. 2022.03; 1 (1): 56-62. ( 医中誌 )

  11. Onishi Iichiroh, Kirimura Susumu, Wakejima Ryo, Okubo Kenichi, Odai Tamami, Kakuta Ryota, Kano Yoshihito, Ikeda Sadakatsu, Akashi Takumi, Kitagawa Masanobu: Primary pulmonary choriocarcinoma with a genomic sequence(和訳中) Pathology International. 2022.02; 72 (2): 141-143. ( 医中誌 )

  12. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. 2022.02; 6 e2100383. ( PubMed , DOI )

  13. Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. 2022.01; 25 (1): 207-217. ( PubMed , DOI )

  14. Aoyagi Y, Kano Y, Tohyama K, Matsudera S, Kumaki Y, Takahashi K, Mitsumura T, Harada Y, Sato A, Nakamura H, Sueoka E, Aragane N, Kimura K, Onishi I, Takemoto A, Akahoshi K, Ono H, Ishikawa T, Tokunaga M, Nakagawa T, Oshima N, Nakamura R, Takagi M, Asakage T, Uetake H, Tanabe M, Miyake S, Kinugasa Y, Ikeda S: Clinical utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study. PloS one. 2022; 17 (3): e0266112. ( PubMed , DOI )

  1. Noji R, Kano Y*(*corresponding author), Hirai H, Onishi I, Nishii N, Yoshimura R, Miyake S, Ikeda S, Harada H: MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral oncology. 2021.12; 124 105666. ( PubMed , DOI )

  2. Shotaro Matsudera, Yoshihito Kano, Yasuko Aoyagi, Kohki Tohyama, Kenta Takahashi, Yuichi Kumaki, Takahiro Mitsumura, Koichiro Kimura, Iichiro Onishi, Akira Takemoto, Daisuke Ban, Hiroaki Ono, Atsushi Kudo, Noriko Oshima, Kei Ogino, Shun Watanabe, Yukiko Tani, Takeshi Yamaguchi, Masanobu Nakajima, Shinji Morita, Satoru Yamaguchi, Masatoshi Takagi, Toshiaki Ishikawa, Tsuyoshi Nakagawa, Kentaro Okamoto, Hiroyuki Uetake, Minoru Tanabe, Satoshi Miyake, Takashi Tsuchioka, Kazuyuki Kojima, Sadakatsu Ikeda: A Pilot Study Analyzing the Clinical Utility of Comprehensive Genomic Profiling Using Plasma Cell-Free DNA for Solid Tumor Patients in Japan (PROFILE Study). Ann Surg Oncol. 2021.12; 28 (13): 8497-8505. ( PubMed , DOI )

  3. Gebregiworgis T*, Kano Y* (*contributed equally), St-Germain J, Radulovich N, Udaskin ML, Mentes A, Huang R, Poon BPK, He W, Valencia-Sama I, Robinson CM, Huestis M, Miao J, Yeh JJ, Zhang ZY, Irwin MS, Lee JE, Tsao MS, Raught B, Marshall CB, Ohh M, Ikura M: The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. Nature communications. 2021.11; 12 (1): 6274. ( PubMed , DOI )

  4. Yatabe Yasushi, Goto Koichi, Matsumoto Shingo, Hatanaka Yutaka, Arakane Naoko, Ikeda Sadakatsu, Inoue Akira, Kinoshita Ichiro, Kimura Hideharu, Sakamoto Tomohiro, Satouchi Miyako, Shimizu Junichi, Sunami Kuniko, Tsuta Koji, Toyooka Shinichi, Nishio Kazuto, Nishino Kazumi, Mikubo Masashi, Yokose Tomoyuki, Dosaka-Akita Hirotoshi: METex14 Skipping Testing Guidance for Lung Cancer Patients: The Guidance from the Biomarker Committee, the Japan Lung Cancer Society(和訳中) 肺癌. 2021.10; 61 (5): 361-370. ( 医中誌 )

  5. Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors. 2021.10; 11 (1): 20003. ( PubMed , DOI )

  6. Kumaki Y, Olsen S, Suenaga M, Nakagawa T, Uetake H, Ikeda S: Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal MET Amplification from Aneuploidy in Diverse Advanced Cancers. Current oncology (Toronto, Ont.). 2021.09; 28 (5): 3717-3728. ( PubMed , DOI )

  7. Mitsumura T, Kumaki Y, Takahashi K, Matsudera S, Sakakibara R, Honda T, Ishizuka M, Iijima Y, Shirai T, Okamoto T, Tateishi T, Sakashita H, Miyake S, Ikeda S, Miyazaki Y: Treatment of advanced lung cancer based on genomic profiling using liquid biopsy (plasma): A review of three cases. Thoracic cancer. 2021.08; 12 (18): 2508-2512. ( PubMed , DOI )

  8. Boku N, Satoh T, Ryu M.H, Chao Y, Kato K, Chung H.C, Chen J.S, Muro K, Kang W.K, Yeh K.H, Yoshikawa T, Oh S.C, Bai L.Y, Tamura T, Lee K.W, Hamamoto Y, Kim J.G, Chin K, Oh D.Y, Minashi K, Cho J.Y, Tsuda M, Nishiyama T, Chen L.T, Kang Y.K: Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab Gastric Cancer. 2021.07; 24 (4): 946-958. ( PubMed , DOI )

  9. Kano Yoshihito, Gebregiworgis Teklab, Marshall Christopher, Ikura Mitsuhiko, Miyake Satoshi, Ohh Michael: KRAS Q61H mutation evades the regulation of tyrosyl phosphorylation and renders cancer cells resistant to SHP2 inhibitor ANNALS OF ONCOLOGY. 2021.07; 32 S306. ( DOI )

  10. Ikeda Sadakatsu, Kudo Ryo, Yamashita Yamato, Noji Rika, Yokobori Jyunko, Ohki Mika, Takamine Eriko, Kobayashi Yumi, Egawa Makiko, Ebana Yusuke, Kimura Koichiro, Yokoyama Kohta, Onishi Iichiro, Takemoto Akira, Kirimura Susumu, Kinowaki Yuko, Tanimoto Kosuke, Miya Fuyuki, Kano Yoshihito, Yoshida Masayuki, Miyake Satoshi: Clinical utility of multi-disciplinary expert panel discussion in precision cancer medicine ANNALS OF ONCOLOGY. 2021.07; 32 S287. ( DOI )

  11. Shimozaki K, Sukawa Y, Sato Y, Horie S, Chida A, Tsugaru K, Togasaki K, Kawasaki K, Hirata K, Hayashi H, Hamamoto Y, Kanai T: Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data Future Oncology. 2021.07; 17 (20): 2593-2603. ( PubMed , DOI )

  12. Hayashi Y, Hosoe N, Takabayashi K, Limpias Kamiya K.J.L, Tsugaru K, Shimozaki K, Hirata K, Fukuhara K, Fukuhara S, Mutaguchi M, Sujino T, Sukawa Y, Hamamoto Y, Naganuma M, Takaishi H, Shimoda M, Ogata H, Kanai T: Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis Digestive Diseases and Sciences. 2021.06; 66 (6): 2129-2134. ( PubMed , DOI )

  13. Nakamura Kohei, Aimono Eriko, Oba Junna, Hayashi Hideyuki, Tanishima Shigeki, Hayashida Tetsu, Chiyoda Tatsuyuki, Kosaka Takeo, Hishida Tomoyuki, Kawakubo Hirohumi, Kitago Minoru, Okabayashi Koji, Funakoshi Takeru, Okita Hajime, Ikeda Sadakatsu, Takaishi Hiromasa, Nishihara Hiroshi: Estimating copy number using next-generation sequencing to determine ERBB2 amplification status MEDICAL ONCOLOGY. 2021.04; 38 (4): 36. ( PubMed , DOI )

  14. Munkhdelger Jijgee, Shimooka Tomoko, Koyama Yoshinori, Ikeda Sadakatsu, Mikami Yoshiki, Fukuoka Junya, Hori Takashi, Bychkov Andrey: Basaloid Squamous Cell Carcinoma of the Uterine Cervix: Report of a Case With Molecular Analysis INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY. 2021.04; 29 (7): 1066896921997132-774. ( PubMed , DOI )

  15. Kato Shumei, McFall Thomas, Takahashi Kenta, Bamel Kasey, Ikeda Sadakatsu, Eskander Ramez N., Plaxe Steven, Parker Barbara, Stites Edward, Kurzrock Razelle: KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery ONCOLOGIST. 2021.04; 26 (4): E530-E536. ( PubMed , DOI )

  16. Mitsukuni Suenaga, W U Zhang, Tetsuo Mashima, Marta Schirripa, Shu Cao, Satoshi Okazaki, Martin D Berger, Yuji Miyamoto, Afsaneh Barzi, Toshiharu Yamaguchi, Heinz-Josef Lenz: Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients. Cancer Genomics Proteomics. 2021.04; 18 (3): 317-324. ( PubMed , DOI )

  17. Matsudera S, Kano Y, Ikeda S: ASO Author Reflections: Impact of Liquid Biopsy Using Plasma Cell-Free DNA in Solid Tumors in Japan. Annals of surgical oncology. 2021.03; ( PubMed , DOI )

  18. Shimozaki K, Hirata K, Horie S, Chida A, Tsugaru K, Hayashi Y, Kawasaki K, Miyanaga R, Hayashi H, Mizuno R, Funakoshi T, Hosoe N, Hamamoto Y, Kanai T: The entire intestinal tract surveillance using capsule endoscopy after immune checkpoint inhibitor administration: A prospective observational study Diagnostics. 2021.03; 11 (3): ( PubMed , DOI )

  19. Mitsukuni Suenaga, Marta Schirripa, Shu Cao, Wu Zhang, Chiara Cremolini, Sara Lonardi, Satoshi Okazaki, Martin D Berger, Yuji Miyamoto, Shivani Soni, Afsaneh Barzi, Toshiharu Yamaguchi, Fotios Loupakis, Alfredo Falcone, Heinz-Josef Lenz: Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. Pharmacogenomics J. 2021.02; ( PubMed , DOI )

  20. Naito Yoichi, Aburatani Hiroyuki, Amano Toraji, Baba Eishi, Furukawa Toru, Hayashida Tetsu, Hiyama Eiso, Ikeda Sadakatsu, Kanai Masashi, Kato Motohiro, Kinoshita Ichiro, Kiyota Naomi, Kohno Takashi, Kohsaka Shinji, Komine Keigo, Matsumura Itaru, Miura Yuji, Nakamura Yoshiaki, Natsume Atsushi, Nishio Kazuto, Oda Katsutoshi, Oda Naoyuki, Okita Natsuko, Oseto Kumiko, Sunami Kuniko, Takahashi Hideaki, Takeda Masayuki, Tashiro Shimon, Toyooka Shinichi, Ueno Hideki, Yachida Shinichi, Yoshino Takayuki, Tsuchihara Katsuya: Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1) INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 2021.02; 26 (2): 233-283. ( PubMed , DOI )

  21. Takahari Daisuke, Shinozaki Eiji, Wakatsuki Takeru, Ooki Akira, Ozaka Masato, Suzuki Takeshi, Nakayama Izuma, Osumi Hiroki, Kamiimabeppu Daisaku, Sato Taro, Ogura Mariko, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei: Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research(和訳中) International Journal of Clinical Oncology. 2021.02; 26 (2): 335-344. ( 医中誌 )

  22. Takeuchi M, Imamura C.K, Booka E, Takeuchi H, Mizukami T, Kawakami T, Funakoshi T, Wakuda K, Aoki Y, Hamamoto Y, Kitago M, Kawakubo H, Boku N, Tanigawara Y, Kitagawa Y: Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application Cancer Science. 2021.02; 112 (2): 751-759. ( PubMed , DOI )

  23. Kazuo Kobayashi, Erika Sugiyama, Eiji Shinozaki, Takeru Wakatsuki, Masataka Tajima, Hiyori Kidokoro, Takeshi Aoyama, Yasuhiro Nakano, Kazuyoshi Kawakami, Koki Hashimoto, Mitsukuni Suenaga, Takashi Ichimura, Mariko Ogura, Keisho Chin, Izuma Nakayama, Akira Ooki, Daisuke Takahari, Wataru Suzuki, Takashi Yokokawa, Yuichi Minowa, Tomoko Hiraoka, Kenichi Suzuki, Hitoshi Sato, Toshihiro Hama, Kensei Yamaguchi: Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers. Cancer Chemother Pharmacol. 2021.02; ( PubMed , DOI )

  24. Kano Yoshihito, Marshall Christopher, Ikura Mitsuhiko: Evasion of KRAS Q61H regulation by tyrosine phosphorylation renders cancer cells resistant to SHP2 inhibitors CANCER SCIENCE. 2021.02; 112 171.

  25. Suenaga M, Cao S, Zhang W, Matsusaka S, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Barzi A, Yamamoto N, Yamaguchi T, Lenz HJ: Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. Pharmacogenetics and genomics. 2021.01; 31 (1): 10-16. ( PubMed , DOI )

  26. Liotti F, Kumar N, Prevete N, Marotta M, Sorriento D, Ieranò C, Ronchi A, Marino FZ, Moretti S, Colella R, Puxeddu E, Paladino S, Kano Y, Ohh M, Scala S, Melillo RM: PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells. Journal of experimental & clinical cancer research : CR. 2021.01; 40 (1): 22. ( PubMed , DOI )

  27. Takahashi Masanobu, Kato Ken, Okada Morihito, Chin Keisho, Kadowaki Shigenori, Hamamoto Yasuo, Doki Yuichiro, Kubota Yutaro, Kawakami Hisato, Ogata Takashi, Hara Hiroki, Muto Manabu, Nakashima Yuichiro, Ishihara Ryu, Tsuda Masahiro, Motoyama Satoru, Kodani Mamoru, Kitagawa Yuko: 日本人進行食道扁平上皮癌患者を対象としたニボルマブ投与と化学療法の比較　多施設無作為化非盲検第3相試験(ATTRACTION-3)のサブグループ解析(Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial(ATTRACTION-3)) Esophagus. 2021.01; 18 (1): 90-99. ( 医中誌 )

  28. Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC. 2021.01; 39 (3): ( DOI )

  29. Satoh T, Kato K, Ura T, Hamamoto Y, Kojima T, Tsushima T, Hironaka S, Hara H, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Doki Y, Matsumura Y, Kitagawa Y: Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07) Esophagus. 2021; 18 (4): 835-843. ( PubMed , DOI )

  1. Matsudera Shotaro, Kano Yoshihito, Aoyagi Yasuko, Tohyama Kohki, Ogino Kei, Okamoto Kentaro, Tsuchioka Takashi, Kojima Kazuyuki, Takagi Masatoshi, Ikeda Sadakatsu: Clinical Utility of Comprehensive Genomic Profiling for Pediatric and AYA Solid Tumor Patients PEDIATRIC BLOOD & CANCER. 2020.12; 67

  2. Matsudera Shotaro, Kano Yoshihito, Aoyagi Yasuko, Tohyama Kohki, Ogino Kei, Okamoto Kentaro, Tsuchioka Takashi, Kojima Kazuyuki, Takagi Masatoshi, Ikeda Sadakatsu: Clinical Utility of Comprehensive Genomic Profiling for Pediatric and AYA Solid Tumor Patients PEDIATRIC BLOOD & CANCER. 2020.12; 67

  3. Katsukura N, Watanabe S, Shirasaki T, Hibiya S, Kano Y, Akahoshi K, Tanabe M, Kirimura S, Akashi T, Kitagawa M, Okamoto R, Watanabe M, Tsuchiya K: Intestinal phenotype is maintained by Atoh1 in the cancer region of intraductal papillary mucinous neoplasm. Cancer science. 2020.12; ( PubMed , DOI )

  4. Ono Hiroaki, Ikeda Sadakatsu, Ishikawa Yoshiya, Watanabe Shuichi, Akahoshi Keiichi, Ogawa Kosuke, Ban Daisuke, Kudo Atsushi, Miyake Satoshi, Tanabe Minoru: 消化器外科とゲノム医療の将来展望　HBP悪性腫瘍におけるゲノムシークエンスの横断研究(Future perspectives of cancer genomic medicine in gastroenterological surgery　Cross-sectional study of genomic sequencing in HBP malignancies) 日本消化器外科学会総会. 2020.12; 75回 WS14-11. ( 医中誌 )

  5. Aoyagi Yasuko, Kano Yoshihito, Ban Daisuke, Tokunaga Masanori, Nakajima Yasuaki, Uetake Hiroyuki, Tanabe Minoru, Miyake Satoshi, Kinugasa Yusuke, Ikeda Sadakatsu: Future perspectives of cancer genomic medicine in gastroenterological surgery　Clinical utility of multiple genomic testing in patients with advanced solid tumor(和訳中) 日本消化器外科学会総会. 2020.12; 75回 WS14-3. ( 医中誌 )

  6. Kawasaki Kenta, Toshimitsu Kohta, Matano Mami, Fujita Masashi, Fujii Masayuki, Togasaki Kazuhiro, Ebisudani Toshiki, Shimokawa Mariko, Takano Ai, Takahashi Sirirat, Ohta Yuki, Nanki Kosaku, Igarashi Ryo, Ishimaru Kazuhiro, Ishida Hiroki, Sukawa Yasutaka, Sugimoto Shinya, Saito Yoshimasa, Maejima Kazuhiro, Sasagawa Shota, Lee Hwajin, Kim Hong-Gee, Ha Kyungsik, Hamamoto Junko, Fukunaga Koichi, Maekawa Aya, Tanabe Minoru, Ishihara Soichiro, Hamamoto Yasuo, Yasuda Hiroyuki, Sekine Shigeki, Kudo Atsushi, Kitagawa Yuko, Kanai Takanori, Nakagawa Hidewaki, Sato Toshiro: An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping CELL. 2020.11; 183 (5): 1420-+. ( PubMed , DOI )

  7. Distribution of Residual Disease and Recurrence Patterns in Pathological Responders After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. 2020.10; ( PubMed , DOI )

  8. Takahari Daisuke, Shinozaki Eiji, Wakatsuki Takeru, Ooki Akira, Ozaka Masato, Suzuki Takeshi, Nakayama Izuma, Osumi Hiroki, Kamiimabeppu Daisaku, Sato Taro, Ogura Mariko, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei: Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 2020.10; ( PubMed , DOI )

  9. Matsudera Shotaro, Kano Yoshihito, Aoyagi Yasuko, Tohyama Kohki, Ogino Kei, Okamoto Kentaro, Tsuchioka Takashi, Kojima Kazuyuki, Takagi Masatoshi, Ikeda Sadakatsu: 小児・AYA世代の進行再発固形がん患者におけるがん遺伝子パネル検査の臨床的有用性の検討(Clinical utility of comprehensive genomic profiling for pediatric and AYA solid tumor patients) 日本小児血液・がん学会雑誌. 2020.10; 57 (4): 243. ( 医中誌 )

  10. 加納 嘉人, Gebregiworgis Teklab, Marshall Christopher, Ikura Mitsuhiko, Ohh Michael: ドライバー遺伝子異常陽性がん治療の新たな局面　KRASQ61H変異によるSHP2阻害剤耐性機構解析 日本癌学会総会記事. 2020.10; 79回 IS1-3. ( 医中誌 )

  11. 松寺 翔太郎, 加納 嘉人, 青柳 康子, 遠山 皓基, 木村 浩一朗, 大西 威一郎, 竹本 暁, 荻野 恵, 岡本 健太郎, 植竹 宏之, 田邉 稔, 三宅 智, 土岡 丘, 小嶋 一幸, 池田 貞勝: Liquid biopsyが変えるがん治療　がんゲノム医療におけるリキッドバイオプシーの臨床的有用性の検討 日本癌治療学会学術集会抄録集. 2020.10; 58回 WS12-4. ( 医中誌 )

  12. Yatabe Y, Sunami K, Goto K, Nishio K, Aragane N, Ikeda S, Inoue A, Kinoshita I, Kimura H, Sakamoto T, Satouchi M, Shimizu J, Tsuta K, Toyooka S, Nishino K, Hatanaka Y, Matsumoto S, Mikubo M, Yokose T, Dosaka-Akita H: Multiplex gene-panel testing for lung cancer patients. Pathology international. 2020.09; ( PubMed , DOI )

  13. Mitsukuni Suenaga, Tetsuo Mashima, Naomi Kawata, Takeru Wakatsuki, Shingo Dan, Hiroyuki Seimiya, Kensei Yamaguchi: Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. Int J Colorectal Dis. 2020.09; ( PubMed , DOI )

  14. Ivette Valencia-Sama, Yagnesh Ladumor, Lynn Kee, Teresa Adderley, Gabriella Christopher, Claire M Robinson, Yoshihito Kano, Michael Ohh, Meredith S Irwin: Status determines sensitivity to SHP2 inhibitor combination therapies targeting the RAS-MAPK pathway in neuroblastoma. Cancer Res. 2020.08; 80 (16): 3413-3423. ( PubMed , DOI )

  15. Takahashi Kenta, Ishibashi Eri, Kubo Toshio, Harada Yohei, Hayashi Hideyuki, Kano Masayuki, Shimizu Yasushi, Shirota Hidekazu, Mori Yukiko, Muto Manabu, Ishioka Chikashi, Dosaka-Akita Hirotoshi, Matsubara Hisahiro, Nishihara Hiroshi, Sueoka-Aragane Naoko, Toyooka Shinichi, Hirakawa Akihiro, Tateishi Ukihide, Miyake Satoshi, Ikeda Sadakatsu: A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial) MEDICINE. 2020.08; 99 (32): e21457. ( PubMed , DOI )

  16. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group. 2020.06; 20 (1): 548. ( PubMed , DOI )

  17. Mitsukuni Suenaga, Marta Schirripa, Shu Cao, Wu Zhang, Dongyun Yang, Chiara Cremolini, Sabina Murgioni, Sara Lonardi, Yan Ning, Satoshi Okazaki, Martin D Berger, Yuji Miyamoto, Afsaneh Barzi, Fotios Loupakis, Alfredo Falcone, Heinz-Josef Lenz: Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers (Basel). 2020.06; 12 (7): ( PubMed , DOI )

  18. Takahashi Kenta, Gen Yasuyuki, Tanimoto Kousuke, Kudo Atsushi, Oshima Noriko, Ban Daisuke, Takemoto Akira, Onishi Iichiro, Kumaki Yuichi, Yokobori Junko, Takamine Eriko, Kano Yoshihito, Miyake Satoshi, Miyasaka Naoyuki, Tanabe Minoru, Inazawa Johji, Ikeda Sadakatsu: Clinical impact of hemizygous deletion detection and panel-size in comprehensive genomic profiling. JOURNAL OF CLINICAL ONCOLOGY. 2020.05; 38 (15):

  19. Berger Martin D., Ning Yan, Stintzing Sebastian, Heinemann Volker, Cao Shu, Zhang Wu, Yang Dongyun, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, Hanna Diana L., Soni Shivani, Puccini Alberto, Tokunaga Ryuma, Naseem Madiha, Battaglin Francesca, Cremolini Chiara, Falcone Alfredo, Loupakis Fotios, Lenz Heinz-Josef: A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials EUROPEAN JOURNAL OF CANCER. 2020.05; 131 89-97. ( PubMed , DOI )

  20. Kato Ken, Doki Yuichiro, Ura Takashi, Hamamoto Yasuo, Kojima Takashi, Tsushima Takahiro, Hironaka Shuichi, Hara Hiroki, Kudo Toshihiro, Iwasa Satoru, Muro Kei, Yasui Hirofumi, Minashi Keiko, Yamaguchi Kensei, Ohtsu Atsushi, Kitagawa Yuko: 日本人食道癌患者に対するニボルマブ反応の長期有効性および同反応を予測する相関因子(Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer) Cancer Science. 2020.05; 111 (5): 1676-1684. ( 医中誌 )

  21. Takahashi Kenta, Gen Yasuyuki, Tanimoto Kousuke, Kudo Atsushi, Oshima Noriko, Ban Daisuke, Takemoto Akira, Onishi Iichiro, Kumaki Yuichi, Yokobori Junko, Takamine Eriko, Kano Yoshihito, Miyake Satoshi, Miyasaka Naoyuki, Tanabe Minoru, Inazawa Johji, Ikeda Sadakatsu: Clinical impact of hemizygous deletion detection and panel-size in comprehensive genomic profiling. JOURNAL OF CLINICAL ONCOLOGY. 2020.05; 38 (15):

  22. Chen L.T, Satoh T, Ryu M.H, Chao Y, Kato K, Chung H.C, Chen J.S, Muro K, Kang W.K, Yeh K.H, Yoshikawa T, Oh S.C, Bai L.Y, Tamura T, Lee K.W, Hamamoto Y, Kim J.G, Chin K, Oh D.Y, Minashi K, Cho J.Y, Tsuda M, Sameshima H, Kang Y.K, Boku N: A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Gastric Cancer. 2020.05; 23 (3): 510-519. ( PubMed , DOI )

  23. Kitagawa Yusuke, Osumi Hiroki, Shinozaki Eiji, Ota Yumiko, Nakayama Izuma, Suzuki Takeshi, Wakatsuki Takeru, Ogura Mariko, Ooki Akira, Takahari Daisuke, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei: Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study BMC CANCER. 2020.04; 20 (1): 358. ( PubMed , DOI )

  24. Nakayama Izuma, Takahari Daisuke, Wakatsuki Takeru, Osumi Hiroki, Chin Keisho, Ogura Mariko, Sato Taro, Suzuki Takeshi, Kamiimabeppu Daisaku, Ooki Akira, Suenaga Mitsukuni, Shinozaki Eiji, Yamaguchi Kensei: Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting ESMO OPEN. 2020.03; 5 (2): ( PubMed , DOI )

  25. Suzuki T, Sukawa Y, Imamura C, Masuishi T, Satake H, Kumekawa Y, Funakoshi S, Kotaka M, Horie Y, Kawai S, Okuda H, Terazawa T, Kondoh C, Kato K, Yoshimura K, Ishikawa H, Hamamoto Y, Boku N, Takaishi H, Kanai T: A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial) Clinical Colorectal Cancer. 2020.03; 19 (1): 13-21. ( PubMed , DOI )

  26. Suenaga Mitsukuni, Wakatsuki Takeru, Mashima Tetsuo, Ogura Mariko, Ichimura Takashi, Shinozaki Eiji, Nakayama Izuma, Osumi Hiroki, Ota Yumiko, Takahari Daisuke, Chin Keisho, Seimiya Hiroyuki, Yamaguchi Kensei: A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study INVESTIGATIONAL NEW DRUGS. 2020.02; 38 (1): 111-119. ( PubMed , DOI )

  27. Suenaga Mitsukuni, Zhang Wu, Mashima Tetsuo, Schirripa Marta, Cao Shu, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Barzi Afsaneh, Lenz Heinz-Josef: Gene polymorphisms of CCL3, CCL4, CCL5, and CCR5 network in metastatic colorectal cancer patients treated with regorafenib JOURNAL OF CLINICAL ONCOLOGY. 2020.02; 38 (4):

  28. Matsusaka Satoshi, Hanna Diana L., Ning Yan, Yang Dongyun, Cao Shu, Berger Martin D., Miyamoto Yuji, Suenaga Mitsukuni, Dan Shingo, Mashima Tetsuo, Seimiya Hiroyuki, Zhang Wu, Lenz Heinz-Josef: Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib CANCER SCIENCE. 2020.02; 111 (2): 441-450. ( PubMed , DOI )

  29. Berger Martin D., Zlobec Inti, Cao Shu, Miyamoto Yuji, Suenaga Mitsukuni, Soni Shivani, Puccini Alberto, Tokunaga Ryuma, Naseem Madiha, Battaglin Francesca, Zhang Wu, Lugli Alessandro, Lenz Heinz-Josef: Polymorphisms of genes encoding for regulatory proteins in the coagulation cascade to predict outcome for stage II and III colon cancer JOURNAL OF CLINICAL ONCOLOGY. 2020.02; 38 (4):

  30. Ota Yumiko, Takahari Daisuke, Suzuki Takeshi, Osumi Hiroki, Nakayama Izuma, Oki Akira, Wakatsuki Takeru, Ichimura Takashi, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei: Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2020.02; 85 (2): 265-272. ( PubMed , DOI )

  31. Suenaga Mitsukuni, Mashima Tetsuo, Kawata Naomi, Wakatsuki Takeru, Seimiya Hiroyuki, Yamaguchi Kensei: Circulating IL-8 levels as candidate marker of antiangiogenic therapy for metastatic colorectal cancer JOURNAL OF CLINICAL ONCOLOGY. 2020.02; 38 (4):

  32. Kunimasa K, Hirotsu Y, Nakamura H, Tamiya M, Iijima Y, Ishida H, Hamamoto Y, Maniwa T, Kimura T, Nishino K, Goto T, Amemiya K, Mochizuki H, Oyama T, Nakatsuka SI, Kumagai T, Okami J, Higashiyama M, Imamura F, Omata M: Rapid progressive lung cancers harbouring multiple clonal driver mutations with big bang evolution model. Cancer genetics. 2020.02; 241 51-56. ( PubMed , DOI )

  33. Kamiimabeppu Daisaku, Wakatsuki Takeru, Takahari Daisuke, Fukuda Naoki, Osumi Hiroki, Nakayama Izuma, Ogura Mariko, Sato Tarou, Ooki Akira, Shinozaki Eiji, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei: Treatment efficacy of ramucirumab-based chemotherapy in patients with alpha-fetoprotein producing gastric cancer (AFPGC) JOURNAL OF CLINICAL ONCOLOGY. 2020.02; 38 (4):

  34. A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer. 2020.02; 27 (2): 460-467. ( PubMed , DOI )

  35. Iijima Y, Sakakibara R, Ishizuka M, Honda T, Shirai T, Okamoto T, Tateishi T, Sakashita H, Tamaoka M, Takemoto A, Kumaki Y, Ikeda S, Miyazaki Y: Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report. Immunotherapy. 2020.01; 12 (8): 563-569. ( PubMed , DOI )

  36. Satoh Taroh, Kang Yoon-Koo, Chao Yee, Ryu Min-Hee, Kato Ken, Chung Hyun Cheol, Chen Jen-Shi, Muro Kei, Kang Won Ki, Yeh Kun-Huei, Yoshikawa Takaki, Oh Sang Cheul, Bai Li-Yuan, Tamura Takao, Lee Keun-Wook, Hamamoto Yasuo, Kim Jong Gwang, Chin Keisho, Oh Do-Youn, Minashi Keiko, Cho Jae Yong, Tsuda Masahiro, Tanimoto Mitsunobu, Chen Li-Tzong, Boku Narikazu: ATTRACTION-2試験においてトラスツズマブを事前使用されていた患者を対象とした探索的サブグループ解析　進行性の胃癌/食道胃接合部癌の患者におけるニボルマブの有効性と安全性を調査するランダム化第III相臨床試験(Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer) Gastric Cancer. 2020.01; 23 (1): 143-153. ( 医中誌 )

  37. Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R: Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology. 2020; 9 (1): 1708065. ( PubMed , DOI )

  38. Miyamoto Y, Schirripa M, Suenaga M, Cao S, Zhang W, Okazaki S, Berger MD, Matsusaka S, Yang D, Ning Y, Baba H, Loupakis F, Lonardi S, Pietrantonio F, Borelli B, Cremolini C, Yamaguchi T, Lenz HJ: A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PloS one. 2020; 15 (9): e0239439. ( PubMed , DOI )

  39. Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors. 2020; 12 4585-4593. ( PubMed , DOI )

  1. Yagasaki K, Takahashi H, Ouchi T, Yamagami J, Hamamoto Y, Amagai M, Komatsu H: Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study Journal of Patient-Reported Outcomes. 2019.12; 3 (1): 27. ( PubMed , DOI )

  2. Ono Hiroaki, Ikeda Sadakatsu, Ogawa Kosuke, Ogura Toshiro, Ban Daisuke, Kudo Atushi, Miyake Satoshi, Tanaka Shinji, Tanabe Minoru: Genomic sequencing in HBP malignancies(和訳中) 日本消化器病学会雑誌. 2019.11; 116 (臨増大会): A893. ( 医中誌 )

  3. Ono Hiroaki, Ikeda Sadakatsu, Ogawa Kosuke, Ogura Toshiro, Ban Daisuke, Kudo Atushi, Miyake Satoshi, Tanaka Shinji, Tanabe Minoru: HBP悪性疾患に関するゲノムシークエンス解析(Genomic sequencing in HBP malignancies) 日本消化器外科学会雑誌. 2019.11; 52 (Suppl.2): 306. ( 医中誌 )

  4. Peled N., Okuma H., Rotem O., Dudnik E., Ikeda S., Stemmer S. M., Olsen S.: Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP) ANNALS OF ONCOLOGY. 2019.11; 30

  5. Osumi Hiroki, Shinozaki Eiji, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Takahari Daisuke, Ooki Akira, Suzuki Takeshi, Ota Yumiko, Nakayama Izuma, Chin Keisho, Miki Yoshio, Yamaguchi Kensei: Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer INTERNATIONAL JOURNAL OF CANCER. 2019.11; 145 (9): 2488-2495. ( PubMed , DOI )

  6. Takahashi K., Kato S., Bamel K., Ikeda S., Plaxe S., Parker B., Kurzrock R.: EXCEPTIONAL RESPONSE WITH COMBINED ANTI-HORMONE AND MEK INHIBITOR THERAPY IN A PATIENT WITH HORMONE RECEPTOR-POSITIVE OVARIAN CANCER AND ISOLATED KRAS ALTERATION. IMPLICATIONS FOR A PRECISION MEDICINE STRATEGY INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2019.11; 29 A524. ( DOI )

  7. Oshima N., Takahashi K., Nakamura R., Yoshino Y., Wakana K., Ikeda S., Miyasaka N.: CANCER GENOMIC AND PERSONALIZED MEDICINE FOR GYNECOLOGIC TUMORS IN OUR HOSPITAL INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2019.11; 29 A416. ( DOI )

  8. Kozuki R., Shinozaki E., Osumi H., Wakatuki T., Suenaga M., Ogura M., Suzuki T., Nakayama I., Takahari D., Chin K., Nagasaki T., Konishi T., Nagayama S., Fukunaga Y., Ueno M., Yamaguchi K.: A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer ANNALS OF ONCOLOGY. 2019.11; 30

  9. Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E, Homma S, Takahashi K, Akamatsu H, Ikeda S, Inase N, Iwasawa T, Ohe Y, Ohta H, Onishi H, Okamoto I, Ogawa K, Kasahara K, Karata H, Kishimoto T, Kitamura Y, Gemma A, Kenmotsu H, Sakashita H, Sakamoto S, Sekine K, Takiguchi Y, Tada Y, Toyooka S, Nakayama Y, Nishioka Y, Hagiwara K, Hanibuchi M, Fukuoka J, Minegishi Y, Yanagihara T, Yamamoto N, Yamamoto H, Gaga M, Fong KM, Powell CA, Kiura K, DLD/TO Assemblies of JRS: Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respiratory investigation. 2019.11; 57 (6): 512-533. ( PubMed , DOI )

  10. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. 2019.11; 20 (11): 1506-1517. ( PubMed , DOI )

  11. Kitaoka Y, Watanabe D, Nonaka Y, Yagishita K, Kano Y, Hoshino D: Effects of clenbuterol administration on mitochondrial morphology and its regulatory proteins in rat skeletal muscle. Physiological reports. 2019.10; 7 (19): e14266. ( PubMed , DOI )

  12. 新規臨床試験最新情報 食道がんに対するニボルマブの開発状況について 2019.10; 57回 SSY14-4. ( 医中誌 )

  13. 武藤 学, 金井 雅史, 鶴山 竜昭, 松本 繁巳, 豊岡 伸一, 秋田 弘俊, 松原 久裕, 西原 広史, 末岡 榮三朗, 池田 貞勝: バイオバンキングが切り拓く新しいがん研究　わが国におけるクリニカルバイオバンクネットワークの構築(Innovative cancer research based on biobanking　Clinical biobank network in Japan) 日本癌学会総会記事. 2019.09; 78回 S11-4. ( 医中誌 )

  14. Konishi Tsuyoshi, Shinozaki Eiji, Murofushi Keiko, Taguchi Senzo, Fukunaga Yosuke, Nagayama Satoshi, Fujimoto Yoshiya, Akiyoshi Takashi, Nagasaki Toshiya, Suenaga Mitsukuni, Chino Akiko, Kawachi Hiroshi, Yamamoto Noriko, Ishikawa Yuichi, Oguchi Masahiko, Ishizuka Naoki, Ueno Masashi, Yamaguchi Kensei: Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer ANNALS OF SURGICAL ONCOLOGY. 2019.08; 26 (8): 2507-2513. ( PubMed , DOI )

  15. Claire M Robinson, Betty P K Poon, Yoshihito Kano, Fred G Pluthero, Walter H A Kahr, Michael Ohh: A hypoxia-inducible HIF1-GAL3ST1-sulfatide axis enhances ccRCC immune evasion via increased tumor cell-platelet binding. Mol Cancer Res. 2019.08; 17 (11): 2306-2317. ( PubMed , DOI )

  16. Suzuki Takeshi, Shinozaki Eiji, Osumi Hiroki, Nakayama Izuma, Ota Yumiko, Ichimura Takashi, Ogura Mariko, Wakatsuki Takeru, Ooki Akira, Takahari Daisuke, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei: Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2019.08; 84 (2): 307-313. ( PubMed , DOI )

  17. Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan BR, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura MI, Carmagnani Pestana R, Qiao W, Xiao L, Morris J, Amin HM, Hassam MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills Shaw KR, George B, Haque A, Raghav K, Wolf RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R: Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019.07; 25 (20): 6107-6118. ( PubMed , DOI )

  18. Exposure-toxicity analysis of unbound regorafenib and its active metabolites by dose escalation strategy with low starting dose in patients with colorectal cancer 2019.07; 79 (13): ( DOI )

  19. Suenaga Mitsukuni, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Schirripa Marta, Soni Shivani, Barzi Afsaneh, Yamaguchi Toshiharu, Lenz Heinz-Josef: Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients INTERNATIONAL JOURNAL OF CANCER. 2019.05; 144 (10): 2567-2577. ( PubMed , DOI )

  20. Yagi Shusuke, Wakatsuki Takeru, Yamamoto Noriko, Chin Keisho, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Nakayama Izuma, Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Fujisaki Junko, Ishikawa Yuichi, Yamaguchi Kensei, Namikawa Ken, Horiuchi Yusuke: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer GASTRIC CANCER. 2019.05; 22 (3): 518-525. ( PubMed , DOI )

  21. Yagi Shusuke, Wakatsuki Takeru, Yamamoto Noriko, Chin Keisho, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Nakayama Izuma, Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Fujisaki Junko, Ishikawa Yuichi, Yamaguchi Kensei, Namikawa Ken, Horiuchi Yusuke: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer (vol 22, pg 518, 2019) GASTRIC CANCER. 2019.05; 22 (3): 526. ( PubMed , DOI )

  22. Kumaki Yuichi, Ikeda Sadakatsu, Rich Thereasa A., Zhao Jing, Yoshino Takayuki, Cho Byoung Chul, Peled Nir, Han Ji-Youn, Shiotsu Yukimasa, Franovic Aleksandra, Raymond Victoria M., Kurzrock Razelle, Lanman Richard B., Lee Jeeyun, Mok Tony S. K.: Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types. JOURNAL OF CLINICAL ONCOLOGY. 2019.05; 37 (15):

  23. Yuichi Kumaki, Sadakatsu Ikeda, Thereasa A. Rich, Jing Zhao, Takayuki Yoshino, Byoung Chul Cho, Nir Peled, Ji-Youn Han, Yukimasa Shiotsu, Aleksandra Franovic, Victoria M. Raymond, Razelle Kurzrock, Richard B. Lanman, Jeeyun Lee, Tony S. K. Mok: Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types. Journal of Clinical Oncology. 2019.05; 37 (15): 3046. ( DOI )

  24. Yagi Shusuke, Wakatsuki Takeru, Yamamoto Noriko, Chin Keisho, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Nakayama Izuma, Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Fujisaki Junko, Ishikawa Yuichi, Yamaguchi Kensei, Namikawa Ken, Horiuchi Yusuke: HER2陽性進行胃癌患者の内視鏡生検検体を用いて評価した、トラスツズマブの有効性に関する腫瘍内HER2不均一性の臨床的意義(Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer) Gastric Cancer. 2019.05; 22 (3): 518-525. ( 医中誌 )

  25. Berger Martin D., Cao Shu, Zlobec Inti, Miyamoto Yuji, Suenaga Mitsukuni, Hanna Diana L., Soni Shivani, Puccini Alberto, Tokunaga Ryuma, Naseem Madiha, Battaglin Francesca, Zhang Wu, Lugli Alessandro, Lenz Heinz-Josef: Association of genetic variations within the T-cell costimulatory LIGHT gene with outcome in stage II and III colon cancer. JOURNAL OF CLINICAL ONCOLOGY. 2019.05; 37 (15):

  26. Small intestinal perforation due to a huge gastrointestinal stromal tumor in a kidney transplant recipient: a case report and literature review. 2019.04; 20 (1): 120. ( PubMed , DOI )

  27. Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima T, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsuji A, Fujii H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen L, Kang Y, Boku N: A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2) Gastric Cancer. 2019.03; 22 (2): 344-354. ( PubMed , DOI )

  28. Kato Ken, Satoh Taroh, Muro Kei, Yoshikawa Takaki, Tamura Takao, Hamamoto Yasuo, Chin Keisho, Minashi Keiko, Tsuda Masahiro, Yamaguchi Kensei, Machida Nozomu, Esaki Taito, Goto Masahiro, Komatsu Yoshito, Eguchi Nakajima Takako, Sugimoto Naotoshi, Yoshida Kazuhiro, Oki Eiji, Nishina Tomohiro, Tsuji Akihito, Fujii Hirofumi, Kunieda Kenji, Saitoh Soh, Omuro Yasushi, Azuma Mizutomo, Iwamoto Yasuo, Taku Keisei, Fushida Sachio, Chen Li-Tzong, Kang Yoon-Koo, Boku Narikazu: 2種類以上の化学療法レジメンに対して不応ないし不耐であった進行胃癌または胃食道接合部癌患者に対するニボルマブの第3相二重盲検プラセボ対照無作為化試験における日本人患者のサブ解析(ONO-4538-12,ATTRACTION-2)(A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12, ATTRACTION-2)) Gastric Cancer. 2019.03; 22 (2): 344-354. ( 医中誌 )

  29. Izawa Yukiko, Ichimura Takashi, Chin Keisho, Shinozaki Eiji, Takahari Daisuke, Suenaga Mitsukuni, Ogura Mariko, Wakatsuki Takeru, Osumi Hiroki, Nakayama Izuma, Mine Shinji, Hiki Naoki, Ishizuka Naoki, Yamaguchi Kensei: Feasibility study of diet counseling (DC) with oral nutritional supplements (ONS) for advanced esophageal and gastric cancer during chemotherapy (CT) or chemoradiotherapy (CRT): First report of ONS compliance from a prospective randomized controlled clinical study (DiCON study). JOURNAL OF CLINICAL ONCOLOGY. 2019.02; 37 (4):

  30. Suenaga Mitsukuni, Cao Shu, Zhang Wu, Matsusaka Satoshi, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Schirripa Marta, Barzi Afsaneh, Ueno Masashi, Lenz Heinz-Josef: Role of enterocyte-specific gene polymorphisms in adjuvant treatment for stage III colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2019.02; 37 (4):

  31. Nakayama Izuma, Takahari Daisuke, Chin Keisho, Ogura Mariko, Wakatsuki Takeru, Osumi Hiroki, Suzuki Takeshi, Ota Yumiko, Ichimura Takashi, Oki Akira, Suenaga Mitsukuni, Shinozaki Eiji, Yamaguchi Kensei: EGJ癌に対する全身化学療法(Systemic chemotherapy for the EGJ tumors) 日本胃癌学会総会記事. 2019.02; 91回 283. ( 医中誌 )

  32. Berger Martin D., Stintzing Sebastian, Heinemann Volker, Cao Shu, Miyamoto Yuji, Suenaga Mitsukuni, Hanna Diana L., Soni Shivani, Puccini Alberto, Tokunaga Ryuma, Naseem Madiha, Battaglin Francesca, Zhang Wu, Cremolini Chiara, Falcone Alfredo, Loupakis Fotios, Lenz Heinz-Josef: Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE JOURNAL OF CLINICAL ONCOLOGY. 2019.02; 37 (4):

  33. Suenaga Mitsukuni, Stintzing Sebastian, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Schirripa Marta, Soni Shivani, Barzi Afsaneh, Heinemann Volker, Lenz Heinz-Josef: Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial EUROPEAN JOURNAL OF CANCER. 2019.01; 107 100-114. ( PubMed , DOI )

  34. Early administration of systemic chemotherapy should be considered for scirrhous gastric cancer: A case report. 2019.01; 10 (1): 113-117. ( PubMed , DOI )

  35. Yoshihito Kano, Teklab Gebregiworgis, Christopher B Marshall, Nikolina Radulovich, Betty P K Poon, Jonathan St-Germain, Jonathan D Cook, Ivette Valencia-Sama, Benjamin M M Grant, Silvia Gabriela Herrera, Jinmin Miao, Brian Raught, Meredith S Irwin, Jeffrey E Lee, Jen Jen Yeh, Zhong-Yin Zhang, Ming-Sound Tsao, Mitsuhiko Ikura, Michael Ohh: Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. Nature communications. 2019.01; 10 (1): 224. ( PubMed , DOI )

  36. Kawakami Kazuyoshi, Wakatsuki Takeru, Soejima Azusa, Kobayashi Kazuo, Yokokawa Takashi, Aoyama Takeshi, Suzuki Kenichi, Suenaga Mitsukuni, Yamaguchi Kensei, Inoue Ayaka, Machida Yoshiaki, Hama Toshihiro: Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer PATIENT PREFERENCE AND ADHERENCE. 2019; 13 1745-1750. ( PubMed , DOI )

  37. Kitagawa Yusuke, Osumi Hiroki, Shinozaki Eiji, Ota Yumiko, Nakayama Izuma, Suzuki Takeshi, Wakatsuki Takeru, Ichimura Takashi, Ogura Mariko, Ooki Akira, Takahari Daisuke, Suenaga Mitsukuni, Chin Keisho, Yamaguchi Kensei: Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study CANCER MANAGEMENT AND RESEARCH. 2019; 11 5757-5764. ( PubMed , DOI )

  38. Nonomiya Yuma, Yokokawa Takashi, Kawakami Kazuyoshi, Kobayashi Kazuo, Aoyama Takeshi, Takiguchi Tomomi, Sugisaki Takahito, Suzuki Kenichi, Suenaga Mitsukuni, Wakatsuki Takeru, Yamaguchi Kensei, Sugimoto Yoshikazu, Hama Toshihiro: Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands ONCOLOGY RESEARCH. 2019; 27 (5): 551-556. ( PubMed , DOI )

  39. Satoh T, Kang Y, Chao Y, Ryu M, Kato K, Cheol Chung H, Chen J, Muro K, Ki Kang W, Yeh K, Yoshikawa T, Oh S, Bai L, Tamura T, Lee K, Hamamoto Y, Kim J, Chin K, Oh D, Minashi K, Cho J, Tsuda M, Tanimoto M, Chen L, Boku N: Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer Gastric Cancer. 2019; 23 (1): 143-153. ( PubMed , DOI )

  40. Kobayashi Kazuo, Kawakami Kazuyoshi, Yokokawa Takashi, Aoyama Takeshi, Suzuki Kenichi, Wakatsuki Takeru, Suenaga Mitsukuni, Sato Hitoshi, Sugiyama Erika, Yamaguchi Kensei, Hama Toshihiro: Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer ONCOLOGY. 2019; 96 (4): 200-206. ( PubMed , DOI )

  1. Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials. 2018.12; 17 (4): e719-e732. ( PubMed , DOI )

  2. Wakatsuki Takeru, Yamamoto Noriko, Sano Takeshi, Chin Keisho, Kawachi Hiroshi, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Nakayama Izuma, Osumi Hiroki, Matsushima Tomohiro, Suenaga Mitsukuni, Shinozaki Eiji, Hiki Naoki, Ishikawa Yuichi, Yamaguchi Kensei: Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer JOURNAL OF GASTROENTEROLOGY. 2018.11; 53 (11): 1186-1195. ( PubMed , DOI )

  3. Kozuki R., Shinozaki E., Osumi H., Wakatsuki T., Suenaga M., Ichimura T., Ogura M., Suzuki T., Ota Y., Nakayama I., Takahari D., Chin K., Nagasaki T., Akiyoshi T., Konishi T., Fujimoto Y., Nagayama S., Fukunaga Y., Ueno M., Yamaguchi K.: A retrospective analysis of the association between perioperative carcinoembryonic antigen level and prognosis in stage III colorectal cancer ANNALS OF ONCOLOGY. 2018.11; 29

  4. Ikeda S., Kumaki Y., Rich T. A., Shiotsu Y., Franovic A., Raymond V. M., Kurzrock R., Lanman R. B., Lee J., Mok T. S. K.: Circulating cell-free DNA molecular profiling among east Asian patients reveals activating MET alterations are common in diverse advanced cancer types ANNALS OF ONCOLOGY. 2018.11; 29 116.

  5. Wakatsuki Takeru, Yamamoto Noriko, Sano Takeshi, Chin Keisho, Kawachi Hiroshi, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Nakayama Izuma, Osumi Hiroki, Matsushima Tomohiro, Suenaga Mitsukuni, Shinozaki Eiji, Hiki Naoki, Ishikawa Yuichi, Yamaguchi Kensei: HER2陽性胃癌患者の腫瘍内HER2 heterogeneityがトラスツズマブの有効性に及ぼす臨床的影響(Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer) Journal of Gastroenterology. 2018.11; 53 (11): 1186-1195. ( 医中誌 )

  6. Minami Kazuhiro, Iwasaki Eisuke, Itoi Takao, Fukuhara Seiichiro, Horibe Masayasu, Seino Takashi, Kawasaki Shintaro, Katayama Tadashi, Takimoto Yoichi, Tamagawa Hiroki, Machida Yujiro, Hamamoto Yasuo, Ogata Haruhiko, Kanai Takanori: Successful EUS-guided antegrade stenting for malignant severe biliary obstruction combined with a newly developed plastic stent ENDOSCOPY INTERNATIONAL OPEN. 2018.11; 6 (11): E1336-E1339. ( PubMed , DOI )

  7. Suenaga M., Wakatsuki T., Ogura M., Ichimura T., Shinozaki E., Nakayama I., Osumi H., Ota Y., Chin K., Mashima T., Seimiya H., Takahari D., Yamaguchi K.: A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study ANNALS OF ONCOLOGY. 2018.10; 29 158.

  8. Osumi H., Shinozaki E., Zembutsu H., Takeda Y., Wakatsuki T., Ichimura T., Ota Y., Nakayama I., Ogura M., Suenaga M., Takahari D., Chin K., Saiura A., Takahashi S., Noda T., Yamaguchi K.: Clinical relevance of circulating tumor DNA using amplicon-based deep sequencing panel in colorectal cancer patients with liver metastasis ANNALS OF ONCOLOGY. 2018.10; 29 181.

  9. Takahashi R., Wakatsuki T., Yamamoto N., Taguchi S., Shinozaki E., Osumi H., Ogura M., Ichimura T., Takahari D., Suenaga M., Chin K., Oguchi M., Ueno M., Yamaguchi K.: p16 and PD-L1 expression in locoregional squamous cell carcinoma of the anal canal: A single center retrospective analysis in Japan ANNALS OF ONCOLOGY. 2018.10; 29

  10. Machiels J-P., Licitra L., Tao Y. G., Yen C-J., Rischin D., Waldron J. N., Burtness B. A., Gregoire V., Agarwala S. S., Yorio J., Delord J-P., Aksoy S., Ikeda S., Hong R-L., Ge J. Y., Brown H., Bidadi B., Siu L. L.: KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC) ANNALS OF ONCOLOGY. 2018.10; 29 398.

  11. Berger M. D., Stintzing S., Heinemann V., Cao S., Yang D., Miyamoto Y., Suenaga M., Hanna D. L., Soni S., Puccini A., Tokunaga R., Naseem M., Battaglin F., McSkane M., Zhang W., Lenz H-J.: Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3 ANNALS OF ONCOLOGY. 2018.10; 29

  12. Ikeda Sadakatsu, Elkin Sheryl K, Tomson Brett N, Carter Jennifer L, Kurzrock Razelle: Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. Cancer Biol Ther. 2018.10; 1-8. ( PubMed , DOI )

  13. Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Cremolini Chiara, Lonardi Sara, Bergamo Francesca, Ning Yang, Yamamoto Noriko, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Gopez Roel Jr., Barzi Afsaneh, Yamaguchi Toshiharu, Stintzing Sebastian, Heinemann Volker, Loupakis Fotios, Falcone Alfredo, Lenz Heinz-Josef: Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer PHARMACOGENOMICS JOURNAL. 2018.09; 18 (5): 623-632. ( PubMed , DOI )

  14. Takahashi K., Oshima N., Nakamura R., Wakana K., Miyake S., Miyasaka N., Ikeda S.: OVARIAN MIXED BRENNER-MUCINOUS BORDERLINE TUMOR WITH BRAF V600E MUTATION INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2018.09; 28 848.

  15. Takeuchi M, Suda K, Hamamoto Y, Kato M, Mayanagi S, Yoshida K, Fukuda K, Nakamura R, Wada N, Kawakubo H, Takeuchi H, Yahagi N, Kitagawa Y: Technical feasibility and oncologic safety of diagnostic endoscopic resection for superficial esophageal cancer Gastrointestinal Endoscopy. 2018.09; 88 (3): 456-465. ( PubMed , DOI )

  16. Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kensei: Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer CANCER SCIENCE. 2018.08; 109 (8): 2567-2575. ( PubMed , DOI )

  17. Osumi Hiroki, Shinozaki Eiji, Zembutsu Hitoshi, Takeda Yoshinori, Wakatsuki Takeru, Ichimura Takashi, Ota Yumiko, Nakayama Izuma, Ogura Mariko, Suenaga Mitsukuni, Takahari Daisuke, Chin Keisho, Saiura Akio, Yamaguchi Kensei: Clinical relevance of circulating cell-free DNA using amplicon-based next-generation sequencing panel in colorectal cancer patients with liver metastasis CANCER RESEARCH. 2018.07; 78 (13): ( DOI )

  18. Siu Lillian L., Licitra Lisa, Tao Yun Gan, Yen Chia-Jui, Rischin Danny, Waldron John, Burtness Barbara, Gregoire Vincent, Agarwala Sanjiv, Yorio Jeffrey, DeLord Jean-Pierre, Aksoy Sercan, Ikeda Sadakatsu, Hong Ruey-Long, Ge Joy Yang, Brown Holly, Bidadi Behzad, Machiels Jean-Pascal: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma CANCER RESEARCH. 2018.07; 78 (13): ( DOI )

  19. Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Cremolini Chiara, Antoniotti Carlotta, Borelli Beatrice, Mashima Tetsuo, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Gopez Roel Jr., Barzi Afsaneh, Lonardi Sara, Yamaguchi Toshiharu, Falcone Alfredo, Loupakis Fotios, Lenz Heinz-Josef: Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib CLINICAL COLORECTAL CANCER. 2018.06; 17 (2): E395-E414. ( PubMed , DOI )

  20. Osumi H., Takahari D., Chin K., Ogura M., Ichimura T., Wakatsuki T., Nakayama I., Ota Y., Suenaga M., Shinozaki E., Yamaguchi K.: First-line mFOLFOX6 for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake ANNALS OF ONCOLOGY. 2018.06; 29

  21. Osumi H., Shinozaki E., Chin K., Takahari D., Ogura M., Ichimura T., Wakatsuki T., Ota Y., Nakayama I., Suenaga M., Yamaguchi K.: Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract ANNALS OF ONCOLOGY. 2018.06; 29 29.

  22. Osumi H., Shinozaki E., Wakatsuki T., Suenaga M., Ichimura T., Ogura M., Ota Y., Nakayama I., Takahari D., Chin K., Yamaguchi K.: Is the PEG-G-CSF useful as the prevention for the severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab? ANNALS OF ONCOLOGY. 2018.06; 29

  23. Ikeda Sadakatsu, Schwaederle Maria, Mohindra Mandakini, Fontes Jardim Denis L, Kurzrock Razelle: MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis. J Hematol Oncol. 2018.06; 11 (1): 76. ( PubMed , DOI )

  24. Ikeda Sadakatsu, Schwaederle Maria, Mohindra Mandakini, Jardim Denis L. Fontes, Kurzrock Razelle: MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis JOURNAL OF HEMATOLOGY & ONCOLOGY. 2018.06; 11 76. ( DOI )

  25. Suenaga Mitsukuni, Schirripa Marta, Loupakis Fotios, Cao Shu, Zhang Wu, Cremolini Chiara, Lonardi Sara, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Soni Shivani, Barzi Afsaneh, Yamaguchi Toshiharu, Falcone Alfredo, Lenz Heinz-Josef: Clinical significance of enterocyte-specific gene polymorphisms as candidate marker of oxaliplatin-based treatment for metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2018.05; 36 (15):

  26. Machiels Jean-Pascal H., Licitra Lisa F., Tao Yungan, Yen Chia-Jui, Rischin Danny, Waldron John, Burtness Barbara, Gregoire Vincent, Agarwala Sanjiv S., Yorio Jeffrey, Delord Jean-Pierre, Aksoy Sercan, Ikeda Sadakatsu, Hong Ruey-Long, Ge Joy Yang, Brown Holly M., Bidadi Behzad, Siu Lillian L.: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study. JOURNAL OF CLINICAL ONCOLOGY. 2018.05; 36 (15):

  27. Ushida Y, Shinozaki E, Chin K, Suenaga M, Takahari D, Ozaka M, Ogura M, Ichimura T, Wakatsuki T, Yamaguchi K: Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab. Case reports in oncology. 2018.05; 11 (2): 601-608. ( PubMed , DOI )

  28. Ikeda Sadakatsu, Lim Jordan S., Kurzrock Razelle: Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics MOLECULAR CANCER THERAPEUTICS. 2018.05; 17 (5): 1114-1122. ( PubMed , DOI )

  29. Ikeda Sadakatsu, Tsigelny Igor F., Skjevik Age A., Kono Yuko, Mendler Michel, Kuo Alexander, Sicklick Jason K., Heestand Gregory, Banks Kimberly C., Talasaz AmirAli, Lanman Richard B., Lippman Scott, Kurzrock Razelle: Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma ONCOLOGIST. 2018.05; 23 (5): 586-593. ( PubMed , DOI )

  30. Shinozaki Eiji, Tanabe Kazuhiro, Akiyoshi Takashi, Tsuchida Tomohiro, Miyazaki Yuko, Kojima Nozomi, Igarashi Masahiro, Ueno Masashi, Suenaga Mitsukuni, Mizunuma Nobuyuki, Yamaguchi Kensei, Nakayama Konosuke, Iijima Sadayo, Yamaguchi Toshiharu: Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker BMC CANCER. 2018.04; 18 (1): 406. ( PubMed , DOI )

  31. Suenaga Mitsukuni, Akiyoshi Takashi, Shinozaki Eiji, Fujimoto Yoshiya, Matsusaka Satoshi, Konishi Tsuyoshi, Nagayama Satoshi, Fukunaga Yosuke, Kawakami Kazuyoshi, Yokokawa Takashi, Sugisaki Takahito, Ueno Masashi, Yamaguchi Toshiharu: A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer -ACTOR Study- ANTICANCER RESEARCH. 2018.03; 38 (3): 1741-1747. ( PubMed , DOI )

  32. Fukuda N, Takahari D, Wakatsuki T, Osumi H, Nakayama I, Matsushima T, Ichimura T, Ogura M, Ozaka M, Suenaga M, Shinozaki E, Chin K, Yamaguchi K: Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel. Oncotarget. 2018.03; 9 (20): 15219-15227. ( PubMed , DOI )

  33. Schirripa Marta, Zhang Wu, Yang Dongyun, Cao Shu, Okazaki Satoshi, Loupakis Fotios, Berger Martin D., Ning Yan, Miyamoto Yuji, Suenaga Mitsukuni, Alberti Giulia, West Jordan D., Lonardi Sara, Khoukaz Taline, Bergamo Francesca, Battaglin Francesca, Antoniotti Carlotta, Falcone Alfredo, Stintzing Sebastian, Heinemann Volker, Lenz Heinz-Josef: NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients PLOS ONE. 2018.03; 13 (3): e0193640. ( PubMed , DOI )

  34. Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis 2018.03; 1-10. ( DOI )

  35. Takahari Daisuke, Wakatsuki Takeru, Mashima Tetsuo, Chin Keisho, Ichimura Takashi, Ogura Mariko, Matsushima Tomohiro, Osumi Hiroki, Nakayama Izuma, Ota Yumiko, Shinozaki Eiji, Suenaga Mitsukuni, Kawata Naomi, Horiike Yuki, Seimiya Hiroyuki, Fujita Naoya, Yamaguchi Kensei: Plasma biomarker analysis of ramucirumab in Japanese patients with advanced gastric cancer. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

  36. Nagaoka Tomoyuki, Shinozaki Eiji, Watanabe Ryosuke, Ueno Eiko, Ota Yumiko, Osumi Hiroki, Nakayama Izuma, Wakatsuki Takeru, Ogura Mariko, Suenaga Mitsukuni, Ichimura Takashi, Takahari Daisuke, Chin Keisho, Yamaguchi Kensei: Clinical significance of morphologic response and tumor shrinkage as predictive factors of Capeox plus bevacizumab in 1st line treatment of metastatic colorectal cancer JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

  37. Ota Yumiko, Wakatsuki Takeru, Mashima Tetsuo, Takahari Daisuke, Chin Keisho, Ichimura Takashi, Ogura Mariko, Matsushima Tomohiro, Osumi Hiroki, Nakayama Izuma, Shinozaki Eiji, Suenaga Mitsukuni, Kawata Naomi, Horiike Yuki, Seimiya Hiroyuki, Fujita Naoya, Yamaguchi Kensei: Plasma biomarker dynamics following ramucirumab treatment and survival analysis after ramucirumab treatment failure in patients with advanced gastric cancer. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

  38. Yagi Shusuke, Shinozaki Eiji, Chin Keisho, Suenaga Mitsukuni, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Wakatsuki Takeru, Ozaka Masato, Nakayama Izuma, MATSUSHIMA T. O. M. O. H. I. R. O., Osumi Hiroki, Yamaguchi Kensei: Clinical impact of diverting ileostomy on the dose intensity of adjuvant chemotherapy for colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

  39. Ushida Yuta, Shinozaki Eiji, Chin Keisho, Suenaga Mitsukuni, Takahari Daisuke, Ozaka Masato, Ogura Mariko, Ichimura Takashi, Wakatsuki Takeru, MATSUSHIMA T. O. M. O. H. I. R. O., Osumi Hiroki, Ota Yumiko, Yamaguchi Kensei: Clinical outcomes of anti-EGFR antibody treatment for right-sided colon cancer patients without RAS, BRAF, and PIK3CA mutations in the later line JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

  40. Takahashi Ryo, Wakatsuki Takeru, Shinozaki Eiji, Taguchi Senzo, Fujimoto Yoshiya, Osumi Hiroki, Ota Yumiko, MATSUSHIMA T. O. M. O. H. I. R. O., Ogura Mariko, Ichimura Takashi, Takahari Daisuke, Suenaga Mitsukuni, Chin Keisho, Oguchi Masahiko, Ueno Masashi, Yamaguchi Kensei: Chemoradiation for the treatment of locoregional squamous cell carcinoma of the anal canal: A single center retrospective analysis in Japan. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

  41. Berger Martin D., Stintzing Sebastian, Heinemann Volker, Cao Shu, Yang Dongyun, Sunakawa Yu, Matsusaka Satoshi, Ning Yan, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, Hanna Diana L., Soni Shivani, Puccini Alberto, Zhang Wu, Cremolini Chiara, Falcone Alfredo, Loupakis Fotios, Lenz Heinz-Josef: A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab CLINICAL CANCER RESEARCH. 2018.02; 24 (4): 784-793. ( PubMed , DOI )

  42. Yokota Tomoya, Yasuda Takushi, Kato Hiroyuki, Nozaki Isao, Sato Hiroshi, Miyata Yoshinori, Kuroki Yoshifumi, Kato Ken, Hamamoto Yasuo, Tsubosa Yasuhiro, Ogawa Hirofumi, Ito Yoshinori, Kitagawa Yuko: 局所切除不能胸部食道癌に対する医師間でのT分類臨床診断の一致(Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer) International Journal of Clinical Oncology. 2018.02; 23 (1): 73-80. ( 医中誌 )

  43. Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Bergamo Francesca, Zagonel Vittorina, Rossini Daniele, Borelli Beatrice, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Gopez Roel, Barzi Afsaneh, Yamaguchi Toshiharu, Loupakis Fotios, Lenz Heinz-Josef: Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

  44. Suenaga Mitsukuni, Mashima Tetsuo, Kawata Naomi, Dan Shingo, Wakatsuki Takeru, Shinozaki Eiji, Ichimura Takashi, Ogura Mariko, Takahari Daisuke, Osumi Hiroki, Ota Yumiko, Chin Keisho, Seimiya Hiroyuki, Yamaguchi Kensei, Yamaguchi Toshiharu: Identification of biomarkers for TAS-102 efficacy in metastatic colorectal cancer patients based on preclinical analysis and clinical validation. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

  45. Berger Martin D., Zlobec Inti, Yang Dongyun, Cao Shu, Sunakawa Yu, Matsusaka Satoshi, Koelzer Viktor H., Inderbitzin Daniel, Ning Yan, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, Soni Shivani, Puccini Alberto, Tokunaga Ryuma, Naseem Madiha, Zhang Wu, Lugli Alessandro, Lenz Heinz-Josef: Association of genetic variations within the PD-L2 immune checkpoint gene with outcome in stage II and III colon cancer. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

  46. Oguri Tomoyo, Takahari Daisuke, Ota Yumiko, Osumi Hiroki, Nakayama Izuma, Wakatsuki Takeru, Ogura Mariko, Ichimura Takashi, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisho, Yamaguchi Kensei: The clinical analysis of thromboembolism in esophagogastric cancer in Japan: A single institute experience. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

  47. Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Cremolini Chiara, Murgioni Sabina, Lonardi Sara, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Gopez Roel, Barzi Afsaneh, Loupakis Fotios, Falcone Alfredo, Lenz Heinz-Josef: Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes to predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab in TRIBE trial. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (4):

  48. Kato Shumei, Kurasaki Kellie, Ikeda Sadakatsu, Kurzrock Razelle: Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach ONCOLOGIST. 2018.02; 23 (2): 171-178. ( PubMed , DOI )

  49. Ning Y., Zhang W., Hanna D. L., Yang D., Okazaki S., Berger M. D., Miyamoto Y., Suenaga M., Schirripa M., El-Khoueiry A., Lenz H-J: Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients PHARMACOGENOMICS JOURNAL. 2018.01; 18 (1): 29-34. ( DOI )

  50. Riviere Paul, Fanta Paul T., Ikeda Sadakatsu, Baumgartner Joel, Heestand Gregory M., Kurzrock Razelle: The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA MOLECULAR CANCER THERAPEUTICS. 2018.01; 17 (1): 297-305. ( PubMed , DOI )

  51. Osumi Hiroki, Takahari Daisuke, Chin Keisho, Ogura Mariko, Ichimura Takashi, Wakatsuki Takeru, Suzuki Takeshi, Ota Yumiko, Nakayama Izuma, Ooki Akira, Suenaga Mitsukuni, Shinozaki Eiji, Yamaguchi Kensei: Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake ONCOTARGETS AND THERAPY. 2018; 11 8301-8307. ( PubMed , DOI )

  52. Jun Hashimoto, Ken Kato, Yoshinori Ito, Takashi Kojima, Tetsuo Akimoto, Hiroyuki Daiko, Yasuo Hamamoto, Hisayuki Matsushita, Susumu Katano, Hiroki Hara, Yoichi Tanaka, Yoshihiro Saito, Kengo Nagashima, Hiroyasu Igaki: Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma. Int J Clin Oncol.. 2018;

  53. Matsuda T, Takeuchi H, Sakurai T, Mayanagi S, Booka E, Fujita T, Higuchi H, Taguchi J, Hamamoto Y, Takaishi H, Kawakubo H, Okamoto M, Sunamura M, Kawakami Y, Kitagawa Y: Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. Oncol Lett.. 2018; 16 (1): 1348-1356. ( PubMed , DOI )

  54. Yasuo Hamamoto: Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors. Future Oncol.. 2018;

  55. Yasuo Hamamoto: Need for prospective collection of experience and repeated samples in esophageal squamous cell carcinoma. Journal of Thoracic Disease. 2018;

  56. Komatsu H, Yagasaki K, Hamamoto Y, Takebayashi T: Falls and Physical Inactivity in Patients with Gastrointestinal Cancer and Hand–Foot Syndrome. Asia Pac J Oncol Nurs.. 2018;

  57. Kato H, Ono H, Hamamoto Y, Ishikawa H: Interaction between Medical Treatment and Minimally Invasive Surgical Treatment for the Malignancies of the Digestive Tract. Digestion. 2018;

  58. Takeuchi M, Suda K, Hamamoto Y, Kato M, Mayanagi S, Yoshida K, Fukuda K, Nakamura R, Wada N, Kawakubo H, Takeuchi H, Yahagi N, Kitagawa Y: Technical feasibility and oncological safety of diagnostic endoscopic resection for superficial esophageal cancer. Gastrointest Endosc.. 2018; 88 (3): 456-465. ( PubMed , DOI )

  59. Yasuo Hamamoto, Naoki Sakakibara, Fumio Nagashima, Yuko Kitagawa, Takahiro Higashi: Treatment selection for esophageal cancer: evaluation from a nationwide database Esophagus. 2018; 15 (2): 109-114. ( PubMed , DOI )

  60. Nakayama Izuma, Chin Keisho, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Wakatsuki Takeru, Osumi Hiroki, Ota Yumiko, Suzuki Takeshi, Suenaga Mitsukuni, Shinozaki Eiji, Yamaguchi Kensei: Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer CANCER MANAGEMENT AND RESEARCH. 2018; 10 5283-5290. ( PubMed , DOI )

  61. Yagasaki K, Komatsu H, Soejima K, Naoki K, Kawada I, Yasuda H, Hamamoto Y: Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients. Asia Pac J Oncol Nurs.. 2018; 5 (2): 172-177. ( PubMed , DOI )

  62. Analysis of sensitivity and cell death pathways mediated by anti-cancer drugs using three-dimensional culture system 2018; 14 (1): 1-12. ( DOI )

  1. Nakayama Izuma, Chin Keisho, Matsushima Tomohiro, Takahari Daisuke, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Ozaka Masato, Wakatsuki Takeru, Ichimura Takashi, Hiroki Osumi, Yamaguchi Kensei: Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 2017.12; 22 (6): 1060-1068. ( PubMed , DOI )

  2. Machiels J-P., Yen C-J., Licitra L., Rischin D., Waldron J., Burtness B., Gregoire V., Tao Y. G., Yorio J., Aksoy S., Ikeda S., Hong R-L., Ge J. Y., Brown H., Bidadi B., Siu L.: Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) ANNALS OF ONCOLOGY. 2017.12; 28

  3. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial 2017.12; 390 (10111): 2461-2471. ( PubMed , DOI )

  4. Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Dadduzio Vincenzo, Salvatore Lisa, Borelli Beatrice, Pietrantonio Filippo, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Gopez Roel Jr., Barzi Afsaneh, Yamaguchi Toshiharu, Loupakis Fotios, Lenz Heinz-Josef: Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer EUROPEAN JOURNAL OF CANCER. 2017.11; 86 197-206. ( PubMed , DOI )

  5. Machiels Jean-Pascal, Yen Chia-Jui, Licitra Lisa, Rischin Danny, Waldron John, Burtness Barbara, Gregoire Vincent, Agarwala Sanjiv, Tao Yun Gan, Yorio Jeffrey, Aksoy Sercan, Ikeda Sadakatsu, Hong Ruey-Long, Ge Joy Yang, Brown Holly, Bidadi Behzad, Siu Lillian: Phase 3 study of Pembrolizumab plus Chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC): KEYNOTE-412 JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2017.11; 5

  6. Yen C-J., Machiels J-P., Licitra L., Rischin D., Waldron J., Burtness B., Gregoire V., Tao Y., Yorio J., Aksoy S., Ikeda S., Hong R-L., Ge J. Y., Brown H., Bidadi B., Siu L.: KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) ANNALS OF ONCOLOGY. 2017.11; 28

  7. Berger M. D., Stintzing S., Heinemann V., Yang D., Cao S., Sunakawa Y., Ning Y., Matsusaka S., Okazaki S., Miyamoto Y., Suenaga M., Schirripa M., Soni S., Zhang W., Falcone A., Loupakis F., Lenz H-J: Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials ANNALS OF ONCOLOGY. 2017.11; 28 (11): 2780-2785. ( DOI )

  8. Okazaki S, Schirripa M, Loupakis F, Cao S, Zhang W, Yang D, Ning Y, Berger MD, Miyamoto Y, Suenaga M, Iqubal S, Barzi A, Cremolini C, Falcone A, Battaglin F, Salvatore L, Borelli B, Helentjaris TG, Lenz HJ: Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Cancer. 2017.11; 123 (22): 4506-4514. ( PubMed , DOI )

  9. Hamamoto Yasuo, Nojima Masanori, Aoki Yu, Suzuki Takeshi, Kawasaki Kenta, Hirata Kenro, Sukawa Yasutaka, Kasuga Akira, Kawakubo Hirofumi, Takeuchi Hiroya, Murakami Koji, Takaishi Hiromasa, Kanai Takanori, Kitagawa Yuko: 局所進行食道扁平上皮癌に対する臨床診断の評価者間不均一性(Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma) Esophagus. 2017.10; 14 (4): 324-332. ( 医中誌 )

  10. Safety and efficacy of gemcitabine plus nab-paclitaxel therapy in elderly patients with advanced pancreatic cancer 2017.10; 28

  11. Schwaederle Maria, Chattopadhyay Ranajoy, Kato Shumei, Fanta Paul T., Banks Kimberly C., Choi In Sil, Piccioni David E., Ikeda Sadakatsu, Talasaz AmirAli, Lanman Richard B., Bazhenova Lyudmila, Kurzrock Razelle: Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing CANCER RESEARCH. 2017.10; 77 (19): 5419-5427. ( DOI )

  12. Curative resectability of gastrointestinal cancer identified from iron deficiency anemia 2017.10; 14 (4): 4301-4304. ( DOI )

  13. Okazaki Satoshi, Stintzing Sebastian, Sunakawa Yu, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Matsusaka Satoshi, Berger Martin D., Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, West Jordan D., Gopez Roel, Akihito Tsuji, Ichikawa Wataru, Heinemann Volker, DePaolo R. William, Lenz Heinz-Josef: Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer INTERNATIONAL JOURNAL OF CANCER. 2017.09; 141 (6): 1222-1230. ( PubMed , DOI )

  14. Schwaederle Maria C, Patel Sandip P, Husain Hatim, Ikeda Megumi, Lanman Richard B, Banks Kimberly C, Talasaz AmirAli, Bazhenova Lyudmila, Kurzrock Razelle: Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res. 2017.09; 23 (17): 5101-5111. ( PubMed , DOI )

  15. Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report 2017.09; 14 (3): 3697-3700. ( DOI )

  16. Cohen Philip R., Kato Shumei, Goodman Aaron M., Ikeda Sadakatsu, Kurzrock Razelle: Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2017.08; 18 (8): 1663. ( DOI )

  17. Khemlina Galina, Ikeda Sadakatsu, Kurzrock Razelle: The biology of Hepatocellular carcinoma: implications for genomic and immune therapies MOLECULAR CANCER. 2017.08; 16 149. ( PubMed , DOI )

  18. Schirripa Marta, Zhang Wu, Heinemann Volker, Cao Shu, Okazaki Satoshi, Yang Dongyun, Loupakis Fotios, Berger Martin D., Ning Yan, Miyamoto Yuji, Suenaga Mitsukuni, Gopez Roel F., West Jordan D., Hanna Diana, Barzi Afsaneh, Falcone Alfredo, Stintzing Sebastian, Lenz Heinz-Josef: Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial INTERNATIONAL JOURNAL OF CANCER. 2017.07; 141 (2): 383-392. ( PubMed , DOI )

  19. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer 2017.06; 143 (6): 1053-1059. ( DOI )

  20. Suenaga Mitsukuni, Cao Shu, Zhang Wu, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Schirripa Marta, Gopez Roel, Melendez Elizabeth, Soni Shivani, Barzi Afsaneh, Yamaguchi Toshiharu, Lenz Heinz-Josef: Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels to predict efficacy of bevacizumab in metastatic colorectal cancer patients receiving first-line chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

  21. Suenaga Mitsukuni, Cao Shu, Stintzing Sebastian, Zhang Wu, Yang Dongyun, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Schirripa Marta, Gopez Roel, Melendez Elizabeth, Soni Shivani, Barzi Afsaneh, Yamaguchi Toshiharu, Heinemann Volker, Lenz Heinz-Josef: Genetic polymorphisms of CCL5 and CCR5 to predict efficacy of cetuximab-based treatment in metastatic colorectal cancer patients depending on primary tumor location. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

  22. Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Wakatsuki Takeru, Nakayama Izuma, Matsushima Tomohiro, Ogura Mariko, Ichimura Takashi, Takahari Daisuke, Chin Keisho, Nagasaki Toshiya, Konishi Tsuyoshi, Akiyoshi Takashi, Fujimoto Yoshiya, Nagayama Satoshi, Fukunaga Yosuke, Ueno Masashi, Yamaguchi Kensei: Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer PLOS ONE. 2017.05; 12 (5): e0176745. ( PubMed , DOI )

  23. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial 2017.05; 18 (5): 631-639. ( DOI )

  24. Berger Martin D., Yamauchi Shinichi, Cao Shu, Hanna Diana L., Sunakawa Yu, Schirripa Marta, Matsusaka Satoshi, Yang Dongyun, Groshen Susan, Zhang Wu, Ning Yan, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, Lonardi Sara, Cremolini Chiara, Falcone Alfredo, Heinemann Volker, Loupakis Fotios, Stintzing Sebastian, Lenz Heinz-Josef: Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials EUROPEAN JOURNAL OF CANCER. 2017.05; 77 13-20. ( PubMed , DOI )

  25. Miyamoto Yuji, Stintzing Sebastian, Heinemann Volker, Zhang Wu, Cao Shu, Okazaki Satoshi, Berger Martin D., Suenaga Mitsukuni, Schirripa Marta, Soni Shivani, Matsusaka Satoshi, Ning Yan, Yang Dongyun, Gopez Roel, Melendez Elizabeth, Hanna Diana L., Barzi Afsaneh, Baba Hideo, Lenz Heinz-Josef: Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

  26. Miyamoto Yuji, Loupakis Fotios, Zhang Wu, Cao Shu, Okazaki Satoshi, Berger Martin D., Suenaga Mitsukuni, Schirripa Marta, Soni Shivani, Matsusaka Satoshi, Ning Yan, Yang Dongyun, Gopez Roel, Melendez Elizabeth, Hanna Diana L., Barzi Afsaneh, Baba Hideo, Falcone Alfredo, Lenz Heinz-Josef: Genetic variations in semaphorin/neuropilin signaling to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab-based chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

  27. Berger Martin D., Stintzing Sebastian, Yang Dongyun, Cao Shu, Miyamoto Yuji, Suenaga Mitsukuni, Soni Shivani, Gopez Roel, Melendez Elizabeth, Zhang Wu, Heinemann Volker, Lenz Heinz-Josef: Genetic variations within the vitamin C transporter genes to predict outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizurnab Data from FIRE-3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 ( DOI )

  28. Suenaga M., Schirripa M., Cao S., Zhang W., Yang D., Murgioni S., Rossini D., Marmorino F., Mennitto A., Ning Y., Okazaki S., Berger M. D., Miyamoto Y., Gopez R. Jr., Barzi A., Yamaguchi T., Loupakis F., Lenz H. -J.: Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer ANNALS OF ONCOLOGY. 2017.05; 28 (5): 1015-1022. ( DOI )

  29. Patel Maulik, Ikeda Sadakatsu, Pilat Susan R., Kurzrock Razelle: JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease JAMA DERMATOLOGY. 2017.05; 153 (5): 449-452. ( DOI )

  30. A systemic review and meta-analysis to evaluate the efficacy and postprogression survival of second-line chemotherapy for gemcitabine-refractory pancreatic cancer. 2017.05; 35 ( DOI )

  31. ABSOLUTE: A phase 3 trial of nanoparticle albumin-bound paclitaxel (nab-PTX) versus solvent-based paclitaxel (sb-PTX) in patients with pre-treated advanced gastric cancer (AGC)-Efficacy and QOL results. 2017.05; 35 ( DOI )

  32. Schwaederle Maria Clemence, Chattopadhyay Ranajoy, Kato Shumei, Fanta Paul T., Banks Kimberly, Piccioni David Eric, Ikeda Sadakatsu, Talasaz AmirAli, Lanman Richard B., Bazhenova Lyudmila, Kurzrock Razelle: Genomic alterations in 670 patients with diverse cancers analyzed by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA). JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 (15): ( DOI )

  33. Kato Shumei, Kurasaki Kellie, Ikeda Sadakatsu, Kurzrock Razelle: Rare tumor clinic: The UCSD Moores Cancer Center experience with a precision therapy approach. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 (15): ( DOI )

  34. Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy 2017.03; 79 (3): 595-602. ( DOI )

  35. Yasuo Hamamoto: Inter-evaluator Heterogeneity of Clinical Diagnosis for Locally Advanced Esophageal Squamous Cell Carcinoma Esophagus. 2017.03; 14 (4): 1-9. ( PubMed , DOI )

  36. Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Marmorino Federica, Bergamo Francesca, Antoniotti Carlotta, Rossini Daniele, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Gopez Roel, Hanna Diana L., Barzi Afsaneh, Mashima Tetsuo, Yamaguchi Toshiharu, Loupakis Fotios, Lenz Heinz-Josef: Role of genetic polymorphisms in CCL5/CCR5 axis to predict efficacy of regorafenib in patients with refractory metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

  37. Berger Martin D., Stintzing Sebastian, Heinemann Volker, Yang Dongyun, Cao Shu, Ning Yan, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, Gopez Roel, Hanna Diana L., Zhang Wu, Lenz Heinz-Josef: Effect of JAK2 SNP rs2274472 on outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

  38. Berger Martin D., Stintzing Sebastian, Yang Dongyun, Suenaga Mitsukuni, Miyamoto Yuji, Cao Shu, Soni Shivani, Gopez Roel, Hanna Diana L., Zhang Wu, Heinemann Volker, Lenz Heinz-Josef: Effect of polymorphisms of genes encoding regulatory proteins in the coagulation cascade on outcome for mCRC patients treated with FOLFIRI and bevacizumab: Data from FIRE-3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

  39. Nagaoka Tomoyuki, Wakatsuki Takeru, Shinozaki Eiji, Nakayama Izuma, Suenaga Mitsukuni, Fukuda Naoki, Osumi Hiroki, Matsushima Tomohiro, Ichimura Takashi, Ogura Mariko, Ozaka Masato, Takahari Daisuke, Chin Keisho, Yamaguchi Kensei: Prognostic impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) at the salvage lines. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

  40. Osumi Hiroki, Takahari Daisuke, Shinozaki Eiji, Chin Keisho, Ogura Mariko, Nakayama Izuma, Matsushima Tomohiro, Wakatsuki Takeru, Ichimura Takashi, Suenaga Mitsukuni, Yamaguchi Kensei: Comparison of early tumor shrinkage between oxaliplatin plus S-1 and cisplatin plus S-1 in first-line chemotherapy with advanced gastric cancer. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

  41. Yagi Shusuke, Wakatsuki Takeru, Yamamoto Noriko, Chin Keisho, Takahari Daisuke, Ogura Mariko, Ichimura Takashi, Nakayama Izuma, Matsushima Tomohiro, Osumi Hiroki, Suenaga Mitsukuni, Ozaka Masato, Shinozaki Eiji, Ishikawa Yuichi, Yamaguchi Kensei: Clinical significance of intratumoral HER2 heterogeneity (IHH) using endoscopic biopsy specimens in patients with HER2-positive gastric cancer (GC) who received T-mab-based chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

  42. Takahari Daisuke, Wakatsuki Takeru, Mashima Tetsuo, Ichimura Takashi, Chin Keisho, Ogura Mariko, Nakayama Izuma, Matsushima Tomohiro, Osumi Hiroki, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Seimiya Hiroyuki, Fujita Naoya, Yamaguchi Kensei: Plasma biomarker analysis of ramucirumab in Japanese patients with advanced gastric cancer: Preliminary results. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

  43. Miyamoto Yuji, Stintzing Sebastian, Zhang Wu, Cao Shu, Ning Yan, Okazaki Satoshi, Berger Martin D., Suenaga Mitsukuni, Schirripa Marta, Soni Shivani, Matsusaka Satoshi, Yang Dongyun, Gopez Roel, Hanna Diana L., Barzi Afsaneh, Baba Hideo, Heinemann Volker, Lenz Heinz-Josef: Polymorphisms in adipokine-related genes to predict treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab-based chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

  44. Fukuda Naoki, Takahari Daisuke, Osumi Hiroki, Matsushima Tomohiro, Nakayama Izuma, Wakatsuki Takeru, Ogura Mariko, Ichimura Takashi, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisho, Yamaguchi Kensei: Analysis of predictive factors of ramucirumab plus paclitaxel for advanced gastric cancer. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

  45. Wakatsuki Takeru, Shinozaki Eiji, Suenaga Mitsukuni, Nakayama Izuma, Matsushima Tomohiro, Osumi Hiroki, Ichimura Takashi, Ogura Mariko, Takahari Daisuke, Ozaka Masato, Chin Keisho, Yamaguchi Kensei: Associations between regorafenib-induced adverse events (AEs) and efficacy in metastatic colorectal cancer (mCRC). JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

  46. Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Salvatore Lisa, Lonardi Sara, Moretto Roberto, Borelli Beatrice, Ning Yan, Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, Gopez Roel, Hanna Diana L., Barzi Afsaneh, Wakatsuki Takeru, Yamaguchi Toshiharu, Loupakis Fotios, Lenz Heinz-Josef: Genetic variants of genes in CCL5/CCR5 pathway to predict regorafenib-induced hand-foot skin reaction in patients with refractory metastatic colorectal cancer: A report of ethnic difference. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

  47. Kawakami Kazuyoshi, Suenaga Mitsukuni, Soejima Azusa, Sugita Kazuo, Yokokawa Takashi, Suzuki Kenichi, Inoue Ayaka, Machida Yohiaki, Wakatsuki Takeru, Yamaguchi Kensei, Hama Toshihiro: Self-reported adherence to regorafenib for metastatic colorectal cancer: A retrospective cohort study. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4):

  48. Ikeda Sadakatsu, Lim Jordan S., Kurzrock Razelle: Analysis of tissue and circulating tumor DNA by next-generation sequencing of hepatocellular carcinoma JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4 S):

  49. Nakayama Izuma, Shinozaki Eiji, Matsushima Tomohiro, Wakatsuki Takeru, Ogura Mariko, Ichimura Takashi, Ozaka Masato, Takahari Daisuke, Suenaga Mitsukuni, Chin Keisho, Mizunuma Nobuyuki, Yamaguchi Kensei: Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients BMC CANCER. 2017.01; 17 (1): 38. ( PubMed , DOI )

  50. Akira Sawaki, Yasuhide, YamadaKensei YamaguchiTomohiro NishinaToshihiko DoiTaroh, SatohKeisho ChinNarikazu BokuYasushi OmuroYoshito KomatsuYasuo HamamotoWasaburo KoizumiShigehira SajiManish A. ShahEric Van Cutsem, Yoon-Koo Kang, Junko Iwasaki, Hiroshi Kuriki, Wataru Ohtsuka, Atsushi Ohtsu: Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm Gastric Cancer. 2017;

  51. Kawakami Kazuyoshi, Yokokawa Takashi, Kobayashi Kazuo, Sugisaki Takahito, Suzuki Kenichi, Suenaga Mitsukuni, Yamaguchi Kensei, Inoue Ayaka, Machida Yoshiaki, Yamaguchi Toshiharu, Hama Toshihiro: Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer ONCOLOGY RESEARCH. 2017; 25 (9): 1625-1631. ( PubMed , DOI )

  52. Yokota T, Yasuda T, Kato H, Nozaki I, Sato H, Miyata Y, Kuroki Y, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Kitagawa Y: Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer. Int J Clin Oncol.. 2017;

  1. Millis Sherri Z., Ikeda Sadakatsu, Reddy Sandeep, Gatalica Zoran, Kurzrock Razelle: Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors JAMA ONCOLOGY. 2016.12; 2 (12): 1565-1573. ( DOI )

  2. Schwaederle Maria, Husain Hatim, Fanta Paul T, Piccioni David E, Kesari Santosh, Schwab Richard B, Patel Sandip P, Harismendy Olivier, Ikeda Megumi, Parker Barbara A, Kurzrock Razelle: Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016.11; 22 (22): 5497-5505. ( PubMed , DOI )

  3. Singh Alok R., Joshi Shweta, Burgoyne Adam M., Sicklick Jason K., Ikeda Sadakatsu, Kono Yuko, Garlich Joseph R., Morales Guillermo A., Durden Donald L.: Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma MOLECULAR CANCER THERAPEUTICS. 2016.11; 15 (11): 2553-2562. ( DOI )

  4. Yoshihito Kano, Jonathan D Cook, Jeffrey E Lee, Michael Ohh: New structural and functional insight into the regulation of Ras. Semin. Cell Dev. Biol. 2016.10; 58 70-78. ( PubMed , DOI )

  5. Okazaki S., Loupakis F., Schirripa M., Cao S., Zhang W., Yang D., Ning Y., Berger M. D., Miyamoto Y., Suenaga M., Gopez R., Borelli B. B., Cremolini C., Falcone A., Lonardi S., Salvatore L., Uetake H., Kawano T., Helentjaris T., Lenz H-J.: Tandemrepeat variation in HIC1 gene predicts outcome for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer ANNALS OF ONCOLOGY. 2016.10; 27 ( DOI )

  6. Ikeda Sadakatsu, Goodman Aaron M., Cohen Philip R., Jensen Taylor J., Ellison Christopher K., Frampton Garrett, Miller Vincent, Patel Sandip P., Kurzrock Razelle: Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy NPJ GENOMIC MEDICINE. 2016.10; 1 16037. ( DOI )

  7. 池田 貞勝: プレシジョン・メディスン　ゲノム医療とその先へ 癌患者におけるゲノム配列分析の取り組み 日本癌学会総会記事. 2016.10; 75回 CS4-CS1. ( 医中誌 )

  8. Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Konishi Tsuyoshi, Akiyoshi Takashi, Fujimoto Yoshiya, Nagayama Satoshi, Fukunaga Yosuke, Ueno Masashi, Mise Yoshihiro, Ishizawa Takeaki, Inoue Yosuke, Takahashi Yu, Saiura Akio, Uehara Hirohumi, Mun Mingyon, Okumura Sakae, Mizunuma Nobuyuki, Miki Yoshio, Yamaguchi Toshiharu: RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy INTERNATIONAL JOURNAL OF CANCER. 2016.08; 139 (4): 803-811. ( PubMed , DOI )

  9. Berger Martin D., Yang Dongyun, Sunakawa Yu, Zhang Wu, Ning Yan, Matsusaka Satoshi, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, Lenz Annika Medea, Bohanes Pierre, Barzi Afsaneh, Figueiredo Jane C., Hanna Diana L., Lenz Heinz-Josef: Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012 ONCOTARGET. 2016.08; 7 (33): 53668-53678. ( PubMed , DOI )

  10. Okazaki Satoshi, Loupakis Fotios, Stintzing Sebastian, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Sunakawa Yu, Stremitzer Stefan, Matsusaka Satoshi, Berger Martin D., Parekh Anish, West Jordan D., Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, Cremolini Chiara, Falcone Alfredo, Heinemann Volker, DePaolo R. William, Lenz Heinz-Josef: Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab MOLECULAR CANCER THERAPEUTICS. 2016.07; 15 (7): 1740-1745. ( PubMed , DOI )

  11. Osumi H., Shinozaki E., Suenaga M., Matsusaka S., Nakayama I., Wakatsuki T., Ogura M., Ozaka M., Takashi I., Takahari D., Chin K., Mizunuma N., Yamaguchi K.: Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer ANNALS OF ONCOLOGY. 2016.06; 27 16.

  12. Suenaga Mitsukuni, Mashima Tetsuo, Kawata Naomi, Wakatsuki Takeru, Horiike Yuki, Matsusaka Satoshi, Dan Shingo, Shinozaki Eiji, Seimiya Hiroyuki, Mizunuma Nobuyuki, Yamaguchi Kensei, Yamaguchi Toshiharu: Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer ONCOTARGET. 2016.06; 7 (23): 34811-34823. ( PubMed , DOI )

  13. West Jordan David, Zhang Wu, Stintzing Sebastian, Sunakawa Yu, Yang Dongyun, Cao Shu, Ning Yan, Berger Martin D., Gopez Roel, Miyamoto Yuji, Okazaki Satoshi, Suenaga Mitsukuni, Schirripa Marta, Barzi Afsaneh, Hanna Diana L., Tsuji Akihito, Ichikawa Wataru, Heinemann Volker, Lenz Heinz-Josef: Genetic variants in immune response genes to predict clinical outcome in mCRC patients treated with FOLFIRI/cetuximab (FIRE-3) or with first line cetuximab-based chemotherapy (JACCRO CC-05/06 AR). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  14. Schirripa Marta, Yang Dongyun, Loupakis Fotios, Antoniotti Carlotta, Cremolini Chiara, Cao Shu, Okazaki Satoshi, Berger Martin D., Ning Yan, Miyamoto Yuji, Suenaga Mitsukuni, Moretto Roberto, Bergamo Francesca, Battaglin Francesca, Lonardi Sara, Gopez Roel, West Jordan David, Zhang Wu, Falcone Alfredo, Lenz Heinz-Josef: Females versus males: Clinical features and outcome differences in large molecularly selected cohort of mCRC patients. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  15. Matsusaka Satoshi, Ning Yan, Yang Dongyun, Zhang Wu, Hanna Diana L., Cao Shu, Suenaga Mitsukuni, Okazaki Satoshi, Berger Martin D., Lenz Heinz-Josef: Epidermal growth factor receptor mRNA expression in circulating tumor cells as a potential mechanism of molecular escape from regorafenib therapy. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  16. Okazaki Satoshi, Stintzing Sebastian, Sunakawa Yu, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Berger Martin D., West Jordan David, Gopez Roel, Miyamoto Yuji, Suenaga Mitsukuni, Barzi SchirripatAfsaneh, Hanna Diana L., Tsuji Akihito, Ichikawa Wataru, Heinemann Volker, DePaolo William, Lenz Heinz-Josef: Polymorphisms in toll-like receptor (TLR) genes in the prediction of outcome for cetuximab-based treatment in patients with metastatic colorectal cancer (mCRC). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  17. Berger Martin D., Stintzing Sebastian, Heinemann Volker, Yang Dongyun, Sunakawa Yu, Ning Yan, Matsusaka Satoshi, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, West Jordan David, Barzi Afsaneh, Hanna Diana L., Zhang Wu, Lenz Heinz-Josef: Polymorphisms of genes encoding for vitamin D binding protein and Wnt5a to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  18. Schirripa Marta, Zhang Wu, Yang Dongyun, Cao Shu, Okazaki Satoshi, Loupakis Fotios, Berger Martin D., Van Ning, Barzit Afsaneh, Miyamoto Yuji, Suenaga Mitsukuni, Gopez Roel, West Jordan David, Hanna Diana L., Lonardi Sara, Bergamo Francesca, Cremolini Chiara, Falcone Alfredo, Lenz Heinz-Josef: NOS2 polymorphisms in the prediction of benefit from FOLFIRI plus bevacizumab in mCRC patients enrolled in TRIBE trial. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  19. Berger Martin D., Stintzing Sebastian, Heinemann Volker, Yang Dongyun, Sunakawa Yu, Ning Yan, Matsusaka Satoshi, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, Schirripa Marta, West Jordan David, Hanna Diana L., Barzi Afsaneh, Zhang Wu, Lenz Heinz-Josef: MKNK1 SNP rs8602 to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  20. Gopez Roel, Schirripa Marta, Zhang Wu, Cao Shu, Okazaki Satoshi, Yang Dongyun, Loupakis Fotios, Berger Martin D., Ning Yan, Miyamoto Yuji, Suenaga Mitsukuni, West Jordan David, Hanna Diana L., Barzi Afsaneh, Falcone Alfredo, Stintzing Sebastian, Heinemann Volker, Lenz Heinz-Josef: IRS1 and IRS2 polymorphisms and outcome in mCRC patients enrolled in the FIRE-3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  21. Cao Shu, Yang Dongyun, Stintzing Sebastian, Loupakis Fotios, Zhang Wu, Ning Yan, Schirripa Marta, Suenaga Mitsukuni, Okazaki Satoshi, Miyamoto Yuji, Barzi Afsaneh, Lenz Heinz-Josef: Identifying predictive SNPs in patients with metastatic colorectal cancer (mCRC) using Random Survival Forests JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  22. Miyamoto Yuji, Stintzing Sebastian, Loupakis Fotios, Zhang Wu, Cao Shu, Ning Yan, Okazaki Satoshi, Berger Martin D., Suenaga Mitsukuni, Schirripa Marta, Matsusaka Satoshi, Yang Dongyun, West Jordan David, Gopez Roel, Hanna Diana L., Barzi Afsaneh, Baba Hideo, Heinemann Volker, Lenz Heinz-Josef: Genetic variations associated with cancer cachexia pathways to predict survival in metastatic colorectal cancer (mCRC): Results from FIRE-3 and TRIBE. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  23. Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Berger Martin D., West Jordan David, Ning Yan, Salvatore Lisa, Rossini Daniele, Antoniotti Carlotta, Inoue Ramu, Matsusaka Satoshi, Okazaki Satoshi, Miyamoto Yuji, Hanna Diana L., Barzi Afsaneh, Loupakis Fotios, Lenz Heinz-Josef: Genetic variants of ATM and XRCC3 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  24. Zhang Wu, Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Yang Dongyun, Berger Martin D., West Jordan David, Ning Yan, Wakatsuki Takeru, Mashima Tetsuo, Okazaki Satoshi, Miyamoto Yuji, Hanna Diana L., Marmorino Federica, Salvatore Lisa, Moretto Roberto, Borelli Beatrice, Barzi Afsaneh, Loupakis Fotios, Lenz Heinz-Josef: Genetic variants of hENT-1 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  25. Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Yang Dongyun, Berger Martin D., West Jordan David, Cremolini Chiara, Lonardi Sara, Battaglin Francesca, Ning Yan, Horiike Yuki, Yamamoto Noriko, Okazaki Satoshi, Miyamoto Yuji, Hanna Diana L., Barzi Afsaneh, Loupakis Fotios, Falcone Alfredo, Lenz Heinz-Josef: Genetic variants of Pint to predict benefit from irinotecan and oxaliplatin based treatment in patients with metastatic colorectal cancer (mCRC). JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  26. Ning Yan, Stintzing Sebastian, Zhang Wu, Yang Dongyun, Hanna Diana L., Okazaki Satoshi, Berger Martin D., Miyamoto Yuji, West Jordan David, Suenaga Mitsukuni, Schirripa Marta, Barzi Afsaneh, Heinemann Volker, Lenz Heinz-Josef: Genetic variants of R-spondin genes to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and bevacizumab (FOLFIRI/BEV) in FIRE-3 cohort. JOURNAL OF CLINICAL ONCOLOGY. 2016.05; 34 (15): ( DOI )

  27. Osumi Hiroki, Yoshio Toshiyuki, Chin Keisho, Ogura Mariko, Kumekawa Yosuke, Suenaga Mitsukuni, Matsusaka Satoshi, Shinozaki Eiji, Miyamoto Yuji, Morishige Kenjiro, Ishiyama Akiyoshi, Hirasawa Toshiaki, Tsuchida Tomohiro, Yamamoto Yorimasa, Fujisaki Junko, Igarashi Masahiro, Mizunuma Nobuyuki: Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer GASTRIC CANCER. 2016.04; 19 (2): 625-630. ( PubMed , DOI )

  28. Konishi Tsuyoshi, Shinozaki Eiji, Murofushi Keiko, Ueno Masashi, Fukunaga Yosuke, Nagayama Satoshi, Fujimoto Yoshiya, Akiyoshi Takashi, Suenaga Mitsukuni, Matsusaka Satoshi, Chino Akiko, Kawachi Hiroshi, Yamamoto Noriko, Ishikawa Yuichi, Igarashi Masahiro, Oguchi Masahiko, Mizunuma Nobuyuki, Sano Takeshi, Yamaguchi Toshiharu: Phase II trial of induction mFOLFOX6 plus bevacizumab followed by neoadjuvant S-1-based chemoradiation for MRI-defined poor-risk rectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2016.02; 34 (4):

  29. Okazaki Satoshi, Stintzing Sebastian, Heinemann Volker, Cao Shu, Zhang Wu, Yang Dongyun, Ning Yan, Matsusaka Satoshi, Berger Martin D., West Jordan D., Miyamoto Yuji, Suenaga Mitsukuni, Lenz Heinz-Josef: Association of TLR9 polymorphism with overall survival in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab enrolled in FIRE3. JOURNAL OF CLINICAL ONCOLOGY. 2016.02; 34 (4):

  30. Berger Martin D., Stintzing Sebastian, Heinemann Volker, Yang Dongyun, Sunakawa Yu, Ning Yan, Matsusaka Satoshi, Okazaki Satoshi, Miyamoto Yuji, Suenaga Mitsukuni, West Jordan David, Zhang Wu, Petasis Nicos, Lenz Heinz-Josef: Serum amyloid a (SAA-1) SNP rs12218 to predict outcome for mCRC patients treated with FOLFIRI and bevacizumab: Data from FIRE-3 trial. JOURNAL OF CLINICAL ONCOLOGY. 2016.02; 34 (4):

  31. Shinozaki Eiji, Tanabe Kazuhiro, Akiyoshi Takashi, Tsuchida Tomohiro, Miyazaki Yuko, Kojima Nozomi, Igarashi Masahiro, Ueno Masashi, Suenaga Mitsukuni, Mizunuma Nobuyuki, Nakayama Konosuke, Iijima Sadayo, Yamaguchi Toshiharu: Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan as a novel tumor marker for colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2016.02; 34 (4):

  32. Sugita Kazuo, Kawakami Kazuyoshi, Yokokawa Takashi, Sugisaki Takahito, Takiguchi Tomomi, Aoyama Takeshi, Suzuki Kenichi, Suenaga Mitsukuni, Yamaguchi Kensei, Inoue Ayaka, Machida Yoshiaki, Yamaguchi Toshiharu, Hama Toshihiro: Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study ONCOLOGY. 2016; 91 (4): 224-230. ( PubMed , DOI )

  1. Khemlina Galina, Ikeda Sadakatsu, Kurzrock Razelle: Molecular landscape of prostate cancer: Implications for current clinical trials CANCER TREATMENT REVIEWS. 2015.11; 41 (9): 761-766. ( DOI )

  2. Osumi H, Matsusaka S, Wakatsuki T, Suenaga M, Shinozaki E, Mizunuma N: Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Molecular and clinical oncology. 2015.11; 3 (6): 1295-1300. ( PubMed , DOI )

  3. Severa Bunda, Kelly Burrell, Pardeep Heir, Lifan Zeng, Amir Alamsahebpour, Yoshihito Kano, Brian Raught, Zhong-Yin Zhang, Gelareh Zadeh, Michael Ohh: Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nature Communications. 2015.11; 6 8859. ( PubMed , DOI )

  4. Sugita Kazuo, Kawakami Kazuyoshi, Yokokawa Takashi, Sugisaki Takahito, Takiguchi Tomomi, Suenaga Mitsukuni, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hama Toshihiro: Self-reported adherence with TAS-102 ANNALS OF ONCOLOGY. 2015.11; 26 100.

  5. Yokokawa Takashi, Kawakami Kazuyoshi, Mae Yutaro, Sugita Kazuo, Watanabe Hiroshi, Suzuki Kenichi, Suenaga Mitsukuni, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hama Toshihiro: Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy ANNALS OF PHARMACOTHERAPY. 2015.10; 49 (10): 1120-1124. ( PubMed , DOI )

  6. Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Kumekawa Yosuke, Ogura Mariko, Ozaka Masato, Matsusaka Satoshi, Chin Keisho, Yamamoto Noriko, Mizunuma Nobuyuki: Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy? BMC CANCER. 2015.10; 15 760. ( PubMed , DOI )

  7. Ikeda Sadakatsu, Hansel Donna E., Kurzrock Razelle: Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma CANCER TREATMENT REVIEWS. 2015.09; 41 (8): 699-706. ( DOI )

  8. Osumi H, Shinozaki E, Osako M, Kawazoe Y, Oba M, Misaka T, Goto T, Kamo H, Suenaga M, Kumekawa Y, Ogura M, Ozaka M, Matsusaka S, Chin K, Hatake K, Mizunuma N: Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. Molecular and clinical oncology. 2015.09; 3 (5): 1053-1057. ( PubMed , DOI )

  9. Wakatsuki T., Suenaga M., Shinozaki E., Nagayama S., Nakayama I., Matsushima T., Ogura M., Ichimura T., Takahari D., Chin K., Kumekawa Y., Sato Y., Fukunaga Y., Ueno M., Mizunuma N., Yamaguchi T.: Genetic variants of UGT1A1 and 1A9 could be associated with Regorafenib induced toxicity in Japanese patients with metastatic colorectal cancer EUROPEAN JOURNAL OF CANCER. 2015.09; 51 S391-S392.

  10. Fukushima Keita, Tsuchiya Kiichiro, Kano Yoshihito, Horita Nobukatsu, Hibiya Shuji, Hayashi Ryohei, Kitagaki Keisuke, Negi Mariko, Itoh Eisaku, Akashi Takumi, Eishi Yoshinobu, Oshima Shigeru, Nagaishi Takashi, Okamoto Ryuichi, Nakamura Tetsuya, Watanabe Mamoru: 腫瘍壊死因子αにより安定化するatonal homolog 1タンパク質は大腸癌細胞株において高悪性度を引き起こす(Atonal homolog 1 protein stabilized by tumor necrosis factor α induces high malignant potential in colon cancer cell line) Cancer Science. 2015.08; 106 (8): 1000-1007. ( 医中誌 )

  11. Nakayama Izuma, Suenaga Mitsukuni, Wakatsuki Takeru, Ichimura Takashi, Ozaka Masato, Takahari Daisuke, Shinozaki Eiji, Chin Keisho, Ueno Masashi, Mizunuma Nobuyuki, Yamaguchi Toshiharu: Safety, tolerability, and efficacy of oxaliplatin-based adjuvant chemotherapy after curative resection of hepatic or extrahepatic metastases of Stage IV colorectal cancer CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2015.07; 76 (1): 133-139. ( PubMed , DOI )

  12. Sugita Kazuo, Kawakami Kazuyoshi, Yokokawa Takashi, Mae Yutaro, Toya Wataru, Hagino Akane, Suzuki Kenichi, Suenaga Mitsukuni, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hama Toshihiro: Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer ANTICANCER RESEARCH. 2015.07; 35 (7): 4059-4062.

  13. Nakayama Izuma, Chin Keisho, Kumekawa Yosuke, Wakatsuki Takeru, Ogura Mariko, Ichimura Takashi, Takahari Daisuke, Suenaga Mitsukuni, Ozaka Masato, Shinozaki Eiji, Mizunuma Nobuyuki: Clinical features and outcome of advanced or metastatic gastric cancer in young adult, analysis of 97 cacses JOURNAL OF CLINICAL ONCOLOGY. 2015.05; 33 (15):

  14. Chin Keisho, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Ozaka Masato, Ichimura Takashi, Wakatsuki Takeru, Matsushima Tomohiro, Mizunuma Nobuyuki: Outcome of marked tumor marker increase in patients with advanced gastric cancer during chemotherapy without progression JOURNAL OF CLINICAL ONCOLOGY. 2015.05; 33 (15):

  15. Keita Fukushima, Kiichiro Tsuchiya, Yoshihito Kano, Nobukatsu Horita, Shuji Hibiya, Ryohei Hayashi, Keisuke Kitagaki, Mariko Negi, Eisaku Itoh, Takumi Akashi, Yoshinobu Eishi, Shigeru Oshima, Takashi Nagaishi, Okamoto Ryuichi, Tetsuya Nakamura, Mamoru Watanabe: Atonal homolog 1 protein stabilized by tumor necrosis factor α induces high malignant potential in colon cancer cell line. Cancer Sci.. 2015.05; ( PubMed , DOI )

  16. Osumi Hiroki, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Ogura Mariko, Ozaka Masato, Kumekawa Yosuke, Chin Keisho, Fujimoto Yoshiya, Ueno Masashi, Mizunuma Nobuyuki: The transition of adjuvant chemotherapy for stage III colorectal cancer: A single institute experience in Japan. JOURNAL OF CLINICAL ONCOLOGY. 2015.05; 33 (15):

  17. Ichimura Takashi, Chin Keisho, Shinozaki Eiji, Suenaga Mitsukuni, Ogura Mariko, Matsushima Tomohiro, Mizunuma Nobuyuki: The long term survival benefit of salvage chemoradiotherapy for local recurrence of esophageal cancer after curative surgery JOURNAL OF CLINICAL ONCOLOGY. 2015.05; 33 (15):

  18. Millis Sherri Z., Ikeda Sadakatsu, Arguello David, Feldman Rebecca, Maney Robert Todd, Xiu Joanne, Reddy Sandeep K., Kurzrock Razelle: PI3K/PTEN/Akt/mTOR pathway aberrations and co-incidence of hormone receptors and HER2 in 19,784 diverse solid JOURNAL OF CLINICAL ONCOLOGY. 2015.05; 33 (15 S):

  19. Suenaga Mitsukuni, Nishina Tomohiro, Mizunuma Nobuyuki, Yasui Hisateru, Ura Takashi, Denda Tadamichi, Ikeda Junichi, Esaki Taito, Nishisaki Hogara, Takano Yoshinao, Sugiyama Yasuyuki, Muro Kei: Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802) BMC CANCER. 2015.03; 15 176. ( PubMed , DOI )

  20. Chin Keisho, Yamamoto Yorimasa, Fujisaki Junko, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Mizunuma Nobuyuki: Endoscopic response evaluation of gastric primary lesion for chemotherapy compared to CT in advanced gastric cancer JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  21. Shinozaki Eiji, Miki Yoshio, Ueno Masashi, Igarashi Masahiro, Suenaga Mitsukuni, Chin Keisho, Ozaka Masato, Ogura Mariko, Takahari Daisuke, Ichimura Takashi, Wakatsuki Takeru, Mizunuma Nobuyuki: Phenotypic differences among RAS mutational variations in colorectal cancer (CRC): Analysis of 1,001 patients in single institute. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  22. Kawakami Kazuyoshi, Yokokawa Takashi, Sugita Kazuo, Hagino Akane, Suzuki Kenichi, Oniyama Sayaka, Kohdo Satoshi, Machida Yohiaki, Suenaga Mitsukuni, Mizunuma Nobuyuki, Yamaguchi Tohiharu, Hama Toshihiro: Patient's self-reported adherence to capecitabine on XELOX as adjuvant therapy for colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  23. Yamada Ikuhiro, Ozaka Masato, Ishii Hiroshi, Sasahira Naoki, Takano Kouichi, Matsuyama Masato, Sasaki Takashi, Saito Kei, Osumi Hiroki, Suenaga Mitsukuni, Igarashi Masahiro: A retrospective study of FOLFOX in the treatment of patients with advanced duodenal adenocarcinoma: A Japanese single-center experience. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  24. Kumekawa Yosuke, Wakatsuki Takeru, Osumi Hiroki, Matsushima Tomohiro, Nakayama Izuma, Ogura Mariko, Ichimura Takashi, Takahari Daisuke, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisho, Mizunuma Nobuyuki: ACEIs/ARBs to improve survival in advanced gastric cancer patients receiving S-1 plus cisplatin. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  25. Suenaga Mitsukuni, Mizunuma Nobuyuki, Matsusaka Satoshi, Shinozaki Eiji, Ozaka Masato, Ogura Mariko, Chin Keisho, Yamaguchi Toshiharu: A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study). JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  26. Wakatsuki Takeru, Yamamoto Noriko, Chin Keisho, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Ozaka Masato, Matsusaka Satoshi, Takahari Daisuke, Ichimura Takashi, Kumekawa Yosuke, Nakayama Izuma, Matsushima Tomohiro, Mizunuma Nobuyuki, Sano Takeshi, Yamaguchi Toshiharu, Ishikawa Yuichi: Association between intratumoral HER2 heterogeneity (IHH) and trastuzumab (T-mab) efficacy in HER2 positive-gastric cancer (GC). JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  27. Nakayama Izuma, Shinozaki Eiji, Wakatsuki Takeru, Kumekawa Yosuke, Ogura Mariko, Ichimura Takashi, Takahari Daisuke, Ozaka Masato, Suenaga Mitsukuni, Chin Keisho, Mizunuma Nobuyuki, Yamaguchi Toshiharu: The significance of EGFR pathway mutations for the efficacy of first line treatment with bevacizumab in metastatic colonrectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2015.01; 33 (3):

  28. Suenaga Mitsukuni, Mizunuma Nobuyuki, Matsusaka Satoshi, Shinozaki Eiji, Ozaka Masato, Ogura Mariko, Chin Keisho, Yamaguchi Toshiharu: A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer DRUG DESIGN DEVELOPMENT AND THERAPY. 2015; 9 1653-1662. ( PubMed , DOI )

  29. Ohhara Yoshihito, Suenaga Mitsukuni, Matsusaka Satoshi, Shinozaki Eiji, Mizunuma Nobuyuki, Yamaguchi Toshiharu: Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer ONCOTARGETS AND THERAPY. 2015; 8 529-537. ( PubMed , DOI )

  30. Suenaga Mitsukuni, Mizunuma Nobuyuki, Matsusaka Satoshi, Shinozaki Eiji, Ozaka Masato, Ogura Mariko, Yamaguchi Toshiharu: Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study DRUG DESIGN DEVELOPMENT AND THERAPY. 2015; 9 3099-3108. ( PubMed , DOI )

  31. Kawakami Kazuyoshi, Nakamoto Eri, Yokokawa Takashi, Sugita Kazuo, Mae Yutarou, Hagino Akane, Suenaga Mitsukuni, Mizunuma Nobuyuki, Oniyama Sayaka, Machida Yoshiaki, Yamaguchi Toshiharu, Hama Toshihiro: Patients' self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis PATIENT PREFERENCE AND ADHERENCE. 2015; 9 561-567. ( PubMed , DOI )

  32. Suenaga Mitsukuni, Fujimoto Yoshiya, Matsusaka Satoshi, Shinozaki Eiji, Akiyoshi Takashi, Nagayama Satoshi, Fukunaga Yosuke, Oya Masatoshi, Ueno Masashi, Mizunuma Nobuyuki, Yamaguchi Toshiharu: Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01) ONCOTARGETS AND THERAPY. 2015; 8 1111-1118. ( PubMed , DOI )

  33. Osumi Hiroki, Matsusaka Satoshi, Suenaga Mitsukuni, Shinozaki Eiji, Mizunuma Nobuyuki: Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab ONCOTARGETS AND THERAPY. 2015; 8 2005-2013. ( PubMed , DOI )

  34. Sato Yasuyoshi, Matsusaka Satoshi, Suenaga Mitsukuni, Shinozaki Eiji, Mizunuma Nobuyuki: Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients ONCOTARGETS AND THERAPY. 2015; 8 3329-3336. ( PubMed , DOI )

  35. Suenaga Mitsukuni, Mizunuma Nobuyuki, Shinozaki Eiji, Matsusaka Satoshi, Ozaka Masato, Ogura Mariko, Chin Keisho, Yamaguchi Toshiharu: Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab ONCOTARGETS AND THERAPY. 2015; 8 243-249. ( PubMed , DOI )

  1. Suenaga Mitsukuni, Mizunuma Nobuyuki, Matsusaka Satoshi, Shinozaki Eiji, Ueno Masashi, Yamaguchi Toshiharu: Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. 2014.12; 10 (4): 322-329. ( PubMed , DOI )

  2. Nobukatsu Horita, Kiichiro Tsuchiya, Ryohei Hayashi, Keita Fukushima, Shuji Hibiya, Masayoshi Fukuda, Yoshihito Kano, Tomohiro Mizutani, Yasuhiro Nemoto, Shiro Yui, Ryuichi Okamoto, Tetsuya Nakamura, Mamoru Watanabe: Fluorescent labelling of intestinal epithelial cells reveals independent long-lived intestinal stem cells in a crypt. Biochem. Biophys. Res. Commun. 2014.10; 454 (4): 493-499. ( PubMed , DOI )

  3. Yoshihito Kano, Sei Kakinuma, Fumio Goto, Seishin Azuma, Yuki Nishimura-Sakurai, Yasuhiro Itsui, Mina Nakagawa, Atsushi Kudo, Minoru Tanabe, Susumu Kirimura, Tomonori Amano, Takashi Ito, Takumi Akashi, Yasuhiro Asahina, Mamoru Watanabe: Primary hepatic neuroendocrine carcinoma with a cholangiocellular carcinoma component in one nodule. Clin J Gastroenterol. 2014.10; 7 (5): 449-454. ( PubMed , DOI )

  4. Kano Yoshihito, Kakinuma Sei, Goto Fumio, Azuma Seishin, Nishimura-Sakurai Yuki, Itsui Yasuhiro, Nakagawa Mina, Kudo Atsushi, Tanabe Minoru, Kirimura Susumu, Amano Tomonori, Ito Takashi, Akashi Takumi, Asahina Yasuhiro, Watanabe Mamoru: 結節の一つに胆管細胞癌部分を合併した原発性肝神経内分泌癌(Primary hepatic neuroendocrine carcinoma with a cholangiocellular carcinoma component in one nodule) Clinical Journal of Gastroenterology. 2014.10; 7 (5): 449-454. ( 医中誌 )

  5. Wakatsuki Takeru, Chin Keisyo, Ogura Mariko, Osaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Matsusaka Satoshi, Kumekawa Yousuke, Nakayama Izuma, Mizunuma Nobuyuki: LOWER CEA AND CA19-9 LEVELS MAY PREDICT LONGER PFS IN PATIENTS WITH HER2 POSITIVE GC TREATED BY T-mab BASED CHEMOTHERAPY ANNALS OF ONCOLOGY. 2014.10; 25 ( DOI )

  6. Kumekawa Yosuke, Chin Keisho, Nakayama Izuma, Wakatsuki Takeru, Ogura Mariko, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Mizunuma Nobuyuki: SURVIVAL ANALYSIS OF UNRESECTABLE GASTRIC CANCER PATIENTS JUDGED RESECTABLE BY INITIAL CT ANNALS OF ONCOLOGY. 2014.10; 25 ( DOI )

  7. Severa Bunda, Pardeep Heir, Tharan Srikumar, Jonathan D Cook, Kelly Burrell, Yoshihito Kano, Jeffrey E Lee, Gelareh Zadeh, Brian Raught, Michael Ohh: Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation. Proc. Natl. Acad. Sci. U.S.A.. 2014.09; 111 (36): E3785-E3794. ( PubMed , DOI )

  8. Sato Yasuyoshi, Matsusaka Satoshi, Nakayama Izuma, Wakatsuki Takeru, Ogura Mariko, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Chin Kelsho, Mizunuma Nobuyuki: Efficacy of cetuximab-containing chemotherapy with or without bevacizumab in prior chemotherapies JOURNAL OF CLINICAL ONCOLOGY. 2014.05; 32 (15):

  9. Suenaga Mitsukuni, Fuse Nozomu, Yamaguchi Tatsuro, Yamanaka Yasuhiro, Motomura Shigeki, Matsumoto Hiroshi, Hamamoto Yasuo, Mizunuma Nobuyuki, Doi Toshihiko, Hatake Kiyohiko, Iwasaki Junko, Ohtsu Atsushi: Pharmacokinetics, Safety, and Efficacy of FOLFIRI Plus Bevacizumab in Japanese Colorectal Cancer Patients With UGT1A1 Gene Polymorphisms JOURNAL OF CLINICAL PHARMACOLOGY. 2014.05; 54 (5): 495-502. ( PubMed , DOI )

  10. Shinozaki Eiji, Miki Yoshio, Ueno Masashi, Igarashi Masahiro, Suenaga Mitsukuni, Chin Keisho, Ozaka Masato, Ogura Mariko, Yamaguchi Toshiharu, Mizunuma Nobuyuki: Molecular profiling of EGFR pathway according to location of colorectal cancer (CRC): Analysis of 1,001 patients in single institute. JOURNAL OF CLINICAL ONCOLOGY. 2014.05; 32 (15):

  11. Suenaga Mitsukuni, Matsuaka Satoshi, Shinozaki Eiji, Ozaka Masato, Chin Keisho, Ogura Mariko, Yamaguchi Toshiharu, Mizunuma Nobuyuki: Analysis of potential circulating angiogenic biomarkers for bevacizumab in patients with Metastatic colorectal cancer JOURNAL OF CLINICAL ONCOLOGY. 2014.05; 32 (15):

  12. Muro Kei, Yamanaka Takeharu, Suenaga Mitsukuni, Nishina Tomohiro, Yasul Hisateru, Ura Takashi, Denda Tadamichi, Ikeda Junichi, Esakl Taito, Nishisaki Hogara, Takano Yoshinao, Kondo Ken, Takeda Koji, Takahashi Yasuo, Endo Kazuya, Sugiyama Yasuyuki: Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV JOURNAL OF CLINICAL ONCOLOGY. 2014.05; 32 (15):

  13. Wakatsuki Takeru, Chin Keisho, Matsusaka Satoshi, Ogura Mariko, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Nakayama Izuma, Mizunuma Nobuyuki: Exploratory analysis to investigate clinical factors that may influence trastsuzumab efficacy in patients with HER2-positive gastric cancer. JOURNAL OF CLINICAL ONCOLOGY. 2014.01; 32 (3):

  14. Suenaga Mitsukuni, Matsusaka Satoshi, Shinozaki Eiji, Ogura Mariko, Ozaka Masato, Nakayama Izuma, Wakatsuki Takeru, Chin Keisho, Mizunuma Nobuyuki, Yamaguchi Toshiharu: SDF-1 and VEGF-C as potential circulating angiogenic biomarkers for bevacizumab in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2014.01; 32 (3):

  15. Osumi Hiroki, Matsusaka Satoshi, Suenaga Mitsukuni, Wakatsuki Takeru, Ogura Mariko, Ozaka Masato, Shinozaki Eiji, Chin Keisho, Mizunuma Nobuyuki: Quantitative analysis of the impact of deepness of response on survival time following patients with metastatic colorectal cancer treated by chemotherapy and anti-EGFR monoclonal antibodies. JOURNAL OF CLINICAL ONCOLOGY. 2014.01; 32 (3):

  16. Nakayama Izuma, Suenaga Mitsukuni, Wakatsuki Takeru, Ogura Mariko, Ozaka Masato, Shinozaki Eiji, Matsusaka Satoshi, Chin Keisho, Mizunuma Nobuyuki, Yamaguchi Toshiharu: The efficacy of oxaliplatin-based adjuvant chemotherapy for stage IV colorectal cancer after R0 resection. JOURNAL OF CLINICAL ONCOLOGY. 2014.01; 32 (3):

  17. Tatsuro Murano, Ryuichi Okamoto, Go Ito, Toru Nakata, Shuji Hibiya, Hiromichi Shimizu, Satoru Fujii, Yoshihito Kano, Tomohiro Mizutani, Shiro Yui, Junko Akiyama-Morio, Yasuhiro Nemoto, Kiichiro Tsuchiya, Tetsuya Nakamura, Mamoru Watanabe: Hes1 promotes the IL-22-mediated antimicrobial response by enhancing STAT3-dependent transcription in human intestinal epithelial cells. Biochem. Biophys. Res. Commun. 2014.01; 443 (3): 840-846. ( PubMed , DOI )

  1. Osumi H, Matsusaka S, Shinozaki E, Suenaga M, Mingyon M, Saiura A, Ueno M, Mizunuma N, Yamaguchi T: Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report. BMC research notes. 2013.12; 6 508. ( PubMed , DOI )

  2. 加納 嘉人, 土屋 輝一郎, 渡辺 守: Atoh1蛋白安定による癌幹細胞形質獲得とニッチ形成(Atoh1 protein stabilization acquired cancer stem cell phenotype and niche in colon cancer) 日本癌学会総会記事. 2013.10; 72回 137. ( 医中誌 )

  3. Kuboki Y, Matsusaka S, Minowa S, Shibata H, Suenaga M, Shinozaki E, Mizunuma N, Ueno M, Yamaguchi T, Hatake K: Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer research. 2013.09; 33 (9): 3905-10. ( PubMed )

  4. Shinozaki Eiji, Yamamoto Noriko, Saiura Akio, Sano Takeshi, Chin Keisho, Ogura Mariko, Matsusaka Satoshi, Suenaga Mitsukuni, Ozaka Masato, Mizunuma Nobuyuki: Concordance of HER2 and its related molecules between primary and paired liver metastatic sites in gastric cancer JOURNAL OF CLINICAL ONCOLOGY. 2013.05; 31 (15):

  5. Kumekawa Yosuke, Chin Keisho, Osumi Hiroki, Ogura Mariko, Ozaka Masato, Suenaga Mitsukuni, Shinozaki Eiji, Matsusaka Satoshi, Sano Takeshi, Mizunuma Nobuyuki: Survival analysis of linitis plastica advanced gastric cancer patients receiving S-1 plus cisplatin. JOURNAL OF CLINICAL ONCOLOGY. 2013.05; 31 (15):

  6. Yoshihito Kano, Kiichiro Tsuchiya, Xiu Zheng, Nobukatsu Horita, Keita Fukushima, Shuji Hibiya, Yuhki Yamauchi, Tatsunori Nishimura, Kunihiko Hinohara, Noriko Gotoh, Shinji Suzuki, Ryuichi Okamoto, Tetsuya Nakamura, Mamoru Watanabe: The acquisition of malignant potential in colon cancer is regulated by the stabilization of Atonal homolog 1 protein. Biochem. Biophys. Res. Commun. 2013.03; 432 (1): 175-181. ( PubMed , DOI )

  7. Ohhara Yoshihito, Matsusaka Satoshi, Shinozaki Eiji, Suenaga Mitsukuni, Mizunuma Nobuyuki, Hatake Kiyohiko, Yamaguchi Toshiharu: Circulating tumor cells as predictive marker in panitumumab after progression of cetuximab in Japanese patients with KRAS wild-type metastatic colorectal cancer JOURNAL OF CLINICAL ONCOLOGY. 2013.02; 31 (4):

  8. Suenaga Mitsukuni, Mizunuma Nobuyuki, Matsusaka Satoshi, Shinozaki Eiji, Ozaka Masato, Ogura Mariko, Chin Keisho, Yamaguchi Toshiharu: A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study): Reports of interim analysis JOURNAL OF CLINICAL ONCOLOGY. 2013.02; 31 (4):

  9. Fukushima Keita, Tsuchiya Kiichiro, Kano Yoshihito, Hibiya Shuji, Horita Nobukatsu, Zheng Xiu, Okamoto Ryuichi, Nakamura Tetsuya, Mamoru Watanabe: 結腸癌においてTNF-αによりAtoh1タンパク質の安定化は癌stemnessを獲得する(Stabilization of Atoh1 Protein by TNF-α in Colon Cancer Acquires Cancer Stemness) 日本消化器病学会雑誌. 2013.02; 110 (臨増総会): A467. ( 医中誌 )

  1. Watanabe Toshiyasu, Kijima Sho, Goto Mayu, Koiso Yasuhiro, Kawagoe Naoyuki, Takemoto Ikutaka, Maeda Tadashi, Miyazaki Taito, Kido Hidenori, Honda Yoshiko, Kikuchi Yoshinori, Ogura Mariko, Koike Junichi, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Funahashi Kimihiko, Shimada Nagato, Nakajima Hitoshi, Urita Yosihisa, Shimada Hiedeaki, Kaneko Hironori, Mizunuma Nobuyuki, Sugimoto Motonobu: Hemodialysis improves 5-FU induced hypreanmonemia with depressed level of conciousness with during 5-FU containing regimen for colon cancer JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. 2012.12; 27 336-337.

  2. Suenaga M., Matsusaka S., Shinozaki E., Ozaka M., Ogura M., Chin K., Hatake K., Mizunuma N., Yamaguchi T.: A PHASE I/II STUDY OF BI-WEEKLY XELIRI PLUS BEVACIZUMAB FOR PATIENT WITH METASTATIC COLORECTAL CANCER AS SECOND-LINE CHEMOTHERAPY (BIXER STUDY): REPORTS OF INTERIM ANALYSIS OF PHASE II PART ANNALS OF ONCOLOGY. 2012.10; 23 130-131.

  3. Matsusaka S., Chin K., Ogur M., Shinozaki E., Suenaga M., Mizunuma N., Sano T., Yamaguchi T., Hatake K.: DETECTION AND HER2 EXPRESSION OF CIRCULATING TUMOR CELLS IN ADVANCED GASTRIC CANCER PATIENTS ANNALS OF ONCOLOGY. 2012.10; 23 118.

  4. Kawakami K., Nakamoto E., Yokokawa T., Mae Y., Sugita K., Suenaga M., Mizunuma N., Yamaguchi T., Hama T.: COMPLIANCE WITH CAPECITABINE ON XELOX TREATMENT ANNALS OF ONCOLOGY. 2012.10; 23 129.

  5. Inoue D., Chin K., Ohara K., Takagi K., Ozaka M., Ogura M., Suenaga M., Shinozaki E., Matsusaka S., Mizunuma N., Hatake K.: ABSENCE OF LIVER METASTASIS, LYMPH NODE METASTASIS AND PERITONEAL METASTASIS PREDICT LONGER PROGRESSION FREE SURVIVAL BY S-1 PLUS CISPLATIN TREATMENT IN ADVANCED GASTRIC CANCER ANNALS OF ONCOLOGY. 2012.10; 23 99.

  6. Kano Y., Tsuchiya K., Watanabe M.: NEW CLASSIFICATION BASED ON ATOH1 EXPRESSION IN COLON CANCER MIGHT BE USEFUL AS BIOMARKER ANNALS OF ONCOLOGY. 2012.10; 23 119.

  7. Matsusaka S., Kuboki Y., Suenaga M., Shinozaki E., Mizunuma N., Hatake K.: CIRCULATING TUMOR CELLS AS A PROGNOSTIC MARKER IN ADVANCE COLORECTAL CANCER PATIENTS TREATED WITH CETUXIMAB-CONTAINING SALVAGE CHEMOTHERAPY ANNALS OF ONCOLOGY. 2012.09; 23 87.

  8. Tsushima Takahiro, Taguri Masataka, Honma Yoshitaka, Takahashi Hideaki, Ueda Shinya, Nishina Tomohiro, Kawai Hiroki, Kato Shunsuke, Suenaga Mitsukuni, Tamura Fumio, Morita Satoshi, Boku Narikazu: Multicenter Retrospective Study of 132 Patients with Unresectable Small Bowel Adenocarcinoma Treated with Chemotherapy ONCOLOGIST. 2012.09; 17 (9): 1163-1170. ( PubMed , DOI )

  9. 加納 嘉人, 土屋 輝一郎, 渡辺 守: Atoh 1蛋白安定による癌幹細胞形質獲得機構解析(The acquirement of cancer stemness in colon cancer by the Atoh1 protein stabilization) 日本癌学会総会記事. 2012.08; 71回 243-244. ( 医中誌 )

  10. 土屋 輝一郎, 加納 嘉人, 渡辺 守: 炎症関連大腸癌におけるAtoh1蛋白安定はがん幹細胞形質と抗がん剤耐性を獲得する(The stabilization of Atoh1 protein in colitic cancer induces cancer stemness and chemoresistance) 日本癌学会総会記事. 2012.08; 71回 98. ( 医中誌 )

  11. Sunshine Sarah B., Dallabrida Susan M., Durand Ellen, Ismail Nesreen S., Bazinet Lauren, Birsner Amy E., Sohn Regina, Ikeda Sadakatsu, Pu William T., Kulke Matthew H., Javaherian Kashi, Zurakowski David, Folkman Judah M., Rupnick Maria: Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2012.07; 109 (28): 11306-11311. ( DOI )

  12. Matsusaka Satoshi, Chin Keisho, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Mizunuma Nobuyuki, Sano Takeshi, Yamaguchi Toshiharu, Yamamoto Noriko, Ishikawa Yuichi, Mishima Yuji, Terui Yasuhito, Hatake Kiyohiko: Detection and HER2 expression of circulating tumor cells in advanced gastric cancer patients JOURNAL OF CLINICAL ONCOLOGY. 2012.05; 30 (15):

  13. Suenaga Mitsukuni, Mizunuma Nobuyuki, Fujimoto Yoshiya, Ueno Masashi, Matsusaka Satoshi, Shinozaki Eiji, Fukunaga Yosuke, Nagayama Satoshi, Yamaguchi Toshiharu: A phase II study of perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01): Report of interim analysis. JOURNAL OF CLINICAL ONCOLOGY. 2012.05; 30 (15):

  14. Ito Yoshinori, Suenaga Mitsukuni, Hatake Kiyohiko, Takahashi Shunji, Yokoyama Masahiro, Onozawa Yusuke, Yamazaki Kentaro, Hironaka Shuichi, Hashigami Kiyoshi, Hasegawa Hirotaka, Takenaka Nobuko, Boku Narikazu: Safety, Efficacy and Pharmacokinetics of Neratinib (HKI-272) in Japanese Patients with Advanced Solid Tumors: A Phase 1 Dose-escalation Study JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2012.04; 42 (4): 278-286. ( PubMed , DOI )

  15. Ito Yoshinori, Suenaga Mitsukuni, Hatake Kiyohiko, Takahashi Shunji, Yokoyama Masahiro, Onozawa Yusuke, Yamazaki Kentaro, Hironaka Shuichi, Hashigami Kiyoshi, Hasegawa Hirotaka, Takenaka Nobuko, Boku Narikazu: 進行固形腫瘍の日本人患者におけるneratinib(HKI-272)の安全性、有効性および薬物動態　第I相用量漸増試験(Safety, Efficacy and Pharmacokinetics of Neratinib (HKI-272) in Japanese Patients with Advanced Solid Tumors: A Phase 1 Dose-escalation Study) Japanese Journal of Clinical Oncology. 2012.04; 42 (4): 278-286. ( 医中誌 )

  16. Bisping Egbert, Ikeda Sadakatsu, Sedej Miriam, Wakula Paulina, McMullen Julie R., Tarnavski Oleg, Sedej Simon, Izumo Seigo, Pu William T., Pieske Burkert: Transcription Factor GATA4 Is Activated but Not Required for Insulin-like Growth Factor 1 (IGF1)-induced Cardiac Hypertrophy JOURNAL OF BIOLOGICAL CHEMISTRY. 2012.03; 287 (13): 9827-9834. ( DOI )

  17. Kawakami Kazuyoshi, Suenaga Mitsukuni, Yokokawa Takashi, Sugita Kazuo, Mae Yutaro, Nakamoto Eri, Imada Hiroshi, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hama Toshihiro: Effect of moisturizers on prevention of hand-foot syndrome associated with capecitabine plus oxaliplatin. JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

  18. Watanabe Toshiyasu, Shinozaki Eiji, Kijima Sho, Ohhara Yoshihito, Kuboki Yasutoshi, Takagi Koichi, Ozaka Masato, Ogura Mariko, Kikuchi Yoshinori, Suenaga Mitsukuni, Chin Keisho, Matsusaka Satoshi, Koike Junichi, Funahashi Kimihiko, Urita Yoshihisa, Mizunuma Nobuyuki, Hatake Kiyohiko, Kaneko Hironori, Sugimoto Motonobu: Does panitumumab have a clinical benefit in cetuximab-refractory KRAS wild-type metastatic colorectal cancer? JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

  19. Ohhara Yoshihito, Suenaga Mitsukuni, Matsusaka Satoshi, Shinozaki Eiji, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hatake Kiyohiko: Comparison between the three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

  20. Matsusaka Satoshi, Suenaga Mitsukuni, Mishima Yuji, Terui Yasuhito, Shinozaki Eiji, Mizunuma Nobuyuki, Hatake Kiyohiko: Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

  21. Suenaga Mitsukuni, Matsusaka Satoshi, Mizunuma Nobuyuki, Shinozaki Eiji, Ogura Mariko, Ozaka Masato, Takagi Koichi, Yamaguchi Toshiharu, Hatake Kiyohiko: Addition of bevacizumab to first-line FOLFOX4 and overall survival in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

  22. Suenaga Mitsukuni, Matsusaka Satoshi, Shinozaki Eiji, Mizunuma Nobuyuki, Hatake Kiyohiko, Yamaguchi Toshiharu: A phase I/II study of biweekly XELIRI plus bevacizumab for patients with metastatic colorectal cancer as second-line chemotherapy (BIXER study): Reports of phase I part and interim analysis of phase II part. JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

  23. Inoue Dai, Matsusaka Satoshi, Yamamoto Noriko, Suenaga Mitsukuni, Mishima Yuji, Shinozaki Eiji, Terui Yasuhito, Mizunuma Nobuyuki, Ishikawa Yuichi, Hatake Kiyohiko: CD133 status influences in prognosis of patients with metastatic colorectal cancer receiving cetuximab. JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

  24. Shinozaki Eiji, Yamamoto Noriko, Chin Keisho, Ogura Mariko, Suenaga Mitsukuni, Matsusaka Satoshi, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hatake Kiyohiko: How many biopsy fragments will be necessary to assess HER2 status for gastric cancer? JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

  25. Ohhara Yoshihito, Chin Keisho, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Matsusaka Satoshi, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hatake Kiyohiko: What are the limiting factors related to discontinuance of chemotherapy after failure of first-line S-1 plus CDDP in Japanese patients with advanced gastric cancer? JOURNAL OF CLINICAL ONCOLOGY. 2012.02; 30 (4): ( DOI )

  26. Itatani Yoshiro, Akiyoshi Takashi, Kuroyanagi Hiroya, Yamakawa Keiko, Noaki Rota, Konishi Tsuyoshi, Fujimoto Yoshiya, Ueno Masashi, Oya Masatoshi, Suenaga Mitsukuni, Yamaguchi Toshiharu: Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case SURGERY TODAY. 2012.01; 42 (1): 75-79. ( PubMed , DOI )

  1. Zheng X, Tsuchiya K, Okamoto R, Iwasaki M, Kano Y, Sakamoto N, Nakamura T, Watanabe M: Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis. Inflamm Bowel Dis. 2011.11; 17 (11): 2251-2260. ( PubMed , DOI )

  2. Matsusaka Satoshi, Suenaga Mitsukuni, Mishima Yuji, Takagi Koichi, Terui Yasuhito, Mizunuma Nobuyuki, Hatake Kiyohiko: Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2011.09; 68 (3): 763-768. ( PubMed , DOI )

  3. Matsusaka Satoshi, Mishima Yuji, Suenaga Mitsukuni, Terui Yasuhito, Kuniyoshi Ryoko, Mizunuma Nobuyuki, Hatake Kiyohiko: Circulating Endothelial Progenitors and CXCR4-Positive Circulating Endothelial Cells Are Predictive Markers for Bevacizumab CANCER. 2011.09; 117 (17): 4026-4032. ( PubMed , DOI )

  4. Osako M., Kawazoe Y., Mizunuma N., Gotoh T., Misaka T., Oba M., Shinozaki E., Suenaga M., Matsusaka S., Hatake K.: Cetuximab Treatment for Metastatic Colorectal Cancer With KRAS p.G130 Mutation may Improve Progression-free Survival in Japanese Patients EUROPEAN JOURNAL OF CANCER. 2011.09; 47 S395-S396.

  5. 土屋 輝一郎, 加納 嘉人, 渡辺 守: 大腸癌におけるAtoh1蛋白安定は粘液癌の形質を模倣する(The stabilization of Atoh1 protein in colorectal cancer mimics mucinous adenocarcinoma) 日本癌学会総会記事. 2011.09; 70回 227. ( 医中誌 )

  6. 加納 嘉人, 土屋 輝一郎, 渡辺 守: 大腸癌におけるAtoh1蛋白安定発現は分化形質だけでなく癌悪性形質を誘導する(Atoh1 protein stabilization in colorectal cancer promotes not only the differentiation but also the malignancy) 日本癌学会総会記事. 2011.09; 70回 338. ( 医中誌 )

  7. Suenaga Mitsukuni, Matsusaka Satoshi, Ueno Masashi, Yamamoto Noriko, Shinozaki Eiji, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hatake Kiyohiko: Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients SURGERY TODAY. 2011.08; 41 (8): 1067-1074. ( PubMed , DOI )

  8. Suenaga Mitsukuni, Matsusaka Satoshi, Ueno Masashi, Yamamoto Noriko, Shinozaki Eiji, Mizunuma Nobuyuki, Yamaguchi Toshiharu, Hatake Kiyohiko: 転移性結腸直腸癌患者に対する二次治療としてのFOLFIRI+bevacizumabによる有効性の予測因子(Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients) Surgery Today. 2011.08; 41 (8): 1067-1074. ( 医中誌 )

  9. Matsusaka Satoshi, Suenaga Mitsukuni, Mishima Yuji, Kuniyoshi Ryoko, Takagi Koichi, Terui Yasuhito, Mizunuma Nobuyuki, Hatake Kiyohiko: Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer CANCER SCIENCE. 2011.06; 102 (6): 1188-1192. ( PubMed , DOI )

  10. Suenaga Mitsukuni, Matsusaka Satoshi, Watanabe Toshiyasu, Kuboki Yasutoshi, Shinozaki Eiji, Chin Keisho, Mizunuma Nobuyuki, Ueno Masashi, Yamaguchi Toshiharu, Hatake Kiyohiko: How do we apply adjuvant FOLFOX to Japanese patients with curatively resected colorectal cancer? ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. 2011.06; 7 (2): 129-135. ( PubMed , DOI )

  11. Matsusaka S., Suenaga M., Mishima Y., Takagi K., Shinozaki E., Terui Y., Mizunuma N., Hatake K.: TIE2-expressing myeloid cells as a predictive marker for bevacizumab-containing chemotherapy in metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2011.05; 29 (15):

  12. Takagi K., Chin K., Oba M., Kuboki Y., Ichimura T., Oto M., Kawazoe Y., Watanabe T., Ozaka M., Ogura M., Suenaga M., Shinozaki E., Matsusaka S., Mizunuma N., Hatake K.: EFFICACY OF PACLITAXEL FOR S-1-REFRACTORY GASTRIC CANCER (JAPAN) JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2011.03; 41 (3): I15.

  13. Matsusaka S., Mizunuma N., Suenaga M., Shinozaki E., Mishima Y., Terui Y., Hatake K.: PREDICTIVE POTENTIAL OF CIRCULATING ENDOTHELIAL CELLS IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS RECEIVING BEVACIZUMAB CONTAINING CHEMOTHERAPY (JAPAN) JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2011.03; 41 (3): I10.

  14. Ozaka M., Ogura M., Matsusaka S., Shinozaki E., Suenaga M., Chin K., Mizunuma N., Hatake K.: THE OPTIMUM TIME FOR SURGERY AFTER RECEIVING IMATINIB: A RETROSPECTIVE ANALYSIS OF GIST PATIENTS ACHIEVING A PARTIAL RESPONSE (JAPAN) JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2011.03; 41 (3): I12.

  15. Tsushima T., Boku N., Honma Y., Takahashi H., Ueda S., Nishina T., Kawai H., Kato S., Suenaga M., Tamura F.: Retrospective analysis of first-line chemotherapy in 132 patients with advanced small-bowel adenocarcinoma. JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

  16. Suenaga M., Mizunuma N., Matsusaka S., Shinozaki E., Ogura M., Kuboki Y., Watanabe T., Ozaka M., Chin K., Hatake K.: Effect of the addition of bevacizumab to first-line FOLFOX on efficacy, including response rate, progression-free survival, and overall survival, in patients with metastatic colorectal cancer JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

  17. Suenaga M., Matsusaka S., Watanabe T., Takagi K., Kuboki Y., Ozaka M., Shinozaki E., Chin K., Mizunuma N., Hatake K.: Coagulo-fibrinolytic activity as a predictor of efficacy in bevacizumab-combined chemotherapy in metastatic colorectal cancer patients. JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

  18. Suenaga M., Imada H., Nakamoto E., Matsusaka S., Watanabe T., Kawazoe Y., Shinozaki E., Chin K., Mizunuma N., Hatake K.: Optimal use of antihypertensive agents in management of bevacizumab-associated hypertension. JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

  19. Matsusaka S., Chin K., Mizunuma N., Ogura M., Suenaga M., Ozaka M., Takagi K., Oba M., Mishima Y., Hatake K.: Use of circulating tumor cells to predict response to chemotherapy in patients with advanced gastric cancer JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

  20. Iwasaki Michiko, Tsuchiya Kiichiro, Okamoto Ryuichi, Zheng Xiu, Kano Yoshihito, Okamoto Eiko, Okada Eriko, Araki Akihiro, Suzuki Shinji, Sakamoto Naoya, Kitagaki Keisuke, Akashi Takumi, Eishi Yoshinobu, Nakamura Tetsuya, Watanabe Mamoru: ヒト全小腸における長軸方向の細胞形成はHath1およびKlf4の局在と相関する(Longitudinal cell formation in the entire human small intestine is correlated with the localization of Hath1 and Klf4) Journal of Gastroenterology. 2011.02; 46 (2): 191-202. ( 医中誌 )

  21. Matsusaka S., Mizunuma N., Suenaga M., Chin K., Shinozaki E., Watanabe T., Kawazoe Y., Kuboki Y., Terui Y., Hatake K.: Use of circulating endothelial cells to predict response to FOLFOX4 plus bevacizumab in metastatic colorectal cancer JOURNAL OF CLINICAL ONCOLOGY. 2011.02; 29 (4):

  22. Oba Masaru, Chin Keisho, Kawazoe Yoshimasa, Takagi Koichi, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Mizunuma Nobuyuki, Hatake Kiyohiko: Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens ONCOLOGY LETTERS. 2011; 2 (2): 247-251. ( PubMed , DOI )

  23. Oba Masaru, Chin Keisho, Kawazoe Yoshimasa, Takagi Koichi, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Mizunuma Nobuyuki, Hatake Kiyohiko: Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens ONCOLOGY LETTERS. 2011; 2 (2): 241-245. ( PubMed , DOI )

  24. Kuboki Yasutoshi, Mizunuma Nobuyuki, Ozaka Masato, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Matsusaka Satoshi, Chin Keishou, Matsuura Masaaki, Hatake Kiyohiko: Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer ONCOLOGY LETTERS. 2011; 2 (3): 493-498. ( PubMed , DOI )

  1. Iwasaki M, Tsuchiya K, Okamoto R, Zheng X, Kano Y, Okamoto E, Okada E, Araki A, Suzuki S, Sakamoto N, Kitagaki K, Akashi T, Eishi Y, Nakamura T, Watanabe M: Longitudinal cell formation in the entire human small intestine is correlated with the localization of Hath1 and Klf4. J Gastroenterol. 2010.12; ( PubMed , DOI )

  2. Kawazoe Yoshimasa, Shinozaki Eiji, Hosonaga Mari, Kuboki Yasutoshi, Ichimura Takashi, Watanabe Toshiyasu, Oba Masaru, Takagi Koichi, Ozaka Masato, Ogura Mariko, Suenaga Mitsukuni, Matsusaka Satoshi, Chin Keisho, Mizunuma Nobuyuki, Hatake Kiyohiko: FOLFOX COULD INDUCE SPLENOMEGALY, WHICH MIGHT WORSEN THROMBOCYTOPENIA ANNALS OF ONCOLOGY. 2010.11; 21 34.

  3. Ogura Mariko, Matsusaka Satoshi, Kuboki Yasutoshi, Takashi Ichimura, Watanabe Toshiyasu, Takagi Kouichi, Nozaki Akira, Ozaka Masato, Shinozaki Eiji, Suenaga Mitsukuni, Chin Keisyou, Mizunuma Nobuyuki, Hatake Kiyohiko: EFFICACY OF FOLFOX4 REJIMEN FOR METASTATIC COLORECTAL CANCER ANNALS OF ONCOLOGY. 2010.11; 21 30.

  4. Takagi Koichi, Chin Keisho, Oba Masaru, Kuboki Yasutoshi, Oto Masafumi, Ichimura Takashi, Kawazoe Yoshimasa, Watanabe Toshiyasu, Ozaka Masato, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Matsusaka Satoshi, Mizunuma Nobuyuki, Hatake Kiyohiko: EFFICACY OF PACLITAXEL FOR S-1-REFRACTORY GASTRIC CANCER ANNALS OF ONCOLOGY. 2010.11; 21 28-29.

  5. Chin Keisho, Yoshimoto Kazuhito, Mizunuma Nobuyuki, Matsusaka Satoshi, Shinozaki Eiji, Suenaga Mitsukuni, Ogura Mariko, Ozaka Masato, Kuboki Yasuhito, Ichimura Takashi, Takagi Koichi, Nozaki Akira, Watanabe Toshiyasu, Hatake Kiyohiko: ENDOSCOPIC EVALUATION OF THE PRIMARY TUMOR CONCERNING OF THE EFFICACY OF CHEMOTHERAPY FOR ADVANCED GASTRIC CANCER ANNALS OF ONCOLOGY. 2010.11; 21 28.

  6. Asai Hiroaki, Shinozaki Eiji, Mizunuma Nobuyuki, Watanabe Toshiyasu, Nozaki Akira, Kuboki Yasutoshi, Ichimura Takashi, Takagi Koichi, Ozaka Masato, Ogura Mariko, Suenaga Mitsukuni, Matsuzaka Satoshi, Chin Keisho, Hatake Kiyohiko: RESPONSE TO CETUXIMAB CONTAINING CHEMOTHERAPY WAS RELATED WITH LONGER TTF:RETROSPECTIVE ANALYSIS OF 72 PATIENTS ANNALS OF ONCOLOGY. 2010.11; 21 33.

  7. Shinozaki Eiji, Mizunuma Nobuyuki, Asai Hiroaki, Watanabe Toshiyasu, Nozaki Akira, Matsusaka Satoshi, Suenaga Mitsukuni, Chin Keisho, Ogura Mariko, Osaka Masato, Kuboki Yasutoshi, Takagi Koichi, Ichimura Takashi, Hatake Kiyohiko: EARLY SERUM MAGNESIUM REDUCTION MAY REPRESENT THE DISEASE CONTROL IN METASTATIC COLORECTAL CANCER TREATED WITH CETUXIMAB ANNALS OF ONCOLOGY. 2010.11; 21 33.

  8. Suenaga Mitsukuni, Mizunuma Nobuyuki, Shinozaki Eiji, Matsusaka Satoshi, Chin Keisho, Kuboki Yasutoshi, Watanabe Toshiyasu, Fujimoto Yoshiya, Ueno Masashi, Kuroyanagi Hiroya, Oya Masatoshi, Yamamoto Noriko, Hatake Kiyohiko: CONTINUATION OF OXALIPLATIN IS A POTENTIAL PREDICTIVE FACTOR IN ADJUVANT FOLFOX FOR STAGE IIIB OR IV COLORECTAL CANCER ANNALS OF ONCOLOGY. 2010.11; 21 30.

  9. Mizunuma Nobuyuki, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Kuboki Yasutoshi, Nozaki Akira, Takagi Kouichi, Watanabe Toshiyasu, Kawazoe Yoshimasa, Hatake Kiyohiko: METASTATIC COLORECTAL CANCER ADVANCES IN CHEMOTHERAPY; THE REVIEW OF FOR 10 YEARS IN ARIAKE CANCER INSTITUTE ANNALS OF ONCOLOGY. 2010.11; 21 15.

  10. Matsusaka Satoshi, Mishima Yuji, Mizunuma Nobuyuki, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisho, Ogura Mariko, Osaka Masato, Takagi Koichi, Watanabe Toshiyasu, Nozaki Akira, Oba Masaru, Kawazoe Yoshimasa, Terui Yasuhito, Hatake Kiyohiko: CEP AND CXCR4+CEC ARE PREDICTIVE MARKERS FOR BEVACIZUMAB CONTAINING CHEMOTHERAPY IN MCRC ANNALS OF ONCOLOGY. 2010.11; 21 13.

  11. Watanabe Toshiyasu, Shinozaki Eiji, Asai Hiroaki, Kuboki Yasutoshi, Oto Masafumi, Kawazoe Yoshimasa, Nozaki Akira, Takagi Kouichi, Ozaka Masato, Ogura Mariko, Suenaga Mitsukuni, Matsusaka Satoshi, Chin Keisho, Mizunuma Nobuyuki, Hatake Kiyohiko: CETUXIMAB INDUCED ACNE LIKE ERUPTION MIGHT BE MILD IN ELDERLY PATIENTS GROUP ANNALS OF ONCOLOGY. 2010.11; 21 31.

  12. Nozaki Akira, Shinozaki Eiji, Watanabe Toshiyasu, Takagi Koichi, Ichimura Takashi, Kuboki Yasutoshi, Ozaka Masato, Ogura Mariko, Matsuzaka Satoshi, Suenaga Mitsukuni, Chin Keisho, Mizunuma Nobuyuki, Hatake Kiyohiko, Matsuura Masaaki, Ushijima Masaru: WHAT HINDERS THE 3RD LINE CHEMOTHERAPY IN COLORECTAL CANCER PATIENTS? ANNALS OF ONCOLOGY. 2010.11; 21 31.

  13. Kuboki Yasutoshi, Shinozaki Eiji, Ichimura Takashi, Ozaka Masato, Oba Masaru, Ogura Mariko, Suenaga Mitukuni, Matusaka Satoshi, Chin Keishou, Mizunuma Nobuyuki, Hatake Kiyohiko: GRADE 2 AND OVER DIGESTIVE TOXICITY IS AN UNFEASIBLE CAUSE OF OUTPATIENT-BASED CDDP IN ADVANCED/RECURRENT GASTRIC CANCER ANNALS OF ONCOLOGY. 2010.11; 21 28.

  14. Ozaka Masato, Kuboki Yasutoshi, Ichimura Takashi, Kawazoe Yoshimasa, Watanabe Toshiyasu, Takagi Koichi, Oba Masaru, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Matsusaka Satoshi, Chin Keisho, Mizunuma Nobuyuki, Hatake Kiyohiko: THE OPTIMAL TIME FOR SURGERY AFTER RECEIVING IMATINIB IN GIST PATIENTS: A RETROSPECTIVE ANALYSIS ANNALS OF ONCOLOGY. 2010.11; 21 18-19.

  15. Watanabe Toshiyasu, Suenaga Mitsukuni, Kuboki Yasutoshi, Ichimura Takashi, Kawazoe Yoshimasa, Nozaki Akira, Ooba Masaru, Takagi Kouichi, Ozaka Masato, Ogura Mariko, Shinozaki Eiji, Matsusaka Satoshi, Chin Keisho, Mizunuma Nobuyuki, Hatake Kiyohiko: THE REASON WHY PATIENTS COULD NOT COMBINE BEVACIZUMAB IN METASTATIC COLORECTAL CANCER ANNALS OF ONCOLOGY. 2010.11; 21 15.

  16. Oto Masafumi, Shinozaki Eiji, Kuboki Yasutoshi, Ichimura Taksahi, Watanabe Toshiyasu, Takagi Koichi, Ozaka Masato, Ogura Mariko, Suenaga Mitsukuni, Matsusaka Satoshi, Chin Keisho, Mizunuma Nobuyuki, Hatake Kiyohiko, Yamamoto Chiriko: SERUM P53 ANTIBODY IN PATIENTS WITH ESOPAHAGEAL CANCER TREATED WITH CURATIVE CHEMORADIOTERAPY(CRT) IS NOT PREDICTIVE ANNALS OF ONCOLOGY. 2010.11; 21 27-28.

  17. Yukisawa S., Fujiwara Y., Yamamoto Y., Ueno T., Matsueda K., Kohno A., Suenaga M.: Upper-extremity deep vein thrombosis related to central venous port systems implanted in cancer patients BRITISH JOURNAL OF RADIOLOGY. 2010.10; 83 (994): 850-853. ( DOI )

  18. Suenaga Mitsukuni, Mizunuma Nobuyuki, Kobayashi Kokoro, Shinozaki Eiji, Matsusaka Satoshi, Chin Keisho, Kuboki Yasutoshi, Ichimura Takashi, Ozaka Masato, Ogura Mariko, Fujiwara Yoshimasa, Matsueda Kiyoshi, Konishi Fumio, Hatake Kiyohiko: Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab MEDICAL ONCOLOGY. 2010.09; 27 (3): 807-814. ( PubMed , DOI )

  19. Zhang Zhiyuan, Wang Hao, Ikeda Sadakatsu, Fahey Frederic, Bielenberg Diane, Smits Patrick, Hauschka Peter V.: Notch3 in Human Breast Cancer Cell Lines Regulates Osteoblast-Cancer Cell Interactions and Osteolytic Bone Metastasis AMERICAN JOURNAL OF PATHOLOGY. 2010.09; 177 (3): 1459-1469. ( DOI )

  20. 加納 嘉人, 土屋 輝一郎, 渡辺 守: Atoh1蛋白可視化による未分化大腸がん分化誘導機構解析(The induction of the differentiation of colorectal cancer cells indicated by the visualization of Atoh1 protein) 日本癌学会総会記事. 2010.08; 69回 256. ( 医中誌 )

  21. Ikeda Sadakatsu, Pu William T: Expression and function of microRNAs in heart disease. Curr Drug Targets. 2010.08; 11 (8): 913-925. ( PubMed )

  22. Ikeda Sadakatsu, Pu William T.: Expression and Function of MicroRNAs in Heart Disease CURRENT DRUG TARGETS. 2010.08; 11 (8): 913-925. ( DOI )

  23. Suenaga M., Matsusaka S., Takagi K., Kuboki Y., Watanabe T., Shinozaki E., Chin K., Mizunuma N., Hatake K.: Potential markers predicting bevacizumab efficacy for metastatic colorectal cancer patients. JOURNAL OF CLINICAL ONCOLOGY. 2010.05; 28 (15):

  24. Matsusaka S., Mishima Y., Suenaga M., Takagi K., Shinozaki E., Terui Y., Mizunuma N., Hatake K.: Use of day 4 CEP and baseline CXCR4 plus CEC as predictive markers for bevacizumb in mCRC JOURNAL OF CLINICAL ONCOLOGY. 2010.05; 28 (15):

  25. Matsusaka S, Chìn K, Ogura M, Suenaga M, Shinozaki E, Mishima Y, Terui Y, Mizunuma N, Hatake K: Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer science. 2010.04; 101 (4): 1067-71. ( PubMed , DOI )

  26. Matsusaka Satoshi, Chin Keisho, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Mishima Yuji, Terui Yasuhito, Mizunuma Nobuyuki, Hatake Kiyohiko: Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer CANCER SCIENCE. 2010.04; 101 (4): 1067-1071.

  27. Matsusaka Satoshi, Chin Keisho, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Mishima Yuji, Terui Yasuhito, Mizunuma Nobuyuki, Hatake Kiyohiko: 進行胃癌患者の化学療法に対する反応を予測する代理マーカーとしての循環腫瘍細胞(Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer) Cancer Science. 2010.04; 101 (4): 1067-1071. ( 医中誌 )

  28. Kong Sek Won, Hu Yong Wu, Ho Joshua W. K., Ikeda Sadakatsu, Polster Sean, John Ranjit, Hall Jennifer L., Bisping Egbert, Pieske Burkert, dos Remedios Cristobal G., Pu William T.: Heart Failure-Associated Changes in RNA Splicing of Sarcomere Genes CIRCULATION-CARDIOVASCULAR GENETICS. 2010.04; 3 (2): 138-U72. ( DOI )

  29. Fuse N., Suenaga M., Yamaguchi T., Matsumoto H., Mizunuma N., Doi T., Hatake K., Ohtsu A.: FIRST EVALUATION OF THE EFFICACY, SAFETY, AND DRUG-DRUG INTERACTION OF COMBINATION THERAPY OF FOLFIRI AND BEVACIZUMAB IN UGT1A1 GENE POLYMORPHISM OF ADVANCED AND RECURRENT COLORECTAL CANCER ANNALS OF ONCOLOGY. 2010; 21 69.

  1. Ikeda Sadakatsu, He Aibin, Ma Qing, Pu William T.: The Novel Mechanism of Posttranscriptional Regulation of Calmodulin and Mef2a by MicroRNA-1 CIRCULATION RESEARCH. 2009.09; 105 (7): E33.

  2. Suenaga Mitsukuni, Mizunuma Nobuyuki, Shouji Daigo, Shinozaki Eiji, Matsusaka Satoshi, Chin Keisho, Oya Masatoshi, Yamaguchi Toshiharu, Muto Tetsuichiro, Hatake Kiyohiko: Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan (vol 43, pg 842, 2008) JOURNAL OF GASTROENTEROLOGY. 2009.07; 44 (7): 801. ( DOI )

  3. Matsusaka S., Chin K., Mizunuma N., Ogura M., Suenaga M., Shinozaki E., Terui Y., Hatake K.: Circulating tumor cells (CTCs) as a surrogate marker for determining response to chemotherapy in advanced gastric cancer (AGC) JOURNAL OF CLINICAL ONCOLOGY. 2009.05; 27 (15):

  4. Ito Y., Hatake K., Takahashi S., Yokoyama M., Suenaga M., Ota M., Onozawa Y., Yamazaki K., Hironaka S., Boku N.: Tolerability and safety of oral neratinib (HKI-272) in Japanese patients with advanced solid tumors JOURNAL OF CLINICAL ONCOLOGY. 2009.05; 27 (15):

  5. Ikeda Sadakatsu, He Aibin, Kong Sek Won, Lu Jun, Bejar Rafael, Bodyak Natalya, Lee Kyu-Ho, Ma Qing, Kang Peter M., Golub Todd R., Pu William T.: MicroRNA-1 Negatively Regulates Expression of the Hypertrophy-Associated Calmodulin and Mef2a Genes MOLECULAR AND CELLULAR BIOLOGY. 2009.04; 29 (8): 2193-2204. ( DOI )

  6. Suenaga Mitsukuni, Mizunuma Nobuyuki, Chin Keisho, Matsusaka Satoshi, Shinozaki Eiji, Oya Masatoshi, Ueno Masashi, Yamaguchi Toshiharu, Muto Tetsuichiro, Konishi Fumio, Hatake Kiyohiko: Chemotherapy for small-bowel Adenocarcinoma at a single institution SURGERY TODAY. 2009.01; 39 (1): 27-31. ( PubMed , DOI )

  1. Suenaga Mitsukuni, Mizunuma Nobuyuki, Shouji Daigo, Shinozaki Eiji, Matsusaka Satoshi, Chin Keisho, Oya Masatoshi, Yamaguchi Toshiharu, Muto Tetsuichiro, Hatake Kiyohiko: Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan JOURNAL OF GASTROENTEROLOGY. 2008.11; 43 (11): 842-848. ( PubMed , DOI )

  2. Suenaga M, Mizunuma N, Shinozaki E, Matsusaka S, Chin K, Muto T, Konishi F, Hatake K: Management of allergic reactions to oxaliplatin in colorectal cancer patients. The journal of supportive oncology. 2008.11; 6 (8): 373-8. ( PubMed )

  3. Suenaga Mitsukuni, Mizunuma Nobuyuki, Shouji Daigo, Shinozaki Eiji, Matsusaka Satoshi, Chin Keisho, Oya Masatoshi, Yamaguchi Toshiharu, Muto Tetsuichiro, Hatake Kiyohiko: 日本の単一施設における転移性大腸癌に対するイリノテカン+ボーラス5-フルオロウラシル/L-ロイコボリン変法(Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan) Journal of Gastroenterology. 2008.11; 43 (11): 842-848. ( 医中誌 )

  4. Zhou Bin, Ma Qing, Rajagopal Satish, Wu Sean M., Domian Ibrahim, Rivera-Feliciano Jose, Jiang Dawei, von Gise Alexander, Ikeda Sadakatsu, Chien Kenneth R., Pu William T.: Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart NATURE. 2008.07; 454 (7200): 109-U5. ( DOI )

  5. Chin Keisho, Baba Satoshi, Hosaka Hisashi, Ishiyama Akiyoshi, Mizunuma Nobuyuki, Shinozaki Eiji, Suenaga Mitsukuni, Kozuka Takuyo, Seto Yasuyuki, Yamamoto Noriko, Hatake Kiyohiko: Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: Report of 12 cases from single institution experience JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2008.06; 38 (6): 426-431. ( PubMed , DOI )

  6. Chin Keisho, Baba Satoshi, Hosaka Hisashi, Ishiyama Akiyoshi, Mizunuma Nobuyuki, Shinozaki Eiji, Suenaga Mitsukuni, Kozuka Takuyo, Seto Yasuyuki, Yamamoto Noriko, Hatake Kiyohiko: 食道の小細胞癌の治療におけるイリノテカンとシスプラチン　単一施設における経験からの12例の報告(Irinotecan Plus Cisplatin for Therapy of Small-cell Carcinoma of the Esophagus: Report of 12 Cases from Single Institution Experience) Japanese Journal of Clinical Oncology. 2008.06; 38 (6): 426-431. ( 医中誌 )

  7. Ozaka M., Shinozaki E., Suenaga M., Matuzaka S., Chin K., Mizunuma N., Hatake K.: A retrospective analysis of patients with complete response (CR) after FOLFOX4: Single institute experience JOURNAL OF CLINICAL ONCOLOGY. 2008.05; 26 (15):

  1. Ikeda Sadakatsu, Kong Sek Won, Lu Jun, Bisping Egbert, Zhang Hao, Allen Paul D., Golub Todd R., Pieske Burkert, Pu William T.: Altered microRNA expression in human heart disease PHYSIOLOGICAL GENOMICS. 2007.11; 31 (3): 367-373. ( DOI )

  2. Robinson Barbara, Ikeda Sadakatsu, Poutias Dimitri, Kazu Kitahori, Friehs Ingelborg, Eddy Mau-Thek, McGowan Frank, del Nido Pedro: Novel pharmacologic induction of and protection with the endogenous cytoprotective myocardial heat shock protein 70i by the anti-ulcer agent, GGA, is associated with improved ventricular function after global ischemia and a reduction in troponin T release. CIRCULATION. 2007.10; 116 (16): 756.

  3. Ikeda Sadakatsu, Kong Sek Won, Lu Jun, Bisping Egbert, Bodyak Natalya, Lee Kyu-Ho, Ma Qing, Kang Peter M., Pieske Burkert, Allen Paul D., Golub Todd, Pu William T.: Downregulation of cardiomyocyte-enriched micromas contributes to altered gene expression in heart failure CIRCULATION. 2007.10; 116 (16 S): 162.

  4. Suenaga M., Mizunuma N., Chin K., Kuboki Y., Shizozaki E., Yamaguchi T., Muto T., Hatake K.: Preventive approach to allergic reaction to oxaliplatin JOURNAL OF CLINICAL ONCOLOGY. 2007.06; 25 (18):

  5. Matsusaka S., Mizunuma N., Matsuda M., Suenaga M., Ogura M., Ichimura T., Shoji D., Oya M., Muto T., Hatake K.: Measures of oxaliplatin-induced neutrotoxicity in 187 patients with FOLFOX4 JOURNAL OF CLINICAL ONCOLOGY. 2007.06; 25 (18):

  1. Bisping Egbert, Ikeda Sadakatsu, Kong Sek Won, Tarnavski Oleg, Bodyak Natalya, McMullen Julie R., Rajagopal Satish, Son Jennifer K., Ma Qing, Springer Zhangli, Kang Peter M., Izumo Seigo, Pu William T.: Gata4 is required for maintenance of postnatal cardiac function and protection from pressure overload-induced heart failure PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2006.09; 103 (39): 14471-14476. ( DOI )

  2. Suenaga M, Oya M, Ueno M, Yamamoto J, Yamaguchi T, Mizunuma N, Hatake K, Kato Y, Muto T: Anal canal carcinoma with pagetoid spread: Report of a case SURGERY TODAY. 2006.07; 36 (7): 666-669. ( PubMed , DOI )

  1. Sato T, Ohyama S, Kokudo N, Suenaga M, Yamamoto J, Yamaguchi T, Muto T: The repeated hepatectomy for frequent recurrence of hepatic metastasis from gastrointestinal stromal tumor of the stomach. Hepato-gastroenterology. 2004.01; 51 (55): 181-3. ( PubMed )

  1. Sato T, Ohta K, Ohyama S, Suenaga M, Ueno M, Oya M, Yamamoto J, Yamaguchi T, Muto T, Kato Y: Klippel-Trenaunay-Weber syndrome and duodenal hemorrhage. Gastrointestinal endoscopy. 2003.11; 58 (5): 756-7. ( PubMed , DOI )

  2. Suenaga M, Ohta K, Toguchi M, Sato T, Ohyama S, Yamaguchi T, Muto T, Yanagisawa A, Kato Y: Colliding gastric and intestinal phenotype well-differentiated adenocarcinoma of the stomach developing in an area of MALT-type lymphoma. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2003; 6 (4): 270-6. ( PubMed , DOI )

  1. 堀江 沙良, 浜本 康夫: 【食道癌2024-基礎・臨床の最新動向-】再発食道癌の治療　高齢者食道癌の再発治療 日本臨床. 2024.05; 82 (増刊3 食道癌2024): 481-484. ( 医中誌 )

  1. 宗 英一郎, 上野 彰久, 大喜多 肇, 浜本 康夫: 免疫関連事象に対するステロイド,免疫抑制薬使用の留意点　腸炎(irAE colitis) 腫瘍内科. 2023.11; 32 (5): 548-553. ( 医中誌 )

  2. 末永 光邦, 植竹 宏之: 【がん薬物療法中の腹部救急疾患・有害事象に対する対策と治療】化学療法中の消化器関連有害事象に対する治療アプローチ　コロナ禍が医療現場へもたらす負担 日本腹部救急医学会雑誌. 2023.03; 43 (3): 629-635. ( 医中誌 )

  3. Ishido Shun, Tsuchiya Kaoru, Kano Yoshihito, Yasui Yutaka, Takaura Kenta, Uchihara Naoki, Suzuki Keito, Tanaka Yuki, Miyamoto Haruka, Yamada Michiko, Matsumoto Hiroaki, Nobusawa Tsubasa, Keitoku Taisei, Tanaka Shohei, Maeyashiki Chiaki, Tamaki Nobuharu, Takahashi Yuka, Nakanishi Hiroyuki, Sakurai Urara, Asahina Yasuhiro, Okamoto Ryuichi, Kurosaki Masayuki, Izumi Namiki: Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma CANCERS. 2023.02; 15 (3): ( PubMed , DOI )

  4. Harada Yohei, Sato Akemi, Nakamura Hideaki, Kai Keita, Kitamura Sho, Nakamura Tomomi, Kurihara Yuki, Ikeda Sadakatsu, Sueoka Eisaburo, Kimura Shinya, Sueoka-Aragane Naoko: Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer BMC CANCER. 2023.01; 23 (1): 77. ( PubMed , DOI )

  5. 末永光邦、植竹宏之: 化学療法中の消化器関連有害事象に対する治療アプローチ～コロナ禍が医療現場へもたらす負担～ 日本腹部救急医学会雑誌. 2023; 43 (3): 1-7.

  1. 加納 嘉人: 【最新・転移性肝腫瘍の外科治療と遺伝子検査の治療への考え方】遺伝子検査の基礎知識　ゲノム検査はどんな場合に行うか?臨床医として知っておくべきこと 肝臓クリニカルアップデート. 2022.12; 8 (2): 102-106. ( 医中誌 )

  2. Uehara Y., Ikeda S., Kim K. H., Lim H. J., Adashek J. J., Persha H. E., Okamura R., Lee S., Sicklick J. K., Kato S., Kurzrock R.: Targeting the FGF/FGFR axis and its co-alteration allies ESMO OPEN. 2022.12; 7 (6): 100647. ( PubMed , DOI )

  3. 大日方 裕紀, 矢ヶ崎 香, 浜本 康夫, 平田 賢郎, 須河 恭敬, 小松 浩子: 抗がん剤変更時における高齢消化器がん患者のフレイルとQOLの関連 日本看護科学会誌. 2022.12; 42 254-262. ( 医中誌 )

  4. Horgan Denis, Mia Rizwana, Erhabor Tosan, Hamdi Yosr, Dandara Collet, Lal Jonathan A., Domgue Joel Fokom, Ewumi Oladimeji, Nyawira Teresia, Meyer Salome, Kondji Dominique, Francisco Ngiambudulu M., Ikeda Sadakatsu, Chuah Chai, De Guzman Roselle, Paul Anupriya, Nallamalla Krishna Reddy, Park Woong-Yang, Tripathi Vijay, Tripathi Ravikant, Johns Amber, Singh Mohan P., Phipps Maude E., Dube France, Whittaker Kate, Mukherji Deborah, Abu Rasheed Hadi Mohamad, Kozaric Marta, Pinto Joseph A., Stefani Stephen Doral, Augustovski Federico, Rueda Maria Eugenia Aponte, Alarcon Ricardo Fujita, Barrera-Saldana Hugo A.: Fighting Cancer around the World: A Framework for Action HEALTHCARE. 2022.11; 10 (11): ( PubMed , DOI )

  5. Aoyama Satoru, Nogami Ayako, Ikeda Sadakatsu, Mori Takehiko: Novel Protease-Mediated Double Antigen Recognizing Chimeric Antigen Receptor (CAR) Enhances Directionality of CAR-T Cell Activity and Improves Target Cell Specificity BLOOD. 2022.11; 140 4533-4534. ( DOI )

  6. Lazar Vladimir, Raynaud Jacques, Magidi Shai, Bresson Catherine, Martini Jean-Francois, Galbraith Susan, Wunder Fanny, Onn Amir, Batist Gerald, Girard Nicolas, Lassen Ulrik, Pramesh C. S., Al-Omari Amal, Ikeda Sadakatsu, Berchem Guy, Blay Jean-Yves, Solomon Benjamin, Felip Enriqueta, Tabernero Josep, Rubin Eitan, Philip Thierry, Porgador Angel, Berindan-Neagoe Ioana, Schilsky Richard L., Kurzrock Razelle: Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2022.10; 14 17588359221133893. ( PubMed , DOI )

  7. 長尾 俊景, 坂東 夏菜, 井浦 亜有子, 角田 龍太, 加納 嘉人, 池田 貞勝, 野上 彩子, 田中 陽典, 桐村 進, 森 毅彦: 多発性骨髄腫と類似の病像を呈した悪性パラガングリオーマ 臨床血液. 2022.10; 63 (10): 1373-1378. ( 医中誌 )

  8. 千田 彰彦, 浜本 康夫: 【実地医家が知っておくべきがんの薬物療法　がんの薬物療法の必要性・重要性】各がん種の最新情報と知っておくべき標準治療　消化管間質腫瘍(GIST) Medical Practice. 2022.10; 39 (10): 1553-1558. ( 医中誌 )

  9. 青木 優, 浜本 康夫: 新型コロナウイルス感染症流行下におけるがん診療の実態調査 癌と化学療法. 2022.08; 49 (8): 867-871. ( 医中誌 )

  10. 樋口 大樹, 松浦 拓人, 高嶺 恵理子, 細川 満由, 小堀 華菜, 池田 貞勝, 原田 俊介, 本間 浩一, 田嶋 敦, 吉田 雅幸, 大塚 伊佐夫: 卵巣癌肉腫を生じたCowden症候群の1例 癌と化学療法. 2022.07; 49 (7): 783-787. ( 医中誌 )

  11. Higuchi D, Matsuura T, Takamine E, Hosokawa M, Kobori K, Ikeda S, Harada S, Honma K, Tajima A, Yoshida M, Otsuka I: [Ovarian Carcinosarcoma Associated with Cowden Syndrome-A Case Report]. Gan to kagaku ryoho. Cancer & chemotherapy. 2022.07; 49 (7): 783-787. ( PubMed )

  12. Matsubara Junichi, Mukai Kumi, Kage Hidenori, Oda Katsutoshi, Kudo Ryo, Ikeda Sadakatsu, Ebi Hiromichi, Muro Kei, Hayashi Ryuji, Tokudome Nahomi, Yamamoto Nobuyuki, Muto Manabu: Prospective trial of comprehensive genomic profiling for patients with chemotherapy-naive cancer (FIRST-Dx trial) ANNALS OF ONCOLOGY. 2022.07; 33 S539. ( DOI )

  13. Ikeda Sadakatsu, Kudo Ryo, Yamashita Yamato, Kubo Toshio, Mori Yukiko, Harada Yohei, Shirota Hidekazu, Hayashi Hideyuki, Kano Masayuki, Shimizu Yasushi, Ishibashi Eri, Tateishi Ukihide, Hirakawa Akihiro, Akita Hirotoshi, Matsubara Hisahiro, Nishihara Hiroshi, Ishioka Chikashi, Sueoka-Aragane Naoko, Muto Manabu, Toyooka Shinichi: Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors. JOURNAL OF CLINICAL ONCOLOGY. 2022.06; 40 (16):

  14. Tsujikawa Takahiro, Ohno Kazuchika, Saburi Sumiyo, Mitsuda Junichi, Yoshimura Kanako, Kimura Alisa, Morimoto Hiroki, Ohmura Gaku, Arai Akihito, Ogi Hiroshi, Shibata Saya, Ariizumi Yosuke, Tasaki Akihisa, Takahashi Ryosuke, Tateishi Yumiko, Kawabe Hiroaki, Ikeda Sadakatsu, Morita Kei-ichi, Tsunoda Tatsuhiko, Akashi Takumi, Kurata Morito, Imoto Issei, Shimizu Yasushi, Watanabe Akihito, Asada Yukinori, Hayashi Ryuichi, Saito Yuki, Ozawa Hiroyuki, Tsukahara Kiyoaki, Oridate Nobuhiko, Horii Arata, Maruo Takashi, Hanai Nobuhiro, Inohara Hidenori, Iwai Hiroshi, Fujii Takashi, Nibu Ken-ichi, Iwae Shigemichi, Ueda Tsutomu, Yasumatsu Ryuji, Umeno Hirohito, Masuda Muneyuki, Itoh Kyoko, Hirano Shigeru, Asakage Takahiro: Tumor immune characterization identifies age-stratified biomarkers for nivolumab in patients with head and neck squamous cell carcinoma: A nationwide collaborative study in Japan CANCER RESEARCH. 2022.06; 82 (12):

  15. Tsujikawa Takahiro, Ohno Kazuchika, Saburi Sumiyo, Mitsuda Junichi, Yoshimura Kanako, Kimura Alisa, Morimoto Hiroki, Ohmura Gaku, Arai Akihito, Ogi Hiroshi, Shibata Saya, Ariizumi Yosuke, Tasaki Akihisa, Takahashi Ryosuke, Tateishi Yumiko, Kawabe Hiroaki, Ikeda Sadakatsu, Morita Kei-ichi, Tsunoda Tatsuhiko, Akashi Takumi, Kurata Morito, Imoto Issei, Shimizu Yasushi, Watanabe Akihito, Asada Yukinori, Hayashi Ryuichi, Saito Yuki, Ozawa Hiroyuki, Tsukahara Kiyoaki, Oridate Nobuhiko, Horii Arata, Maruo Takashi, Hanai Nobuhiro, Inohara Hidenori, Iwai Hiroshi, Fujii Takashi, Nibu Ken-ichi, Iwae Shigemichi, Ueda Tsutomu, Yasumatsu Ryuji, Umeno Hirohito, Masuda Muneyuki, Itoh Kyoko, Hirano Shigeru, Asakage Takahiro: Tumor immune characterization identifies age-stratified biomarkers for nivolumab in patients with head and neck squamous cell carcinoma: A nationwide collaborative study in Japan. CANCER RESEARCH. 2022.06; 82 (12):

  16. 加納嘉人: 【革新的技術が変える肝疾患診療】リキッドバイオプシーがもたらすがん診療の変革 消化器・肝臓内科. 2022.04; 11 (4): 479-482. ( 医中誌 )

  17. 松寺 翔太郎, 池田 貞勝: 【がんゲノム医療時代の分子腫瘍学】(第1部)がんの分子病理学(序論)　解析法　次世代シークエンシング　リキッドバイオプシー 病理と臨床. 2022.04; 40 (臨増): 083-086. ( 医中誌 )

  18. 池田 貞勝: 【泌尿器腫瘍と遺伝性/家族性疾患:2022アップデート】前立腺癌におけるBRCA遺伝子検査 泌尿器外科. 2022.04; 35 (4): 294-297. ( 医中誌 )

  19. 加納 嘉人: 【革新的技術が変える肝疾患診療】リキッドバイオプシーがもたらすがん診療の変革 消化器・肝臓内科. 2022.04; 11 (4): 479-482. ( 医中誌 )

  20. 清水 智子, 浜本 康夫: 【1ページでわかる内科疾患の診療ノート-"あたりまえ"のなかにある大事な視点】(第6章)消化管　食道がん 内科. 2022.04; 129 (4): 808-811. ( 医中誌 )

  21. 末永 光邦, 植竹 宏之: 【大腸がん診療の最近の進歩】進行・再発大腸癌の薬物療法 Medical Science Digest. 2022.03; 48 (3): 139-142. ( 医中誌 )

  22. 末永光邦、植竹宏之: 進行・再発大腸癌の薬物療法 メディカル・サイエンス・ダイジェスト. 2022.03; 48 (3): 139-142.

  23. Matsumiya Yuriko, Suenaga Mitsukuni, Ishikawa Toshiaki, Hanaoka Marie, Iwata Noriko, Masuda Taiki, Yamauchi Shinichi, Tokunaga Masanori, Kinugasa Yusuke: Clinical significance of Bacteroides fragilis as potential prognostic factor in colorectal cancer patients JOURNAL OF CLINICAL ONCOLOGY. 2022.02; 40 (4): ( DOI )

  24. 浜本 康夫: 【がん患者さんと家族のはてなにこたえる　Q&A100　OKワード・NGワードを知ってコミュ力UP!】(第3章)患者さんからの質問-がん治療中の生活-　とにかく死ぬのが怖い… YORi-SOUがんナーシング. 2022.02; (2022春季増刊): 194-195. ( 医中誌 )

  25. 浜本 康夫: 【がん患者さんと家族のはてなにこたえる　Q&A100　OKワード・NGワードを知ってコミュ力UP!】(第3章)患者さんからの質問-がん治療中の生活-　不安だらけ。誰に何を相談したらよいのかもわからない YORi-SOUがんナーシング. 2022.02; (2022春季増刊): 196-197. ( 医中誌 )

  26. 浜本 康夫: 【がん患者さんと家族のはてなにこたえる　Q&A100　OKワード・NGワードを知ってコミュ力UP!】(第3章)患者さんからの質問-がん治療中の生活-　病気や治療で家族に迷惑をかけている自分なんかいないほうがいい YORi-SOUがんナーシング. 2022.02; (2022春季増刊): 192-193. ( 医中誌 )

  27. 浜本 康夫: 【がん患者さんと家族のはてなにこたえる　Q&A100　OKワード・NGワードを知ってコミュ力UP!】(第3章)患者さんからの質問-がん治療中の生活-　私の人生は何だったんだろう? YORi-SOUがんナーシング. 2022.02; (2022春季増刊): 190-191. ( 医中誌 )

  28. Nagao T, Bando K, Iura A, Kakuta R, Kano Y, Ikeda S, Nogami A, Tanaka Y, Kirimura S, Mori T: [Malignant paraganglioma mimicking multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2022; 63 (10): 1373-1378. ( PubMed , DOI )

  1. Onishi Iichiroh, Kirimura Susumu, Wakejima Ryo, Okubo Kenichi, Odai Tamami, Kakuta Ryota, Kano Yoshihito, Ikeda Sadakatsu, Akashi Takumi, Kitagawa Masanobu: Primary pulmonary choriocarcinoma with a genomic sequence pathology international. 2021.12; 72 (2): 141-143. ( PubMed , DOI )

  2. 遠山 皓基, 加納 嘉人, 野地 理夏, 青柳 康子, 松寺 翔太郎, 大野 十央, 有泉 陽介, 道 泰之, 富岡 寛文, 島本 裕彰, 吉村 亮一, 朝蔭 孝宏, 原田 浩之, 三宅 智, 三浦 雅彦, 池田 貞勝: 再発・転移頭頸部癌に対する網羅的がんゲノム解析と臨床的有用性 頭頸部癌. 2021.12; 47 (4): 359-365. ( 医中誌 )

  3. 井浦 亜有子, 坂東 夏菜, 長尾 俊景, 角田 龍太, 加納 嘉人, 池田 貞勝, 野上 彩子, 田中 陽典, 森 毅彦: 胸腰椎圧迫骨折、高カルシウム血症を契機に診断されたパラガングリオーマの1例 日本内科学会関東地方会. 2021.09; 671回 32. ( 医中誌 )

  4. 平田 賢郎, 吉田 佳代, 堅田 親利, 對馬 隆浩, 紀 貴之, 山本 幸子, 石川 秀樹, 佐藤 泰憲, 伊藤 芳紀, 加藤 健, 浜本 康夫: Vulnerable臨床病期IB-III食道癌に対するパクリタキセル併用放射線療法の第I相試験 日本食道学会学術集会プログラム・抄録集. 2021.09; 75回 124. ( 医中誌 )

  5. 松宮 由利子, 末永 光邦, 角田 龍太, 岩田 乃理子, 増田 大機, 山内 慎一, 松山 貴俊, 徳永 正則, 石川 敏昭, 絹笠 祐介: 大腸癌術後患者におけるBacteroides fragilisと予後の検討 日本消化器外科学会総会. 2021.07; 76回 P161-7. ( 医中誌 )

  6. 堀江 沙良, 浜本 康夫: 【薬物療法に活用される検査】抗腫瘍療法における臨床検査の活用 臨床検査. 2021.07; 65 (7): 736-742. ( 医中誌 )

  7. 野地 理夏, 加納 嘉人, 平井 秀明, 山下 大和, 工藤 亮, 富岡 寛文, 島本 裕彰, 道 泰之, 大西 威一郎, 三浦 雅彦, 吉村 亮一, 三宅 智, 池田 貞勝, 原田 浩之: がんゲノム解析によりニボルマブ耐性機構が示唆された再発頬粘膜癌の一例 頭頸部癌. 2021.05; 47 (2): 182. ( 医中誌 )

  8. 千田 彰彦, 浜本 康夫: 【内科疾患の診断基準・病型分類・重症度】(第2章)消化器　診断メモ　消化管間質腫瘍(GIST) 内科. 2021.04; 127 (4): 606. ( 医中誌 )

  9. 池田 貞勝: 乳癌診療におけるゲノム医療の進歩　がんゲノム医療の最先端 Japanese Journal of Diagnostic Imaging. 2021.02; 39 46. ( 医中誌 )

  10. 千田 彰彦, 川崎 健太, 櫻井 陽奈子, 堀江 沙良, 津軽 開, 戸ヶ崎 和博, 下嵜 啓太郎, 平田 賢郎, 林 秀幸, 浜本 康夫, 河原 徹, 牧内 里美, 岩原 彰秀, 川合 未来, 杉山 和俊, 目黒 周, 金井 隆典: イマチニブ休薬による急性増悪を背景にNICTHを合併した胃GIST術後再発の1例 日本消化器病学会関東支部例会プログラム・抄録集. 2021.02; 363回 27. ( 医中誌 )

  11. 千田 彰彦, 川崎 健太, 櫻井 陽奈子, 堀江 沙良, 津軽 開, 戸ヶ崎 和博, 下嵜 啓太郎, 平田 賢郎, 林 秀幸, 浜本 康夫, 河原 徹, 牧内 里美, 岩原 彰秀, 川合 未来, 杉山 和俊, 目黒 周, 金井 隆典: イマチニブ休薬による急性増悪を背景にNICTHを合併した胃GIST術後再発の1例 日本消化器病学会関東支部例会プログラム・抄録集. 2021.02; 363回 27. ( 医中誌 )

  12. 池田 貞勝: 【どうなる?!ゲノム医療2020-2021】米国のがんゲノム医療の現状 臨床病理レビュー. 2021.01; (165): 21. ( 医中誌 )

  1. 池田 貞勝: がん遺伝子パネル検査の実臨床での課題と展望 日本皮膚悪性腫瘍学会学術大会プログラム・抄録集. 2020.12; 36回 96. ( 医中誌 )

  2. 加納 嘉人, 朝比奈 靖浩: 【肝癌治療の進歩】ゲノム医療の肝癌診療への応用 消化器・肝臓内科. 2020.11; 8 (5): 509-512. ( 医中誌 )

  3. 熊木 裕一, 中川 剛士, 小川 あゆみ, 細矢 徳子, 小田 剛史, 池田 貞勝, 植竹 宏之: がん遺伝子パネル検査を施行した乳癌患者20例の検討 日本乳癌学会総会プログラム抄録集. 2020.10; 28回 521. ( 医中誌 )

  4. 山田 浩貴, 井上 大, 池田 貞勝: 当院におけるがんゲノム医療の成績とその課題に関する検討 日本消化器病学会雑誌. 2020.10; 117 (臨増大会): A757. ( 医中誌 )

  5. 遠藤 駿, 三ツ村 隆弘, 石塚 聖洋, 本多 隆行, 榊原 里江, 池田 貞勝, 宮崎 泰成: 当初EGFR遺伝子変異陰性であったが、遺伝子パネル検査でuncommon mutationが検出されアファチニブが奏効した非小細胞肺癌の1例 肺癌. 2020.10; 60 (5): 429-433. ( 医中誌 )

  6. 松寺 翔太郎, 加納 嘉人, 遠山 皓基, 青柳 康子, 木村 浩一朗, 大西 威一郎, 竹本 暁, 荻野 恵, 岡本 健太郎, 植竹 宏之, 土岡 丘, 小嶋 一幸, 高木 正稔, 三宅 智, 池田 貞勝: 小児・AYA世代の固形がん患者におけるがん遺伝子パネル検査の有用性の検討 日本小児外科学会雑誌. 2020.09; 56 (5): 586. ( 医中誌 )

  7. 池田 貞勝: 大腸癌におけるprecision medicineの可能性　未来を開くがんゲノム医療 日本大腸肛門病学会雑誌. 2020.09; 73 (9): A35. ( 医中誌 )

  8. 安東 敬大, 西山 直樹, 本多 隆行, 桐村 進, 榊原 里江, 三ツ村 隆弘, 遠山 皓基, 加納 嘉人, 池田 貞勝, 宮崎 泰成: 遺伝子パネル検査を組み合わせることで、確定診断と適正な治療選択が可能となった、上顎洞癌の胸膜転移の1例 肺癌. 2020.08; 60 (4): 364-370. ( 医中誌 )

  9. 青柳 康子, 遠山 皓基, 松寺 翔太郎, 加納 嘉人, 絹笠 祐介, 田邉 稔, 池田 貞勝: 【遺伝性腫瘍とゲノム医療を学ぶ】ゲノム医療　がん遺伝子パネル検査と連携協力体制 臨床外科. 2020.08; 75 (8): 947-951. ( 医中誌 )

  10. 青柳康子、加納嘉人、遠山皓基、松寺翔太郎、熊木裕一、馬場裕信、菊池章史、山内慎一、岡崎　聡、石川敏明、伴　大輔、工藤　篤、松山貴俊、徳永正則、中島康晃、植竹宏之、田邉　稔、三宅　智、絹笠祐介、池田貞勝: がんゲノム医療は外科手術を変えるか　消化器がん患者におけるFoundationOne CDxを用いたがんゲノム解析の有用性の検討 日本外科学会定期学術集会抄録集. 2020.08; 120回 SY-14. ( 医中誌 )

  11. 青柳康子、遠山皓基、松寺翔太郎、加納嘉人、絹笠祐介、田邉稔、池田貞勝: ゲノム医療　がん遺伝子パネル検査と連携協力体制 臨床外科. 2020.08; 75 (8): 947-951.

  12. 加納嘉人: KRASチロシンリン酸化がスイッチI/II領域の構造変化を起こしGTPサイクルを制御する 東京都医師会雑誌. 2020.07; 73 (6): 497-500. ( 医中誌 )

  13. 浜本 康夫: 【便秘・下痢-医師必見のUp-to-Date 2020】免疫チェックポイント阻害薬による大腸炎 内科. 2020.07; 126 (1): 111-115. ( 医中誌 )

  14. 遠山 皓基, 加納 嘉人, 青柳 康子, 松寺 翔太郎, 大野 十央, 有泉 陽介, 富岡 寛文, 島本 裕彰, 道 泰之, 吉村 亮一, 朝蔭 孝宏, 原田 浩之, 三宅 智, 三浦 雅彦, 池田 貞勝: 再発・転移頭頸部癌に対するがんゲノムリアルワールド解析と有用性 頭頸部癌. 2020.07; 46 (2): 190. ( 医中誌 )

  15. 浜本 康夫: 【消化管症候群(第3版)-その他の消化管疾患を含めて-】空腸、回腸、盲腸、結腸、直腸(上)　炎症性疾患　免疫チェックポイント阻害薬による腸炎 日本臨床. 2020.04; 別冊 (消化管症候群III): 150-153. ( 医中誌 )

  16. 浜本 康夫: 【有害事象の専門診療科からみた免疫チェックポイント阻害薬の副作用対策】大腸炎 癌と化学療法. 2020.02; 47 (2): 214-218. ( 医中誌 )

  1. 青柳 康子, 池田 貞勝: 【がんゲノム医療の新しい時代-胆道癌・膵癌におけるPrecision Medicine-】FoundationOne CDxの特徴 胆と膵. 2019.12; 40 (12): 1341-1345. ( 医中誌 )

  2. 三ツ村 隆弘, 石塚 聖洋, 榊原 里江, 本多 隆行, 飯島 裕基, 立石 知也, 高橋 健太, 熊木 裕一, 坂下 博之, 池田 貞勝, 三宅 智, 宮崎 泰成: 実地診療における肺癌患者のリキッドバイオプシー(血漿)を用いたがんゲノム検査の意義 肺癌. 2019.11; 59 (6): 754. ( 医中誌 )

  3. 熊木 裕一, 高橋 健太, 三ツ村 隆弘, 横堀 潤子, 高嶺 恵理子, 石橋 恵理, 坂下 博之, 石川 敏昭, 小野 宏晃, 伴 大輔, 工藤 篤, 大島 乃里子, 中川 剛士, 木村 浩一朗, 久保田 一徳, 大西 威一郎, 田邉 稔, 植竹 宏之, 三宅 智, 池田 貞勝: FoundationOne CDx検査を用いたがんゲノム解析の臨床的有用性(PROFILE-F Study) 癌と化学療法. 2019.11; 46 (11): 1715-1719. ( 医中誌 )

  4. 浜本 康夫: 【免疫関連副作用としての自己免疫疾患】消化管障害 リウマチ科. 2019.11; 62 (5): 415-420. ( 医中誌 )

  5. 下嵜 啓太郎, 猪口 和美, 浜本 康夫: 【大腸腫瘍-診断・治療の最前線-】大腸癌化学療法の変遷と展望 日本消化器病学会雑誌. 2019.11; 116 (11): 902-912. ( 医中誌 )

  6. 三ツ村隆弘、飯島裕基、榊原里江、本多隆行、熊木裕一、高橋健太、加納嘉人、坂下博之、宮崎泰成、池田貞勝: リキッドバイオプシーによりALK阻害薬耐性変異が検出された1例 日本内科学会関東地方会. 2019.10; 654回 37. ( 医中誌 )

  7. 浜本 康夫: 【希少癌に備える-いざという時のための基礎知識】後腹膜腫瘍　薬物療法　軟部肉腫を中心に 臨床泌尿器科. 2019.10; 73 (11): 820-826. ( 医中誌 )

  8. 遠藤 駿, 三ツ村 隆弘, 石塚 聖洋, 飯島 裕基, 榊原 里江, 本多 隆行, 白井 剛, 岡本 師, 立石 知也, 玉岡 明洋, 宮崎 泰成, 池田 貞勝: 以前にはEGFR遺伝子変異陰性とされたが、遺伝子パネル検査でEGFR minor mutationが検出されAfatinibが奏効した1例 肺癌. 2019.08; 59 (4): 441. ( 医中誌 )

  9. 須河 恭敬, 浜本 康夫, 金井 隆典: 【IBD類縁疾患を考える】自己免疫性疾患関連副作用(irAE)としての腸炎 消化器・肝臓内科. 2019.08; 6 (2): 101-107. ( 医中誌 )

  10. 池田 貞勝: がんゲノム医療と乳がん治療　リキッドバイオプシーを用いた新規治療戦略 日本乳癌学会総会プログラム抄録集. 2019.07; 27回 234. ( 医中誌 )

  11. 熊木 裕一, 池田 貞勝, 矢部 早希子, 笠原 舞, 小田 剛史, 高嶺 恵理子, 横堀 潤子, 石橋 恵理, 高橋 健太, 坂下 博之, 中川 剛士, 三宅 智, 植竹 宏之: 乳癌患者の治療選択におけるがんゲノム検査の有用性の検討 日本乳癌学会総会プログラム抄録集. 2019.07; 27回 526. ( 医中誌 )

  12. 熊木 裕一, 久保田 一徳, 小川 あゆみ, 細谷 徳子, 小田 剛史, 中川 剛士, 藤岡 友之, 池田 貞勝, 植竹 宏之: 【Women's Imaging 2019　Breast Imaging(Vol.14)　Precision Medicine時代におけるライフステージと乳がん画像診断】画像診断技術の動向と臨床応用　がんゲノム医療と画像診断の現状および今後の展望 INNERVISION. 2019.07; 34 (8): 59-61. ( 医中誌 )

  13. 須河 恭敬, 浜本 康夫, 金井 隆典: 【免疫チェックポイント阻害薬の副作用(irAE)-わかってきたこと-】免疫チェックポイント阻害剤の副作用　下痢?大腸炎 癌の臨床. 2019.07; 64 (5): 299-305. ( 医中誌 )

  14. 高橋 健太, 池田 貞勝: 【悪性腫瘍の病理・遺伝子診断に基づくプレシジョンメディシン】HER2がんの特徴と治療戦略(乳がん、胃がん、胆管がん、肺がんなど) 医学のあゆみ. 2019.04; 269 (3): 199-202. ( 医中誌 )

  15. 浜本 康夫: 【診療力を上げる!　症例問題集】(第2章)消化器　症例問題　スキルス胃がんに対する全身化学療法 内科. 2019.04; 123 (4): 565-566. ( 医中誌 )

  16. 山内 敏正, 後藤 悌, 池田 貞勝: 【肺癌　免疫・ゲノム医療で急展開する肺癌治療】 最新の科学技術で発展する肺癌治療 Medical Practice. 2019.02; 36 (2): 174-189. ( 医中誌 )

  17. 三ツ村 隆弘, 池田 貞勝: 【肺癌　免疫・ゲノム医療で急展開する肺癌治療】 最新の実地診療のポイントと整理　次世代シークエンサーを用いた遺伝子診断(血漿) Medical Practice. 2019.02; 36 (2): 247-250. ( 医中誌 )

  1. 高橋 健太, 池田 貞勝: 【がんゲノム医療】 がんLiquid biopsy 遺伝子医学. 2018.10; 8 (1): 84-88. ( 医中誌 )

  2. 高橋　健太、池田　貞勝: がんLiquid biopsy 遺伝子医学. 2018.10; (26): 84-88.

  3. 下嵜 啓太郎, 平田 賢郎, 浜本 康夫: 【食道癌(第2版)-基礎・臨床研究の進歩-】再発食道癌の治療　化学療法・化学放射線療法 日本臨床. 2018.10; 76 (増刊8 食道癌): 417-423. ( 医中誌 )

  4. 川崎 健太, 浜本 康夫: 【大腸腫瘍の分子生物学】大腸癌化学療法と分子生物学 Intestine. 2018.09; 22 (5): 457-462. ( 医中誌 )

  5. 高橋 健太, 池田 貞勝, 若菜 公雄, 宮坂 尚幸: 【婦人科がん最近の話題】 婦人科がん領域のがんゲノム医療 東京産婦人科医会誌. 2018.08; (51): 28-30. ( 医中誌 )

  6. 津軽 開, 平田 賢郎, 浜本 康夫: 【免疫チェックポイント療法の新潮流】消化器癌治療における位置付けと今後の展望 医薬ジャーナル. 2018.08; 54 (8): 1849-1852. ( 医中誌 )

  7. 小笹 由香, 青木 美紀子, 武田 祐子, 高嶺 恵理子, 池田 貞勝, 高橋 謙太, 吉田 雅幸: 看護師による、看護師のためのゲノム医療に関する教育とは? 日本遺伝看護学会誌. 2018.08; 17 (1): 35. ( 医中誌 )

  8. 高橋 健太, 池田 貞勝, 若菜 公雄, 宮坂 尚幸: 【婦人科がん最近の話題】 婦人科がん領域のがんゲノム医療 東京産婦人科医会誌. 2018.08; (51): 28-30. ( 医中誌 )

  9. 小笹 由香, 青木 美紀子, 武田 祐子, 高嶺 恵理子, 池田 貞勝, 高橋 謙太, 吉田 雅幸: 看護師による、看護師のためのゲノム医療に関する教育とは? 日本遺伝看護学会誌. 2018.08; 17 (1): 35. ( 医中誌 )

  10. 須河 恭敬, 浜本 康夫, 金井 隆典: 【免疫チェックポイント阻害剤の副作用と対策】大腸炎 癌と化学療法. 2018.07; 45 (7): 1027-1030. ( 医中誌 )

  11. 北川 雄光, 西原 広史, 和田 則仁, 林田 晢, 八木 洋, 浜本 康夫: 【婦人科がん(第2版)-最新の研究動向-】わが国のがん医療 総論 次世代がん医療の展望 日本臨床. 2018.03; 76 (増刊2 婦人科がん): 11-17. ( 医中誌 )

  12. 北川 雄光, 西原 広史, 和田 則仁, 林田 晢, 八木 洋, 浜本 康夫: 【婦人科がん(第2版)-最新の研究動向-】わが国のがん医療　総論　次世代がん医療の展望 日本臨床. 2018.03; 76 (増刊2 婦人科がん): 11-17. ( 医中誌 )

  13. 加納嘉人、Michael Ohh、三宅智: 消化器癌に対する標準化学療法と今後の展望 Bio Clinica. 2018.02; 33 (2): 11-16.

  14. 加納 嘉人, Ohh Michael, 三宅 智: 【がんの化学療法】 消化器癌に対する標準化学療法と今後の展望 BIO Clinica. 2018.02; 33 (2): 111-116. ( 医中誌 )

  15. 戸ヶ崎 和博, 浜本 康夫: 【消化管治療薬 外来での使いどころ】領域別消化管治療薬の使い方　《悪性腫瘍》　経口抗腫瘍薬(消化器領域)の使い方 内科. 2018.02; 121 (2): 287-292. ( 医中誌 )

  1. 平山 佳愛, 篠崎 英司, 若槻 尊, 市村 崇, 小倉 真理子, 高張 大亮, 末永 光邦, 陳 勁松, 長嵜 寿矢, 秋吉 高志, 小西 毅, 藤本 佳也, 長山 聡, 福永 洋介, 上野 雅資, 山口 研成: 直腸癌に対する術前化学放射線療法および化学療法の病理組織学的治療効果判定 日本消化器外科学会雑誌. 2017.10; 50 (Suppl.2): 380. ( 医中誌 )

  2. 橋爪 顕子, 池田 貞勝, 坂下 博之, 新田 健太郎, 武田 浩文: 免疫関連有害事象(irAE)における情報共有(Immune Active Monitoring)への取り組み 日本癌治療学会学術集会抄録集. 2017.10; 55回 O32-5. ( 医中誌 )

  3. 高橋 遼, 若槻 尊, 篠崎 英司, 室伏 景子, 藤本 佳也, 大隅 寛木, 松島 知広, 小倉 真理子, 市村 崇, 高張 大亮, 末永 光邦, 陳 勁松, 小口 正彦, 上野 雅資, 山口 研成: 当院における限局性肛門扁平上皮癌に対する化学放射線療法の治療成績 日本癌治療学会学術集会抄録集. 2017.10; 55回 P131-6. ( 医中誌 )

  4. 橋爪 顕子, 池田 貞勝, 坂下 博之, 新田 健太郎, 武田 浩文: 免疫関連有害事象(irAE)における情報共有(Immune Active Monitoring)への取り組み 日本癌治療学会学術集会抄録集. 2017.10; 55回 O32-O35. ( 医中誌 )

  5. 青木 優, 浜本 康夫: 【患者さんからよく尋ねられる内科診療のFAQ】(第2章)消化器　母が膵がんで,見つかったときには手遅れでした.自分もそうなるのが怖いのですが,膵がんは検査では見つけにくいと聞きました.どうしたらよいのでしょうか?　[38歳 男性,膵がんの家族歴] 内科. 2017.09; 120 (3): 457-459. ( 医中誌 )

  6. 青木 優, 浜本 康夫: 【患者さんからよく尋ねられる内科診療のFAQ】(第2章)消化器　父も兄も大腸がんで他界しました.私も大腸がんで死ぬのでしょうか?　[47歳 男性,大腸がんの家族歴] 内科. 2017.09; 120 (3): 466-467. ( 医中誌 )

  7. 伊藤 芳紀, 加藤 健, 大幸 宏幸, 小島 隆嗣, 浜本 康夫, 松下 尚之, 原 浩樹, 田中 洋一, 井垣 弘康: 化学放射線療法における照射野を問う 臨床病期II/III期胸部食道癌に対する術前化学放射線療法の照射体積の妥当性の検討 日本食道学会学術集会プログラム・抄録集. 2017.06; 71回 PD3-6. ( 医中誌 )

  8. 池田 貞勝: 米国におけるPrecision Medicineの現状と展望 日本気管食道科学会会報. 2017.04; 68 (2): 65-67. ( 医中誌 )

  9. 池田 貞勝: 米国におけるPrecision Medicineの現状と展望 日本気管食道科学会会報. 2017.04; 68 (2): 65-67. ( 医中誌 )

  10. 池田 貞勝: Liquid Biopsyの実臨床への応用と課題　米国での経験から 日本病理学会会誌. 2017.03; 106 (1): 547. ( 医中誌 )

  11. 池田 貞勝, 植竹 宏之: 【ゲノム解析に基づく固形がん個別化治療】将来展望　クリニカルシークエンスにかかわる日米の医療制度比較 最新医学. 2017.03; 72 (3): 415-418. ( 医中誌 )

  12. 池田 貞勝, 植竹 宏之: 【ゲノム解析に基づく固形がん個別化治療】 将来展望　クリニカルシークエンスにかかわる日米の医療制度比較 最新医学. 2017.03; 72 (3): 415-418. ( 医中誌 )

  13. 池田 貞勝: Liquid Biopsyの実臨床への応用と課題　米国での経験から 日本病理学会会誌. 2017.03; 106 (1): 547. ( 医中誌 )

  1. 加納嘉人: 【my laboratoryー海外留学生だより一】トロントラボライフ G.I.Research . 2016.06; 24 (3): 202-205.

  2. 福島 啓太, 土屋 輝一郎, 加納 嘉人, 白崎 友彬, 日比谷 秀爾, 岡本 隆一, 中村 哲也, 渡辺 守: ヒトLgr5発現可視化による粘液産生大腸癌ニッチ解析 日本消化器病学会雑誌. 2016.03; 113 (臨増総会): A236. ( 医中誌 )

  1. 加納 嘉人, Ohh Michael, 渡辺 守: シグナル伝達を理解するために必要な知識(第48回)(No.95)　Rasを介したシグナル伝達 分子消化器病. 2015.12; 12 (4): 404-408. ( 医中誌 )

  2. 土屋輝一郎, 福島啓太, 日比谷秀爾, 加納嘉人: 【特集　下部消化管：炎症からの発癌】炎症発癌の基礎研究（３）炎症発癌の癌形質獲得機構 INTESTINE. 2015.08; 19 (4): 342-347.

  3. 土屋 輝一郎, 福島 啓太, 日比谷 秀爾, 加納 嘉人: 【下部消化管:炎症からの発癌】 炎症発癌の基礎研究　炎症発癌の癌形質獲得機構 Intestine. 2015.07; 19 (4): 342-347. ( 医中誌 )

  4. 末永 光邦: 【最新臨床大腸癌学-基礎研究から臨床応用へ-】大腸癌の治療　化学療法　切除不能進行・再発大腸癌の治療戦略におけるTAS102の位置づけ 日本臨床. 2015.04; 73 (増刊4 最新臨床大腸癌学): 510-514. ( 医中誌 )

  5. 加納 嘉人, 土屋 輝一郎, 渡辺 守: 【炎症と(悪性)腫瘍】 IBD(炎症性腸疾患)と腫瘍 臨床免疫・アレルギー科. 2015.01; 63 (1): 7-12. ( 医中誌 )

  1. 荒木 昭博, 新田 沙由梨, 渡辺 守, 藤井 俊光, 宍戸 華子, 岡田 英理子, 鈴木 康平, 竹中 康人, 長堀 正和, 和田 祥城, 加納 嘉人, 齊藤 詠子: カプセル内視鏡の画像保存 Gastroenterological Endoscopy. 2014.04; 56 (Suppl.1): 1073. ( 医中誌 )

  2. 川上 和宜, 末永 光邦: 【薬と検査2014　薬物治療&服薬指導プラクティカルガイド】皮膚疾患　手足症候群 薬局. 2014.03; 65 (4): 1571-1578. ( 医中誌 )

  3. 末永 光邦: 血管新生阻害剤における抗腫瘍効果の予測因子と耐性獲得因子のバイオマーカー解析 大和証券ヘルス財団研究業績集. 2014.03; (37): 149-154. ( 医中誌 )

  4. 土屋 輝一郎, 堀田 伸勝, 林 亮平, 日比谷 秀爾, 福島 啓太, 加納 嘉人, 渡辺 守: 病態生理から見た腸管病変 全小腸マッピング生検によるクローン病病態解析 栄養-評価と治療. 2014.02; 31 (1): 74. ( 医中誌 )

  5. 中山 厳馬, 末永 光邦: 【がん化学療法看護のいま〜ケアの質を高めるためのエッセンス〜】(第I章)がん化学療法のいま　支持療法のいま がん看護. 2014.02; 19 (2): 114-121. ( 医中誌 )

  1. Osumi H, Shinozaki E, Kumekawa Y, Ogura M, Ozaka M, Suenaga M, Matsusaka S, Chin K, Mizunuma N, Yokoyama M: [Three cases of fatal thrombocytopenia after oxaliplatin-based chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy. 2013.11; 40 (11): 1557-60. ( PubMed )

  2. 加納 嘉人, 土屋 輝一郎, 渡辺 守: 【Colitic cancerの発生メカニズムと予防】 免疫異常・炎症性サイトカインとIBD発癌 G.I.Research. 2013.10; 21 (5): 326-331. ( 医中誌 )

  3. 熊木 裕一, 加納 嘉人, 東 正新, 柿沼 晴, 永石 宇司, 大岡 真也, 中村 哲也, 朝比奈 靖浩, 渡辺 守, 明石 巧: 肝細胞癌、肝内胆管癌に合併した肝原発Neuroendocrine carcinomaの1例 日本内科学会関東地方会. 2013.09; 599回 59. ( 医中誌 )

  4. 加納 嘉人, 土屋 輝一郎, 渡辺 守: 消化器癌に対する幹細胞研究の現状と展望 Atoh 1発現大腸癌における幹細胞形質獲得とニッチ形成 日本消化器病学会雑誌. 2013.09; 110 (臨増大会): A792. ( 医中誌 )

  5. 仁部 洋一, 金子 俊, 竹中 健人, 後藤 文男, 岡本 英子, 加納 嘉人, 福田 将義, 新田 沙由梨, 藤井 俊光, 齊藤 詠子, 櫻井 幸, 岡田 英理子, 鈴木 伸治, 荒木 昭博, 大塚 和朗, 朝比奈 靖浩, 渡辺 守: 抗血栓薬内服患者におけるヘパリン置換法下での大腸内視鏡的粘膜切除術後出血の検討 Gastroenterological Endoscopy. 2013.09; 55 (Suppl.2): 2847. ( 医中誌 )

  6. 藤本 祐未, 荒木 昭博, 金子 俊, 河合 富貴子, 加納 嘉人, 後藤 文男, 仁部 洋一, 新田 沙由梨, 長堀 正和, 岡田 英理子, 大塚 和朗, 渡辺 守, 天野 与稔, 伊藤 栄作, 河内 洋, 江石 義信: ESDを施行した胃底腺型腺癌の1例 Progress of Digestive Endoscopy. 2013.06; 82 (1): 144,11-145,11. ( 医中誌 )

  7. 岡田 英理子, 土屋 輝一郎, 岩嵜 美智子, 堀田 伸勝, 福島 啓太, 日比谷 秀爾, 加納 嘉人, 大塚 和朗, 荒木 昭博, 渡辺 守: NSAIDs服用患者における全長小腸粘膜の病理学的検討 Gastroenterological Endoscopy. 2013.04; 55 (Suppl.1): 1043. ( 医中誌 )

  1. Mukai T, Akiyoshi T, Koga R, Arita J, Saiura A, Ikeda A, Nagasue Y, Oikawa Y, Yamakawa K, Konishi T, Fujimoto Y, Nagayama S, Fukunaga Y, Ueno M, Suenaga M, Mizunuma N, Shinozaki E, Yamamoto C, Yamaguchi T: [A case of transverse colon cancer with multiple liver metastases and hepatic pedicle lymph node involvement showing pathological complete response by XELOX plus bevacizumab]. Gan to kagaku ryoho. Cancer & chemotherapy. 2012.12; 39 (13): 2561-3. ( PubMed )

  2. 向井 俊貴, 秋吉 高志, 古賀 倫太郎, 有田 淳一, 齋浦 明夫, 池田 篤志, 永末 裕友, 及川 芳徳, 山川 景子, 小西 毅, 藤本 佳也, 長山 聡, 福長 洋介, 上野 雅資, 末永 光邦, 水沼 信之, 篠崎 英司, 山本 智理子, 山口 俊晴: XELOX+Bevacizumab療法によりPathological Complete Responseを得た肝門部リンパ節転移を伴う横行結腸癌多発肝転移の1切除例 癌と化学療法. 2012.12; 39 (13): 2561-2563. ( 医中誌 )

  3. 藤本 祐未, 金子 俊, 河合 富貴子, 加納 嘉人, 後藤 文男, 仁部 洋一, 新田 沙由梨, 中川 美奈, 東 正新, 長堀 正和, 岡田 英理子, 鈴木 伸治, 荒木 昭博, 大塚 和朗, 渡辺 守, 天野 与稔, 伊藤 栄作, 河内 洋, 北川 昌伸, 江石 義信: ESDを施行した胃底腺型胃癌の一例 Progress of Digestive Endoscopy. 2012.12; 82 (Suppl.): s102. ( 医中誌 )

  4. 末永 光邦: 【臨床現場が知りたい大腸がん薬物治療】効果的な治療法の選択　専門医からのアドバイス　有害事象が発現したレジメンを再び用いることは可能か? 臨床腫瘍プラクティス. 2012.11; 8 (4): 369-374. ( 医中誌 )

  5. 加納 嘉人, 土屋 輝一郎, 渡辺 守: 分子診断学からみた大腸腫瘍の治療成績と予後 新たな「分化度」スケーリングを用いた大腸癌形質制御と個別化医療への可能性 日本消化器病学会雑誌. 2012.09; 109 (臨増大会): A631. ( 医中誌 )

  6. 末松 聡史, 加納 嘉人, 長堀 正和, 荒木 昭博, 大塚 和朗, 朝比奈 靖浩, 渡辺 守, 杉原 健一, 根木 真理子, 明石 巧: MRIが有用であった孤発性小腸間膜原発デスモイド腫瘍の1例 日本内科学会関東地方会. 2012.09; 590回 54. ( 医中誌 )

  7. 土屋 輝一郎, 鄭 秀, 加納 嘉人, 水谷 知裕, 油井 史郎, 岡本 隆一, 中村 哲也, 渡辺 守: 小腸上皮細胞初代培養による生理的フラジェリン応答解析 栄養-評価と治療. 2012.02; 29 (1): 72. ( 医中誌 )

  1. 岡本 隆一, 清水 寛路, 村野 竜朗, 伊藤 剛, 堀田 伸勝, 鄭 秀, 加納 嘉人, 野崎 賢吾, 福田 将義, 水谷 知裕, 油井 史郎, 土屋 輝一郎, 中村 哲也, 渡辺 守: 【特集：免疫統御からみた新しいIBD治療】 腸管細胞の分化・再生の制御機構からみたIBD治療へのアプローチ IBD Research. 2011.12; 5 (4): 226-231. ( 医中誌 )

  2. 加納 嘉人, 土屋 輝一郎, 渡辺 守: 【大腸癌研究の新たな展開と治療戦略】 Hath1蛋白可視化による未分化大腸癌分化誘導機構解析 消化器内科. 2011.12; 53 (6): 607-612. ( 医中誌 )

  3. 岡本 隆一, 清水 寛路, 村野 竜朗, 伊藤 剛, 堀田 伸勝, 鄭 秀, 加納 嘉人, 野崎 賢吾, 福田 将義, 水谷 知裕, 油井 史郎, 土屋 輝一郎, 中村 哲也, 渡辺 守: 【免疫統御からみた新しいIBD治療】 腸管細胞の分化・再生の制御機構からみたIBD治療へのアプローチ IBD Research. 2011.12; 5 (4): 226-231. ( 医中誌 )

  4. 前 勇太郎, 横川 貴志, 川上 和宜, 八木 奈央, 末永 光邦, 篠崎 英司, 松阪 諭, 水沼 信之, 濱 敏弘: XELOX療法における薬剤師外来の有用性 医療薬学. 2011.11; 37 (11): 611-615. ( 医中誌 )

  5. 加納 嘉人, 土屋 輝一郎, 渡辺 守: 消化器癌の悪性度・予後における分子診断 Atoh 1発現大腸癌における悪性形質獲得機構解析 日本消化器病学会雑誌. 2011.09; 108 (臨増大会): A639. ( 医中誌 )

  6. 鄭 秀, 土屋 輝一郎, 岩嵜 美智子, 加納 嘉人, 水谷 知裕, 油井 史郎, 岡本 隆一, 中村 哲也, 渡辺 守: 初代培養小腸上皮細胞による生理的フラジェリン応答解析 日本消化器病学会雑誌. 2011.09; 108 (臨増大会): A825. ( 医中誌 )

  7. Asai H, Shinozaki E, Nozaki A, Watanabe T, Suenaga M, Matuzaka S, Chin K, Mizunuma N, Yasukawa M, Hatake K: [Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. 2011.08; 38 (8): 1285-91. ( PubMed )

  8. Oya M, Sameshima S, Tagaya N, Takeshita E, Koketsu S, Sugamata Y, Yoshiba H, Ueno M, Fujimoto Y, Suenaga M: [Colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. 2011.08; 38 (8): 1252-5. ( PubMed )

  9. 朝井 洋晶, 篠崎 英司, 野崎 明, 渡邉 利泰, 末永 光邦, 松阪 諭, 陳 勁松, 水沼 信之, 安川 正貴, 畠 清彦: 切除不能進行再発大腸癌に対する三次治療としてのCetuximab+Irinotecan併用化学療法の治療効果とKRAS遺伝子変異の相関 癌と化学療法. 2011.08; 38 (8): 1285-1291. ( 医中誌 )

  10. 大矢 雅敏, 鮫島 伸一, 多賀谷 信美, 竹下 恵美子, 纐纈 真一郎, 菅又 嘉剛, 吉羽 秀麿, 上野 雅資, 藤本 佳也, 末永 光邦: 【Marginally Resectable Tumorに対する治療戦略】大腸癌 癌と化学療法. 2011.08; 38 (8): 1252-1255. ( 医中誌 )

  11. 中本 恵理, 川上 和宜, 今田 洋司, 式部 さあ里, 杉田 一男, 篠崎 英司, 末永 光邦, 松阪 諭, 水沼 信之, 濱 敏弘: Cetuximab投与後に生じる低マグネシウム血症の発現頻度と発現時期の調査とその対策 医療薬学. 2011.07; 37 (7): 403-409. ( 医中誌 )

  12. Kawazoe Y, Hatake K, Suenaga M, Mizunuma N: [Administration-limiting factor of bevacizumab for patient with metastatic colorectal cancer]. Nihon rinsho. Japanese journal of clinical medicine. 2011.04; 69 Suppl 3 472-6. ( PubMed )

  13. 河添 悦昌, 末永 光邦, 畠 清彦, 水沼 信之: 【大腸癌　最新の研究動向】大腸癌の治療戦略　化学療法　大腸癌患者へのbevacizumabの適応選択(投与規定因子) 日本臨床. 2011.04; 69 (増刊3 大腸癌): 472-476. ( 医中誌 )

  14. 土屋 輝一郎, 岩嵜 美智子, 鄭 秀, 岡本 英子, 加納 嘉人, 岡本 隆一, 中村 哲也, 荒木 昭博, 渡辺 守: ダブルバルーン内視鏡による全小腸マッピング生検の有用性 日本大腸検査学会雑誌. 2011.01; 27 (2): 58. ( 医中誌 )

  1. Mitsuhashi K, Matsusaka S, Mizunuma N, Ichimura T, Ozaka M, Ogura M, Shinozaki E, Suenaga M, Chin K, Fujimoto Y, Saiura A, Yamamoto N, Hatake K: [Successful treatment with cetuximab combination chemotherapy in a case of FOLFOX-refractory rectal cancer with previously unresectable multiple liver metastases leading to complete resection]. Gan to kagaku ryoho. Cancer & chemotherapy. 2010.11; 37 (11): 2203-7. ( PubMed )

  2. Ichimura T, Chin K, Kobayashi K, Osaka M, Kuboki Y, Ogura M, Shinozaki E, Suenaga M, Matsuzaka S, Mizunuma N, Hatake K: [The incidence of gastrointestinal bleeding, thromboembolic events, and gastrointestinal perforation in metastatic or unresectable gastric cancer during chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy. 2010.11; 37 (11): 2131-6. ( PubMed )

  3. 三橋 健次郎, 松阪 諭, 水沼 信之, 市村 崇, 尾阪 将人, 小倉 真理子, 篠崎 英司, 末永 光邦, 陳 勁松, 藤本 佳也, 齋浦 明夫, 山本 智理子, 畠 清彦: Cetuximab療法により完全切除可能となったFOLFOX療法抵抗性・切除不能直腸癌多発肝転移の1症例 癌と化学療法. 2010.11; 37 (11): 2203-2207. ( 医中誌 )

  4. 末永 光邦: 【消化器癌・悪性腫瘍の分子標的治療薬を用いた薬物療法】消化器癌・悪性腫瘍の分子標的治療薬の有害事象とその対策 消化器の臨床. 2010.10; 13 (5): 570-577. ( 医中誌 )

  5. 加納 嘉人, 土屋 輝一郎, 渡辺 守: 大腸がん研究の新たな展開と治療戦略 Hath 1蛋白可視化による未分化大腸がん分化誘導機構解析 日本消化器病学会雑誌. 2010.09; 107 (臨増大会): A634. ( 医中誌 )

  6. 池田 貞勝: 【ホスピタリストと病院総合医】　ホスピタリストの仕事内容 外科ホスピタリスト JIM: Journal of Integrated Medicine. 2010.09; 20 (9): 670-673. ( 医中誌 )

  7. 岡本 隆一, 秋山 純子, 鄭 秀, 加納 嘉人, 水谷 知裕, 油井 史郎, 岩嵜 美智子, 土屋 輝一郎, 中村 哲也, 渡辺 守: 【トピックス第14回：IBDの最新の話題　基礎編】　炎症粘膜上皮の再生制御機構 IBD Research. 2010.06; 4 (2): 121-126. ( 医中誌 )

  8. 岡本 隆一, 秋山 純子, 鄭 秀, 加納 嘉人, 水谷 知裕, 油井 史郎, 岩嵜 美智子, 土屋 輝一郎, 中村 哲也, 渡辺 守: IBDの最新の話題　基礎編(第14回)　炎症粘膜上皮の再生制御機構 IBD Research. 2010.06; 4 (2): 121-126. ( 医中誌 )

  9. 土屋 輝一郎, 加納 嘉人, 渡辺 守: 消化器癌に対する分子標的治療の現状 大腸がんの未分化形質維持機構による分化誘導療法の検討 日本消化器病学会雑誌. 2010.03; 107 (臨増総会): A93. ( 医中誌 )

  10. 伊藤 剛, 吉村 築, 池邉 佐和子, 鎌田 和明, 加納 嘉人, 水谷 知裕, 大木 史郎, 相馬 友子, 永山 和宜, 草野 史彦, 酒井 義法, 田沢 潤一, 松井 則明, 藤原 秀臣: コイルによる動脈塞栓後、印象的な内視鏡像を呈した出血性十二指腸潰瘍の1例 茨城県臨床医学雑誌. 2010.03; (45): 21-22. ( 医中誌 )

  11. 末永 光邦: 【消化器がん化学療法看護完全マスターBOOK　分子標的薬と従来型抗がん剤のケア 副作用 治療のしくみがやさしくわかる!】分子標的薬の必須情報と副作用対策　分子標的薬の副作用マネジメント　急性心筋梗塞 消化器外科Nursing. 2010.02; (2010臨時増刊): 190-191. ( 医中誌 )

  12. 末永 光邦: 【消化器がん化学療法看護完全マスターBOOK　分子標的薬と従来型抗がん剤のケア 副作用 治療のしくみがやさしくわかる!】分子標的薬の必須情報と副作用対策　分子標的薬の副作用マネジメント　高血圧 消化器外科Nursing. 2010.02; (2010臨時増刊): 182-189. ( 医中誌 )

  1. 岡本 隆一, 秋山 純子, 鄭 秀, 加納 嘉人, 水谷 知裕, 油井 史郎, 岩嵜 美智子, 土屋 輝一郎, 中村 哲也, 渡辺 守: 【特集：幹細胞を用いた消化器再生医療の展望】 クローン病・潰瘍性大腸炎の難治性潰瘍も幹細胞を用いた再生医療で治せるか 分子消化器病. 2009.12; 6 (4): 353-358. ( 医中誌 )

  2. 岡本 隆一, 秋山 純子, 鄭 秀, 加納 嘉人, 水谷 知裕, 油井 史郎, 岩嵜 美智子, 土屋 輝一郎, 中村 哲也, 渡辺 守: 【幹細胞を用いた消化器再生医療の展望】 クローン病・潰瘍性大腸炎の難治性潰瘍も幹細胞を用いた再生医療で治せるか 分子消化器病. 2009.12; 6 (4): 353-358. ( 医中誌 )

  3. 末永 光邦: わかりやすい臨床試験(No.3)　GCP(good clinical practice) Drug Delivery System. 2009.11; 24 (6): 627-629. ( 医中誌 )

  4. 吉本 和仁, 陳 勁松, 小倉 真理子, 末永 光邦, 篠崎 英司, 松阪 諭, 水沼 信之, 石山 晃世志, 山本 頼正, 土田 知宏, 藤崎 順子, 星野 惠津夫, 畠 清彦: 【消化管癌の化学・放射線療法の効果判定と問題点】胃癌化学療法における原発巣効果判定　CTでの効果判定と内視鏡検査の意義 胃と腸. 2009.11; 44 (12): 1859-1870. ( 医中誌 )

  5. 末永 光邦: 【癌治療の現状と展望　標準治療の連携と分子標的薬剤のバイオマーカー】治療薬解説　ベバシズマブ(アバスチン) カレントテラピー. 2009.11; 27 (11): 1046-1052. ( 医中誌 )

  6. 末永 光邦, 水沼 信之, 畠 清彦: 【大腸癌化学療法の最前線】分子標的薬を使うタイミングとコツ　bevacizumab(アバスチン) Intestine. 2009.11; 13 (6): 611-616. ( 医中誌 )

  7. 末永 光邦: 【大腸癌治療の現在　化学療法と外科手術のコンビネーション】大腸癌化学療法の副作用とその対策 Pharma Medica. 2009.11; 27 (11): 35-39. ( 医中誌 )

  8. 横川 貴志, 松阪 諭, 庄司 大悟, 今田 洋司, 中本 恵理, 神杉 香代子, 鈴木 亘, 白井 健之, 高橋 郷, 川上 和宜, 篠崎 英司, 末永 光邦, 水沼 信之, 畠 清彦, 濱 敏弘: FOLFOX4療法における遅発性悪心・嘔吐に対する予防療法の有効性の検討 薬学雑誌. 2009.08; 129 (8): 949-955. ( 医中誌 )

  9. Yokokawa T, Matsusaka S, Shouji D, Imada H, Nakamoto E, Kamisugi K, Suzuki W, Shirai T, Takahashi G, Kawakami K, Shinozaki E, Suenaga M, Mizunuma N, Hatake K, Hama T: [Efficacy of preventive treatment for delayed emesis induced by FOLFOX4 chemotherapy]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2009.08; 129 (8): 949-55. ( PubMed , DOI )

  10. Yokokawa Takashi, Matsusaka Satoshi, Shouji Daigo, Imada Hiroshi, Nakamoto Eri, Kamisugi Kayoko, Suzuki Wataru, Shirai Takeshi, Takahashi Gou, Kawakami Kazuyoshi, Shinozaki Eiji, Suenaga Mitsukuni, Mizunuma Nobuyuki, Hatake Kiyohiko, Hama Toshihiro: Efficacy of Preventive Treatment for Delayed Emesis Induced by FOLFOX4 Chemotherapy YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN. 2009.08; 129 (8): 949-955.

  11. 鎌田 和明, 草野 史彦, 池邉 佐和子, 加納 嘉人, 水谷 知裕, 相馬 友子, 大木 史郎, 永山 和宜, 酒井 義法, 田沢 潤一: 小腸多発性憩室に合併した小腸穿孔の1例 日本内科学会関東地方会. 2009.06; 563回 30. ( 医中誌 )

  12. 池邉 佐和子, 伊藤 剛, 吉村 築, 鎌田 和明, 加納 嘉人, 水谷 知裕, 大木 史郎, 相馬 友子, 草野 史彦, 酒井 義法, 田沢 潤一: 食道・胃・小腸・大腸・内視鏡検査と治療　偶発症とその対策 コイルによる動脈塞栓後、印象的な内視鏡像を呈した出血性十二指腸潰瘍の一例 Progress of Digestive Endoscopy. 2009.06; 75 (1): 63. ( 医中誌 )

  13. 永山 和宜, 山根 道雄, 池邊 佐和子, 加納 嘉人, 鎌田 和明, 今西 暁, 伊藤 祐子, 大木 史郎, 相馬 友子, 望月 奈穂子, 草野 史彦, 酒井 義法, 田沢 潤一, 松井 則明, 藤原 秀臣: 在宅経腸栄養療法・アミノサリチル酸製剤と1回の手術のみで15年間加療できたクローン病の1例 茨城県臨床医学雑誌. 2009.03; (44): 6. ( 医中誌 )

  1. 鎌田 和明, 草野 史彦, 池邉 佐和子, 加納 嘉人, 水谷 知裕, 相馬 友子, 大木 史郎, 永山 和宜, 酒井 義法, 田沢 潤一: 脳梗塞治療後に発症した腸間膜血腫の1例 日本内科学会関東地方会. 2008.12; 559回 29. ( 医中誌 )

  2. 庄司 大悟, 松阪 諭, 渡邊 知映, 末永 光邦, 篠崎 英司, 松田 正典, 久保木 恭利, 小倉 真理子, 市村 崇, 陳 勁松, 水沼 信之, 畠 清彦: FOLFOX4療法におけるRDI(Relative Dose Intensity)の検討 癌と化学療法. 2008.11; 35 (11): 1895-1900. ( 医中誌 )

  3. Shouji D, Matsusaka S, Watanabe C, Suenaga M, Shinozaki E, Matsuda M, Kuboki K, Ogura M, Ichimura T, Keisho C, Mizunuma N, Hatake K: [Relative dose intensity of FOLFOX4 regimen]. Gan to kagaku ryoho. Cancer & chemotherapy. 2008.11; 35 (11): 1895-900. ( PubMed )

  4. 渡邉 利泰, 水沼 信之, 末永 光邦, 畠 清彦: 【大腸癌の化学療法】大腸癌化学療法における副作用対策をどう行うか主な薬剤の特徴的な副作用とその対策　ベバシズマブ 消化器の臨床. 2008.10; 11 (5): 564-568. ( 医中誌 )

  5. 加納 嘉人, 草野 史彦, 池邉 佐和子, 鎌田 和明, 伊藤 祐子, 相馬 友子, 大木 史郎, 望月 奈穂子, 永山 和宜, 酒井 義法, 田沢 潤一, 渡辺 守: 特徴的な画像所見を示し経乳頭的ドレナージにて内瘻化に成功したラジオ波熱凝固療法(RFA)後Bilomaの1例 日本消化器病学会雑誌. 2008.09; 105 (臨増大会): A870. ( 医中誌 )

  6. Kamisugi K, Matsusaka S, Imada H, Shoji D, Nakamoto E, Yokokawa T, Kawakami K, Hirata Y, Nawano K, Ogawa M, Shinozaki E, Suenaga M, Mizunuma N, Hatake K, Hama T: [Preparation of a brochure for patients undergoing FOLFIRI chemotherapy based on survey of adverse reactions]. Gan to kagaku ryoho. Cancer & chemotherapy. 2008.08; 35 (8): 1331-5. ( PubMed )

  7. 神杉 香代子, 松阪 諭, 今田 洋司, 庄司 大悟, 中本 恵理, 横川 貴志, 川上 和宜, 平田 良美, 縄野 一美, 小川 恵, 篠崎 英司, 末永 光邦, 水沼 信之, 畠 清彦, 濱 敏弘: FOLFIRI療法の副作用調査に基づいた患者向け説明書の作成 癌と化学療法. 2008.08; 35 (8): 1331-1335. ( 医中誌 )

  8. 加納 嘉人, 永山 和宜, 池邊 佐和子, 鎌田 和明, 今西 暁, 伊藤 祐子, 大木 史郎, 望月 奈穂子, 相馬 友子, 草野 史彦, 酒井 義法, 田沢 潤一, 渡辺 守: 多数の胃内異物により出血性胃潰瘍を生じたステロイド内服中の1例 Progress of Digestive Endoscopy. 2008.06; 72 (2): 58,4-59,4. ( 医中誌 )

  9. Kuboki Y, Ichimura T, Ogura M, Matsuda M, Suenaga M, Shinozaki E, Matsuzaka S, Chin K, Mizunuma N, Hatake K: [Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients]. Gan to kagaku ryoho. Cancer & chemotherapy. 2008.05; 35 (5): 781-5. ( PubMed )

  10. 久保木 恭利, 市村 崇, 小倉 真理子, 松田 正典, 末永 光邦, 篠崎 英司, 松阪 諭, 陳 勁松, 水沼 信之, 畠 清彦: 高齢者進行・再発大腸癌症例に対するFOLFOX4療法の検討 癌と化学療法. 2008.05; 35 (5): 781-785. ( 医中誌 )

  11. 末永 光邦: 【大腸癌治療UPDATE】サポート・医療環境　チーム・アバスチンと癌短期化学療法研修 医学のあゆみ. 2008.04; 225 (1): 67-73. ( 医中誌 )

  12. 末永 光邦: 【大腸疾患の実地診療　増加する大腸癌と炎症性腸疾患への対応】大腸疾患の実地診療・トピックス　大腸癌　大腸癌の分子標的併用療法の有効性 Medical Practice. 2008.04; 25 (4): 661-662. ( 医中誌 )

  13. Matsuda M, Matsusaka S, Kuboki Y, Itimura T, Ogura M, Suenaga M, Syouji D, Watanabe C, Chin K, Mizunuma N, Hatake K: [Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. 2008.03; 35 (3): 461-6. ( PubMed )

  14. 松田 正典, 松阪 諭, 久保木 恭利, 市村 崇, 小倉 真理子, 末永 光邦, 庄司 大吾, 渡邊 知映, 陳 勁松, 水沼 信之, 畠 清彦: 進行大腸癌に対するFOLFOX4療法による末梢神経障害の回復の解析 癌と化学療法. 2008.03; 35 (3): 461-466. ( 医中誌 )

  15. Suenaga M, Nishina T, Hyodo I, Munakata M, Koizumi W, Mishima H, Sato A, Mizunuma N, Hatake K: [A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/l-LV (FOLFOX4 regimen) for advanced colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. 2008.02; 35 (2): 255-60. ( PubMed )

  16. 末永 光邦, 仁科 智裕, 兵頭 一之介, 棟方 正樹, 小泉 和三郎, 三嶋 秀行, 佐藤 温, 水沼 信之, 畠 清彦: 治癒切除不能の進行・再発結腸・直腸癌に対するOxaliplatin(L-OHP)+Infusional 5-FU/l-LV療法(FOLFOX4レジメン)の安全性確認試験 癌と化学療法. 2008.02; 35 (2): 255-260. ( 医中誌 )

  1. 加納 嘉人, 永山 和宜, 池邉 佐和子, 鎌田 和明, 今西 暁, 伊藤 祐子, 大木 史郎, 相馬 友子, 望月 奈穂子, 草野 史彦, 酒井 義法, 田沢 潤一: 拘置所収容中に包装袋の大量異食により出血性胃潰瘍を生じたステロイド内服中の一例 Progress of Digestive Endoscopy. 2007.11; 72 (1): 94. ( 医中誌 )

  2. Imada H, Kawakami K, Hiraoka T, Higuchi S, Takahashi G, Aoyama T, Shinozaki E, Suenaga M, Matsuzaka S, Hama T: [Drug information brochure for patients undergoing FOLFOX 4 chemotherapy based on survey of adverse reactions]. Gan to kagaku ryoho. Cancer & chemotherapy. 2007.09; 34 (9): 1425-30. ( PubMed )

  3. 今田 洋司, 川上 和宜, 平岡 知子, 樋口 秀太郎, 高橋 郷, 青山 剛, 篠崎 英司, 末永 光邦, 松阪 諭, 濱 敏弘: FOLFOX 4療法の副作用集計データに基づく患者向け説明書の作成 癌と化学療法. 2007.09; 34 (9): 1425-1430. ( 医中誌 )

  4. 末永 光邦: 【がん外来化学療法コンセプトシート】新規導入薬剤　新規抗癌剤を導入するための準備　Avastin 医学のあゆみ. 2007.09; 222 (13): 1139-1143. ( 医中誌 )

  5. 酒井 義法, 鎌田 和明, 加納 嘉人, 池辺 佐和子, 伊藤 裕子, 今西 暁, 大木 史郎, 望月 奈穂子, 草野 史彦, 田沢 潤一: 電子クリニカルパスを用いた大腸癌に対するFOLOFOX療法 日本農村医学会雑誌. 2007.09; 56 (3): 229. ( 医中誌 )

  6. 加納 嘉人, 西尾 誠人, 岡野 義夫, 堀池 篤, 大柳 文義, 宝来 威, 今清水 恒太, 小川 史洋, 安江 英晴, 佐藤 之俊, 奥村 栄, 中川 健, 平松 美也子, 二宮 浩範, 石川 雄一: 小細胞癌として治療を行った前縦隔腫瘍の2例 肺癌. 2007.06; 47 (3): 293. ( 医中誌 )

  1. 末永 光邦: 【がん診療における重症感染と化学療法を含む総括的治療】消化器癌治療における感染症 化学療法の領域. 2006.04; 22 (5): 792-794. ( 医中誌 )

  2. 庄司 大悟, 水津 ちづる, 渡邊 知映, 水沼 信之, 陳 勁松, 高橋 俊二, 伊藤 良則, 徳留 なほみ, 末永 光邦, 宇良 敬, 畠 清彦: 固形がん化学療法施行患者における貧血発現状況に関する調査研究 血液・腫瘍科. 2006.02; 52 (2): 226-236.

  1. 榎戸 克年, 大東 誠司, 竹井 淳子, 堀田 亮, 熊倉 香, 林 直樹, 池田 貞勝, 西尾 剛毅: 悪性腫瘍に起因した成人腸重積症の3例 日本腹部救急医学会雑誌. 2004.11; 24 (7): 1163-1167. ( 医中誌 )

  2. 末永 光邦, 大山 繁和, 佐藤 貴弘, 山本 順司, 山口 俊晴: 胃癌術後に抗血漿タンパク質抗体による非溶血性輸血副作用を呈した1例 臨床外科. 2004.10; 59 (10): 1361-1364. ( 医中誌 )

  3. 永野 秀樹, 大山 繁和, 末永 光邦, 佐藤 貴弘, 瀬戸 泰之, 山口 俊晴, 武藤 徹一郎, 山口 明夫: 食事制限とBMI変化からみた胃癌術後栄養指導評価 日本消化器外科学会雑誌. 2004.06; 37 (6): 648-655. ( 医中誌 )

  4. 池田 貞勝, 松藤 凡, 榎戸 克年, 堀田 亮, 横山 穣太郎: 腹部外傷を契機に発見された男児膵solid and cystic tumor(SCT)の1例 日本小児外科学会雑誌. 2004.02; 40 (1): 126. ( 医中誌 )

  1. 池田 貞勝, 中村 清吾: ゲイルモデルは日本人乳癌ハイリスク患者の予測には改良が必要である 聖路加健康科学誌. 2003.12; 11 34. ( 医中誌 )

  2. 林 直輝, 大東 誠司, 加藤 楽, 池田 貞勝, 柵瀬 信太郎, 西尾 剛毅, 鈴木 高祐: 大腸癌術後補助化学療法の効果予測因子としてTS・DPD発現度は有用である 日本外科学会雑誌. 2003.04; 104 (臨増): 346. ( 医中誌 )

  3. 永野 秀樹, 大山 繁和, 大平 寛典, 末永 光邦, 細井 則人, 佐藤 貴弘, 太田 惠一朗, 太田 博俊, 山口 俊晴, 武藤 徹一郎: 患者からみた噴門側胃切除術後のQOL評価 日本外科学会雑誌. 2003.04; 104 (臨増): 621. ( 医中誌 )

  4. 太田 惠一朗, 末永 光邦, 佐藤 貴弘, 阪本 良弘, 大山 繁和, 上野 雅資, 関 誠, 山本 順司, 大矢 雅敏, 畦倉 薫, 太田 博俊, 山口 俊晴: 【胃全摘後の再建法】十二指腸への再建ルートのpros and cons　胃全摘後の再建方法;空腸間置法とdouble tract法 消化器外科. 2003.02; 26 (2): 203-211. ( 医中誌 )

  5. 佐藤 貴弘, 山口 俊晴, 太田 惠一朗, 大山 繁和, 上野 雅資, 永野 秀樹, 大平 寛典, 細井 則人, 末永 光邦, 武藤 徹一郎: Stage IV胃癌穿孔症例に対し好中球エラスターゼ阻害薬を投与し,救命し得た1例 Progress in Medicine. 2003.01; 23 (1): 457-458. ( 医中誌 )

  1. 末永 光邦, 徳重 正弘, 久保 文武, 福留 哲朗, 肝付 兼達, 愛甲 孝: 慢性膵炎に対する十二指腸温存膵頭切除術・膵空腸側々吻合術後11年目に発症した肝膿瘍破裂の1例 日本消化器外科学会雑誌. 2001.03; 34 (3): 224-228. ( 医中誌 )

  1. 末永 光邦, 松本 英彦, 坂元 史典, 小川 洋樹, 豊山 博信, 柳 正和, 西島 浩雄, 下高原 哲朗, 愛甲 孝: 特異な形態を呈した後縦隔気管支原性嚢腫の1例 日本呼吸器外科学会雑誌. 1999.11; 13 (7): 862-867. ( 医中誌 )

  1. Optimizing Organ Preservation Strategies through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results from the CROC Multi-Institutional Phase II Clinical Trial 2024.07; ( DOI )

  2. Definitive chemoradiotherapy with paclitaxel for locally advanced esophageal squamous cell carcinoma in older patients (PARADISE-1): a phase I trial 2024.07; 24 (1): ( DOI )

  1. Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis 2023.12; 2 100008. ( DOI )

  2. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis 2023.08; 29 (1): e108-e117. ( DOI )

  3. Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study) 2023.08; 129 (6): 1032-1039. ( DOI )

  4. Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program 2023.03; (7): ( DOI )

  5. Real-world management and outcomes of older patients with locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study 2023.03; 23 (1): ( DOI )

  1. Prospective feasibility study of indigo naturalis ointment for chemotherapy-induced oral mucositis 2021.10; 13 (e3): e1001-e1007. ( DOI )

  2. Katada C, Sugawara M, Hara H, Fujii H, Nakajima T.E, Ando T, Kojima T, Watanabe A, Sakamoto Y, Ishikawa H, Hosokawa A, Hamamoto Y, Muto M, Tahara M, Koizumi W: A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma Japanese journal of clinical oncology. 2021.02; 51 (2): 199-204. ( DOI )

  3. Takahashi M, Kato K, Okada M, Chin K, Kadowaki S, Hamamoto Y, Doki Y, Kubota Y, Kawakami H, Ogata T, Hara H, Muto M, Nakashima Y, Ishihara R, Tsuda M, Motoyama S, Kodani M, Kitagawa Y: Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3) Esophagus. 2021.01; 18 (1): 90-99. ( PubMed , DOI )

  1. Kato K, Doki Y, Ura T, Hamamoto Y, Kojima T, Tsushima T, Hironaka S, Hara H, Kudo T, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Kitagawa Y: Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer Cancer Science. 2020.05; 111 (5): 1676-1684. ( DOI )

  2. Hamamoto Y, Piao Y, Makiyama A: Achieving sequential therapy in advanced gastric cancer: the importance of appropriate patient management for the elderly and/or those with ascites Gastric Cancer. 2020.05; 23 (3): 363-372. ( DOI )

  3. Hamamoto Y: Immune checkpoint inhibitor related enterocolitis Japanese Journal of Cancer and Chemotherapy. 2020.02; 47 (2): 214-218.

  1. Hamamoto Y: Retroperitoneal tumor: Chemotherapy Japanese Journal of Clinical Urology. 2019.10; 73 (11): 820-826.

  2. Yoshikawa T, Muro K, Shitara K, Oh D, Kang Y, Chung H, Kudo T, Chin K, Kadowaki S, Hamamoto Y, Hironaka S, Yoshida K, Yen C, Omuro Y, Bai L, Maeda K, Ozeki A, Yoshikawa R, Kitagawa Y: Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial JAMA network open. 2019.08; 2 (8): ( DOI )

  3. Komatsu H, Yagasaki K, Hirata K, Hamamoto Y: Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: A qualitative study European Journal of Oncology Nursing. 2019.02; 38 65-69. ( DOI )

  4. Shimozaki K, Inokuchi K, Hamamoto Y: Systemic chemotherapy for metastatic colorectal cancer: History and New era Journal of Japanese Society of Gastroenterology. 2019; 116 (11): 902-912. ( DOI )

  1. Komatsu H, Yagasaki K, Hamamoto Y, Takebayashi T: Falls and Physical Inactivity in Patients with Gastrointestinal Cancer and Hand-Foot Syndrome Asia-Pacific Journal of Oncology Nursing. 2018.07; 5 (3): 307-313. ( DOI )

  2. Sukawa Y, Hamamoto Y, Kanai T: Immune checkpoint induced colitis Japanese Journal of Cancer and Chemotherapy. 2018.07; 45 (7): 1027-1030.

  1. Kasuga, A, Hamamoto, Y, Takeuchi, A, Kawasaki, K, Suzuki, T, Hirata, K, Sukawa, Y, Takaishi, H, Kanai, T: Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy Cancer Chemother Pharmacol. 2017.03; 79 (3): 595-602. ( DOI )

  2. Yoshino Takayuki, Shinozaki Eiji, Yamazaki Kentaro, Komatsu Yoshito, Nishina Tomohiro, Baba Hideo, Tsuji Akihito, Tsuji Yasushi, Yamaguchi Kensei, Sugimoto Naotoshi, Denda Tadamichi, Muro Kei, Takayama Tetsuji, Esaki Taito, Hamamoto Yasuo, Moriwaki Toshikazu, Shimada Yasuhiro, Goto Masahiro, Tanase Takanori, Ohtsu Atsushi: Effect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: Results from two randomized studies of TAS-102 versus a placebo. JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4): ( DOI )

このページの先頭へ▲